US20110172415A1 - Nitrogen-containing heterocycle derivatives substituted with cyclic group - Google Patents

Nitrogen-containing heterocycle derivatives substituted with cyclic group Download PDF

Info

Publication number
US20110172415A1
US20110172415A1 US13/050,465 US201113050465A US2011172415A1 US 20110172415 A1 US20110172415 A1 US 20110172415A1 US 201113050465 A US201113050465 A US 201113050465A US 2011172415 A1 US2011172415 A1 US 2011172415A1
Authority
US
United States
Prior art keywords
general formula
compound represented
compound
substituted
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/050,465
Inventor
Moriyasu Masui
Makoto Adachi
Hidenori Mikamiyama
Akira Matsumura
Naoki Tsuno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Priority to US13/050,465 priority Critical patent/US20110172415A1/en
Publication of US20110172415A1 publication Critical patent/US20110172415A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08Radicals containing only hydrogen and carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18Benzotriazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Definitions

  • the present invention relates to a nitrogen-containing heterocycle derivative useful as a drug such as an analgesic and the like, which exhibits the specific antagonism to a glutamic acid receptor of a central nervous cell, particularly, an NR1/NR2B receptor which is one kind of NMDA receptors and, preferably, has little side effect on the motion function (e.g.: abnormal sensation) and mental symptom (e.g.: schizophrenia).
  • An amino acid such as L-glutamic acid and L-aspartic acid is important as a neurotransmitter in a central nervous system for activating a nerve cell.
  • excessive accumulation of these excitatory amino acids outside a cell is thought to cause loss of nerve and motion functions seen in various cerebro-neurological diseases such as Parkinson's disease, senile dementia, Huntington's chorea, and epilepsia, as well as at anoxia, ischemia, hypoglycemia state, or head or spinal cord damage.
  • a glutamic acid receptor antagonist is thought to be useful as a remedy for the aforementioned diseases and symptoms, and for example, as an anti-epileptic drug, a preventive for ischemic brain injury, or a drug for anti-Parkinsonism.
  • the NMDA receptor which is one kind of glutamic acid receptors is composed of two subunits of NR1 and NR2, and there are further 4 kinds (NR2A, 2B, 2C, 2D) of subfamilies in the NR2 subunit. It is said that the NR1/NR2A receptor is exclusively involved in memory formation or learning acquisition, and the NR1/NR2B receptor is involved in transmission of neurodegenerative cell death or pain at ischemia. Therefore, a drug exhibiting high affinity for the NR1/NR2B receptor has a high possibility that it becames an effective analgesic having little side effect.
  • An object of the present invention is to provide a NMDA receptor antagonist which is highly active and, more preferably, exhibits high affinity for a subtype, particularly a NR1/NR2B receptor, particularly an analgesic for cancer pain or the like.
  • the present invention provides the following.
  • Z is N or CR 1 ;
  • Z is N or CR 1 ;
  • Z is N or CR 1 ;
  • Z is N or CR 1 ;
  • the present compound is not only used in treating neurodegeneration such as cerebral stroke and cerebral trauma, but also is useful as an analgesic (e.g. cancer pain analgesic) having little side effect.
  • an analgesic e.g. cancer pain analgesic
  • the “optionally protected hydoxy” includes, for example, hydroxy optionally protected with a protecting group selected from lower alkyl (methyl, tert-butyl etc.), aryl lower alkyl (triphenylmethyl, benzyl etc.), tri lower alkylsilyl (trimethylsilyl, tert-butyldimethylsilyl, triethylsilyl, triisopropylsilyl etc.), lower alkyldiarylsilyl (tert-butyldiphenylsilyl etc.), triaryl lower alkylsilyl (tribenzylsilyl etc.), lower alkoxy lower alkyl (methoxymethyl, 1-ethoxyethyl, 1-methyl-1-methoxymethyl etc.), lower alkoxy lower alkoxy lower alkyl (methoxyethoxymethyl etc.), lower alkylthio lower alkyl (methylthiomethyl etc.), tetrahydropyranyl (te)
  • the “optionally protected amino” includes, for example, amino optionally protected with a protecting group selected from lower alkoxycarbonyl (tert-butyloxycarbonyl etc.), lower alkenyloxycarbonyl (vinyloxycarbonyl, allyloxycarbonyl etc.), halogeno lower alkoxycarbonyl (2-iodinated ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl etc.), aryl lower alkoxycarbonyl (benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, phenyloxycarbonyl etc.), tri lower alkylsilyl (trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl etc.), diazo, acyl (formyl, acetyl, pivaloyl, benzoyl etc.), halogen
  • Examples of a substituent of the “optionally substituted aminooxy” include lower alkyl and acyl.
  • the “nitrogen-containing aromatic monocyclic group” includes a 5- to 6-membered aromatic cyclic group having at least one N in the ring and, further, optionally having O or S, such as:
  • the “nitrogen-containing aromatic fused cyclic group” includes:
  • Examples include:
  • a bond may be present on any ring.
  • the “nitrogen-containing aromatic monocyclic group which is optionally substituted, or nitrogen-containing aromatic fused cyclic group which is optionally substituted”, and the “nitrogen-containing aromatic monocyclic group or the nitrogen-containing aromatic fused cyclic group having at least one of optionally protected hydroxy, optionally protected amino or optionally substituted aminooxy and, further optionally substituted with other group” satisfying the condition of “i) having at least one group selected from optionally protected hydroxy, optionally protected amino and optionally substituted aminooxy” includes the “nitrogen-containing aromatic monocyclic group” having at least one group selected from optionally protected hydroxy, optionally protected amino and optionally substituted aminooxy on the ring and, further, optionally substituted with one or more groups selected from Substituent group ⁇ , and the “nitrogen-containing aromatic fused cyclic group” having at least one group selected from optionally protected hydroxy, optionally protected amino and optionally substituted aminooxy on the ring and, further, optionally substituted with one or more groups selected from Substituent group
  • Substituent group ⁇ is a group consisting of halogen, lower alkyl, halogeno lower alkyl, lower alkoxy, halogeno lower alkoxy, acyl, acyloxy, lower alkylamino, carboxy, lower alkoxycarbonyl, cyano and nitro.
  • the “pyridyl substituted with at least hydroxy”, the “quinolyl substituted with at least hydroxy”, the “benzoxyazolyl substituted with at least hydroxy” and the “benzimidazolyl substituted with at least hydroxy” include pyridyl, quinolyl, benzoxazolyl and benzimidazolyl having at least one hydroxy as a substituent and, optionally substituted with 1 or more groups selected from Substituent group ⁇ , respectively. Examples are 6-hydroxypyridin-3-yl, 2-hydroxypyridin-3-yl, 6-hydroxy-4-methyl-pyridin-3-yl, 4-acetyl-2-hydroxy-benzoxazol-6-yl.
  • the “pyridyl substituted with at least optionally protected amino” includes pyridyl having at least one amino or protected amino as a substituent and, further, optionally substituted with 1 or more groups selected from Substituent group ⁇ .
  • the “nitrogen-containing aromatic monocyclic group which is optionally substituted, or the nitrogen-containing aromatic fused cyclic group which is optionally substituted” and the “nitrogen-containing aromatic monocyclic group or the nitrogen-containing aromatic fused cyclic group containing —NH— in the ring, and in which other ring constituting atoms may be substituted with a substituent other than optionally protected hydroxy, optionally protected amino and optionally substituted aminooxy” satisfying the condition of “ii) containing —NH— in the ring” includes groups containing a —NH— group in the ring among the “nitrogen-containing aromatic monocyclic group” and the “nitrogen-containing aromatic fused cyclic group”.
  • a bond may be present on any ring, and arbitrary ring constituting atoms other than —NH— may be substituted with one or more groups selected from Substituent group ⁇ .
  • Substituent group ⁇ is halogen, lower alkyl, halogeno lower alkyl, acyl, carboxy, lower alkoxycarbonyl, cyano and nitro.
  • the “imidazolyl in which ring constituting atoms other than —NH— may be substituted”, the “pyrrolyl in which ring constituting atoms other than —NH— may be substituted”, the “pyrazolyl in which ring constituting atoms other than —NH— may be substituted”, the “benzpyrazolyl in which ring constituting atoms other than —NH— may be substituted”, the “benzimidazolyl in which ring constituting atoms other than —NH— may be substituted” and the “indolyl in which ring constituting atoms other than —NH— may be substituted” include imidazolyl, pyrrolyl, pyrazolyl, benzpyrazolyl, benzimidazolyl and indolyl in which arbitrary ring constituting atoms other than —NH— may be substituted with 1 or more groups selected from Substituent group ⁇ , respectively.
  • aromatic hydrocarbon cyclic group includes phenyl, naphthyl, phenanthryl and the like.
  • Examples of a substituent of the “aromatic hydrocarbon cyclic group which is optionally substituted” include halogen, hydroxy, lower alkyl, halogeno lower alkyl, lower alkoxy, halogeno lower alkoxy, lower alkylsulfonyloxy, halogeno lower alkylsulfonyloxy, acyl, acyloxy, amino, lower alkylamino, acylamino, nitro, cyano, carboxy, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, aromatic hydrocarbon cyclic group optionally substituted with 1 or more groups selected from Substituent group ⁇ , arylthio optionally substituted with one or more groups selected from Substituent group ⁇ , aryloxy optionally substituted with one or more groups selected from Substituent group ⁇ , arylamino optionally substituted with one or more groups selected from Substituent group ⁇ , arylsul
  • Substituent group ⁇ is a group consisting of halogen, hydroxy, lower alkyl, halogeno lower alkyl, lower alkoxy, halogeno lower alkoxy, acyl, acyloxy, amino, lower alkylamino, acylamino, carboxy, lower alkoxycarbonyl, cyano and nitro.
  • a preferable example of the “aromatic hydrocarbon cyclic group which is optionally substituted” is phenyl substituted at a para-position or phenyl substituted at a meta-position and a para-position, and a substituent is preferably halogen and/or halogeno lower alkyl.
  • aryl part of the “arylsulfonyl”, the “arylsulfonyloxy”, the “aryloxy”, the “arylthio”, the “arylamino”, the “aryl lower alkyl”, the “lower alkyldiarylsilyl”, the “triaryl lower alkylsilyl”, the “aryl lower alkoxy lower alkyl”, the “lower alkylarylsulfonyl”, or the “aryl lower alkoxycarbonyl” is the same as that of the “aromatic hydrocarbon cyclic group”.
  • Preferable is phenyl.
  • the “aromatic heterocyclic group” includes a 5- to 6-membered aromatic monocyclic group containing 1 to 4 hetero atom(s) selected from the group consisting of N, O and S (e.g. pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, tetrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, thiadiazolyl, furyl and thienyl), and an aromatic fused cyclic group (e.g.
  • indolyl isoindolyl, indolizidinyl, benzimidazolyl, benzpyrazolyl, indazolyl, cinnolinyl, phthalazinyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzisothiazolyl, benzthiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl, triazolopyridyl, imidathiazolyl, pyrazinopyridazinyl, quinazolinyl, quinolyl, isoquinolyl, quinoxalinyl, purinyl, pteridinyl, naphthyridinyl and pyrazinopyridazinyl etc.).
  • non-aromatic heterocyclic group include a 5- to 6-membered aromatic monocyclic group containing 1 to 4 hetero atom(s) selected from the group consisting of N, O and S (e.g. thiranyl, oxylanyl, azetidinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, tetrahydrofuryl, dihydrofuryl, oxazolinyl, oxazolidinyl, isoxazolinyl, isoxazolidinyl, oxadiazolinyl, oxathiolanyl, dioxolanyl, dioxolyl, tetrahydrothienyl, dihydrothienyl, thiazolinyl, thiazolidinyl, isothiazolinyl, isothi
  • the “aromatic hydrocarbon cyclic group”, the “aromatic heterocyclic group” and the “non-aromatic heterocyclic group” in A 3 include a divalent group of the “aromatic hydrocarbon cyclic group”, the “aromatic heterocyclic group” and the “non-aromatic heterocyclic group”.
  • a bond may be present at any possible position and, specifically, examples include the following groups:
  • R x is hydrogen or lower alkyl
  • a substituent of the “aromatic heterocyclic group which is optionally substituted” and the “non-aromatic heterocyclic group which is optionally substituted” is the same as that of the “aromatic hydrocarbon cyclic group which is optionally substituted”.
  • a preferable example of the “aromatic heterocyclic group which is optionally substituted” in A 2 is optionally substituted pyridyl, and examples of a preferable substituent include halogen, halogeno lower alkyl, lower alkoxy, halogeno lower alkoxy and the like.
  • the “halogen” includes F, Cl, Br and I.
  • a lower alkyl part and a halogen part of the “halogeno lower alkyl”, the “halogeno lower alkoxy”, the “halogeno lower alkoxycarbonyl”, the “halogenoacyl”, “halogeno lower alkylsulfonyl”, and the “halogeno lower alkylsulfonyloxy” are the same as the “halogen”.
  • the “lower alkyl” includes a linear or branched alkyl of a carbon number of 1 to 10, preferably a carbon number of 1 to 6, further preferably a carbon number of 1 to 3, and examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl and n-decyl. Particularly preferable is methyl or ethyl.
  • Examples of a substituent of the “optionally substituted lower alkyl” include halogen, hydroxy, lower alkoxy, halogeno lower alkoxy, acyl, acyloxy, amino, lower alkylamino, acylamino, carboxy, lower alkoxycarbonyl, cyano, nitro and the like, and a preferable example of substituted lower alkyl is trihalogeno lower alkyl and the like.
  • a substituent of the “optionally substituted lower alkoxy” is the same as the substituent of the “optionally substituted lower alkyl”.
  • the “lower alkenyl” includes a linear or branched alkenyl of a carbon number of 2 to 10, preferably a carbon number of 2 to 8, further preferably a carbon number of 3 to 6, having one or more double bonds at an arbitrary position.
  • examples include vinyl, allyl, propenyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl and decenyl.
  • a lower alkenyl part of the “lower alkenyloxycarbonyl” is the same as the “lower alkenyl”.
  • acyl includes aliphatic acyl and aroyl of a carbon number of 1 to 7. Specifically, examples include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, pivaloyl, hexanoyl, acryloyl, propionyl, methacryloyl, crotonolyl and benzoyl.
  • acyl part of the “acyloxy”, the “acylamino” and the “halogeno acyl” is the same as the “acyl”.
  • X a is —CO—, —CONR 5 —, —NR 5 CO—, —NR 5 CONR 6 —, —C( ⁇ N—OR 7 )—, —(CR 8 R 9 )rO—, —(CR 8 R 9 )rS—, —(CR 8 R 9 )rSO—, —(CR 8 R 9 )rSO 2 —, —CR 9 ⁇ N—O—, —C( ⁇ O)O—, —CH(OR 8 )—, —NR 5 COCO—, —COCONR 5 —, —NR 5 COCH(OR 8 )—, -A 3 -, -A 3 NR 6 — or -A 3 -CR 10 ⁇ CR 11 —, and other symbols are as defined above.
  • the present compound (I) is not limited to a specified isomer, but includes all possible isomers and racemates.
  • a tautomer is included as follows.
  • a compound represented by the general formula (I-a) can be synthesized by condensing ketone represented by the general formula (II) and an organophosphorus compound represented by the general formula (III) or (IV) in the presence of a base:
  • X 1 is optionally substituted lower alkenylene, or -A 3 -(CR 3 R 4 )s, s is an integer of 0 to 3, Z is a chlorine atom or a bromine atom, a wave line indicates a cis or trans form, and other respective symbols are as defined above.
  • the ketone represented by the general formula (II) can be synthesized by the method described in Reference Examples 8 to 9 described later, and a method similar thereto.
  • the organophosphorus compound represented by the general formula (III) and (IV) can be synthesized by the method described in New Experimental Chemistry Course 14, MARUZEN Co., Ltd (1977), or a method similar thereto.
  • the organophosphorus compound represented by the general formula (III) or (IV) can be used at 1 to 5 mole equivalent based on the compound represented by the general formula (II).
  • reaction solvent examples include tetrahydrofuran, diethyl ether, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, liquid ammonia and the like.
  • Examples of the base include lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, potassium tert-butoxide, n-butyllithium, lithiumhexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, sodium amide and the like.
  • the base can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (II).
  • reaction temperature is ⁇ 70 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-a) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a compound represented by the general formula (I-b) can be synthesized by reducing a compound represented by the general formula (I-a) with hydrogen in the presence of a metal catalyst:
  • reaction solvent examples include methanol, ethanol, ethyl acetate, tetrahydrofuran, N,N-dimethylformamide and the like.
  • the metal catalyst examples include 5% palladium-carbon, 10% palladium-carbon, platinum oxide, chlorotris(triphenylphosphine)rhodium (I).
  • the metal catalyst can be used at 0.01 to 0.5 weight percent based on the compound represented by the general formula (I-a).
  • An example of a hydrogen pressure is 1 to 50 atm.
  • reaction temperature is 20° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-b) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a compound represented by the general formula (I-c) can be synthesized by reacting the ketone represented by the general formula (II) with an organometallic compound represented by the general formula (V):
  • X 2 is optionally substituted lower alkenylene, or -A 3 -(CR 3 R 4 )n
  • L 1 is lithium, MgCl, MgBr or MgI, and other respective symbols are as defied above.
  • the compound represented by the general formula (V) can be used at 1 to 3 mole equivalent based on the ketone represented by the general formula (II).
  • reaction solvent diethyl ether, tetrahydrofuran and the like.
  • reaction temperature is ⁇ 70 to 50° C.
  • reaction time is 0.5 to 24 hours.
  • the resulting compound represented by the general formula (I-c) can be isolated and purified by the known method (e.g. chromatography, recrystallization etc.).
  • R 13 is C 1-4 alkyl, and other respective symbols are as defined above.
  • Carboxylic acid represented by the general formula (VII) can be synthesized by hydrolyzing the compound represented by the general formula (VI).
  • Lithium hydroxide, sodium hydroxide or potassium hydroxide can be used at 1 to 5 mole equivalent based on the compound represented by the general formula (VI).
  • reaction solvent examples include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and they can be used alone or in combination.
  • reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 24 hours.
  • the resulting compound represented by the general formula (VII) can be isolated and purified by the known method (e.g. chromatography, recrystallization etc.).
  • An amide compound represented by the general formula (I-d) can be synthesized by condensing carboxylic acid represented by the general formula (VII) and an amine compound represented by the general formula (VIII) in the presence of a condensing agent.
  • the compound represented by the general formula (VIII) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (VII).
  • reaction solvent examples include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • the condensing agent examples include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyldiimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (VII).
  • 1-Hydroxybenzotriazole may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of the base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or in combination.
  • the base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (VII).
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-d) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • An alcohol represented by the general formula (IX) can be synthesized by the method described in Reference Examples 1 to 7 described later, and a method similar thereto.
  • a compound represented by the general formula (X) can be synthesized by condensing the alcohol represented by the general formula (IX) and phthalimide in the presence of an azo compound and a trivalent phosphorus compound.
  • the phthalimide can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (IX).
  • reaction solvent examples include tetrahydrofuran, diethyl ether, acetonitrile and the like.
  • azo compound examples include diethyl azodicarboxylate, diisopropyl azodicarboxylate and the like, and the azo compound can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (IX).
  • trivalent phosphorus compound examples include triphenylphosphine, tributylphosphine and the like, and the trivalent phosphorus compound can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (IX).
  • reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (X) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • An amine compound represented by the general formula (XI) can be synthesized by treating the compound represented by the general formula (XI) with hydrazine hydrate.
  • the hydrazine hydrate can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (X).
  • reaction solvent examples include methanol, ethanol, dichloromethane, N,N-dimethylformamide and the like.
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 24 hours.
  • the resulting compound represented by the general formula (XI) can be isolated and purified by the known means (e.g. chromatography, recrystalization etc.).
  • An amide compound represented by the general formula (I-e) can be synthesized by condensing the amine compound represented by the general formula (XII) with carboxylic acid represented by the general formula (X) in the presence of a condensing agent.
  • the compound represented by the general formula (X) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XII).
  • reaction solvent examples include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • the condensing agent examples include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XII).
  • 1-Hydroxybenzotriazole may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of the base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and they may be used alone, or in combination.
  • the base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XI).
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-e) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a compound represented by the general formula (I-f) can be synthesized by reacting the amine represented by the general formula (XI) with isocyanate represented by the general formula (XIII) or carbamate represented by (XIV):
  • R 14 is phenyl, or 4-nitrophenyl, and other respective symbols are as defined above.
  • the compound represented by the general formula (XIII) or (XIV) can be used at 0.5 to 3 mole equivalent based on the compound represented by the general formula (XI).
  • reaction solvent examples include methylene chloride, 1,2-dichloroethane, toluene, acetonitrile, tetrahydrofuran and the like.
  • amine such as triethylamine, diisopropylethylamine and the like can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XII).
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-f) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a compound represented by the general formula (XVII) can be synthesized by condensing the ketone represented by the general formula (II) with an organophosphorus compound represented by the general formula (XV) or (XVI) in the presence of a base.
  • the organophosphorus compound represented by the general formula (XV) or (XVI) can be used at 1 to 5 mole equivalent based on the compound represented by the general formula (II).
  • reaction solvent examples include tetrahyrofuran, diethyl ether, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, liquid ammonia and the like.
  • Examples of the base include lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, potassium tert-butoxide, n-butyllithium, lithiumhexamethyldisilazide, sodium hexaethyldisilazide, potassium hexamethyldisilazide, sodium amide and the like.
  • the base can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (II).
  • reaction temperature is ⁇ 70 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (XVII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Carboxylic acid represented by the general formula (XVIII) can be synthesized by hydrolyzing the compound represented by the general formula (XVII).
  • Lithium hydroxide, sodium hydroxide, potassium hydroxide or the like can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XVII).
  • reaction solvent examples include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or in combination.
  • reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 24 hours.
  • the resulting compound represented by the general formula (XVIII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • An amide compound represented by the general formula (I-g) can be synthesized by condensing carboxylic acid represented by the general formula (XVIII) with an amine compound represented by the general formula (XIX) in the presence of a condensing agent.
  • the compound represented by the general formula (XIX) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XVIII).
  • reaction solvent examples include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • the condensing agent examples include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyldiimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XVIII).
  • 1-Hydroxybenzotriazole may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of the base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or in combination.
  • the base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XVIII).
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-g) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a compound represented by the general formula (XX) can be synthesized by reducing the compound represented by the general formula (XVII) with hydrogen in the presence of a metal catalyst.
  • reaction solvent examples include methanol, ethanol, ethyl acetate, tetrahydrofuran, N,N-dimethylformamide and the like.
  • the metal catalyst examples include 5% palladium-carbon, 10% palladium-carbon, platinum oxide, chlorotris(triphenylphosphine)rhodium (I) and the like, and the metal catalyst can be used at 0.01 to 0.5 weight percent based on the compound represented by the general formula (VXII).
  • An example of a hydrogen pressure is 1 atm to 50 atm.
  • reaction temperature is 20° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (XX) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Carboxylic acid represented by the general formula (XXI) can be synthesized by hydrolyzing the compound represented by the general formula (XXI).
  • Lithium hydroxide, sodium hydroxide, potassium hydroxide, and the like can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XX).
  • reaction solvent examples include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or in combination.
  • reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 24 hours.
  • the resulting compound represented by the general formula (XXI) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • An amide compound represented by the general formula (I-h) can be synthesized by condensing carboxylic acid represented by the general formula (XXI) with an amine compound represented by the general formula (XIX) in the presence of a condensing agent.
  • the compound represented by the general formula (XIX) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXI).
  • reaction solvent examples include methylene chloride, tetrahydrofuran, N,N-dimetylformamide and the like.
  • the condensing agent examples include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonylimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXI).
  • 1-Hydroxybenzotriazole may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of the base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone or in combination.
  • the base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXI).
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-h) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • An alcohol represented by the general formula (XXII) can be synthesized by reducing a compound represented by the general formula (XVII-a) or (XX-a) in the presence of a reducing agent.
  • reaction solvent examples include diethyl ether, tetrahydrofuran, toluene, ethanol and the like, and these can be used alone, or in combination.
  • the reducing agent examples include sodium borohydride, lithium borohydride, lithium aluminum borohydride, diisobutyl aluminum hydride and the like, and the reducing agent can be used at 0.5 to 6 mole equivalent based on the compound represented by the general formula (XVII-a) or (XX-a).
  • reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (XXII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a compound represented by the general formula (XXIII) can be synthesized by condensing an alcohol represented by the general formula (XXII) with phthalimide in the presence of an azo compound and a trivalent phosphorus compound.
  • the phthalimide can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (XXII).
  • reaction solvent examples include tetrahydrofuran, diethyl ether, acetonitrile and the like.
  • azo compound examples include diethyl azodicarboxylate, diisopropyl azo dicarboxylate, and the like, and the azo compound can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (XXII).
  • trivalent phosphorus compound examples include triphenylphosphine, tributylphosphine and the like, and the trivalent phosphorus compound can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (XXII).
  • reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (XXIII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • An amine compound represented by the general formula (XXIV) can be synthesized by treating the compound represented by the general formula (XXIII) with hydrazine hydrate.
  • the hydrazine hydrate can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XXIII).
  • reaction solvent examples include methanol, ethanol, dichloromethane, N,N-dimethylformamide and the like.
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 24 hours.
  • the resulting compound represented by the general formula (XXIV) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • An amide compound represented by the general formula (I-i) can be synthesized by condensing the amine compound represented by the general formula (XXIV) with carboxylic acid represented by the general formula (XII) in the presence of a condensing agent.
  • the compound represented by the general formula (XII) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXIV).
  • reaction solvent examples include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • the condensing agent examples include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarobodiimide hydrochloride, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXIV).
  • 1-Hydroxybenzotriazole may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of the base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or in combination.
  • the base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXIV).
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-i) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a compound represented by the general formula (I-j) can be synthesized by reacting amine represented by the general formula (XXIV) with isocyanate represented by the general formula (XIII) or carbamate represented by (XIV):
  • the compound represented by the general formula (XIII) or (XIV) can be used at 0.5 to 3 mole equivalent based on the compound represented by the general formula (XXIV).
  • reaction solvent examples include methylene chloride, 1,2-dichloroethane, toluene, acetonitrile, tetrahydrofuran and the like.
  • amine such as triethylamine, diisopropylethylamine and the like can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXV).
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-j) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a compound represented by the general formula (XXV) can be synthesized by reacting the compound represented by the general formula (XXII) with a halogenating agent, alkylsulfonyl chloride or arylsulfonyl chloride.
  • reaction solvent examples include acetonitrile, methylene chloride, tetrahydrofuran, toluene, N,N-dimethylformamide and the like.
  • halogenating agent examples include carbon tetrachloride/triphenhylphosphine, carbon tetrabromide/triphenylphosphine, and carbon tetrachloride or carbon tetrabromide can be used at 0.5 to 4 mole equivalent, and triphenylphosphine can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXII).
  • alkylsulfonyl chloride and the arylsulfonyl chloride examples include methanesulfonyl chloride benzenesulfonyl chloride, toluenesulfonyl chloride and the like, and it can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXX).
  • triethylamine or the like can be used at 1 to 6 mole equivalent based on the compound represented by the general formula (XXII).
  • reaction temperature is 20° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (XXV) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a cyan compound represented by the general formula (XXVI) can be synthesized by reacting the compound represented by the general formula (XXV) with a cyanidating agent.
  • reaction solvent examples include methylene chloride, tetrahydrofulan, N,N-dimethylformamide, dimethyl sulfoxide and the like, and these can be used alone, or in combination.
  • cyanidating agent examples include sodium cyanide, potassium cyanide, tetrabutylammonium cyanide, tetramethylammonium cyanide and the like, and the cyanidating agent can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (XXV).
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (XXVI) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Carboxylic acid represented by the general formula (XXVII) can be synthesized by hydrolyzing the compound represented by the general formula (XXVI).
  • Sodium hydroxide, potassium hydroxide or the like can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XXVI).
  • reaction solvent examples include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or in combination.
  • reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 48 hours.
  • the resulting compound represented by the general formula (XXVII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • An amide compound represented by the general formula (I-k) can be synthesized by condensing carboxylic acid represented by the general formula (XXVII) with an amine compound represented by the general formula (XIX) in the presence of a condensing agent.
  • the compound represented by the general formula (XIX) can be used at 0.5 to 2 mole based on the compound represented by the general formula (XXVII).
  • reaction solvent examples include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • the condensing agent examples include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyldimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXVII). 1-Hydroxybenzotriazole or the like may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of a base include triethylamine, N-methylmorpholine, 4-dimethyl aminopyridine and the like, and they can be used alone, or by mixing.
  • the base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXVII).
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-k) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a compound represented by the general formula (XXVIII) can be synthesized by reacting the compound represented by the general formula (XXII) with an oxidizing agent.
  • reaction solvent examples include ethyl acetate, methylene chloride, dimethyl sulphoxide and the like.
  • oxidizing agent examples include 1-hydroxy-1,2-benziodooxol-3(1H)-one 1-oxide, 1,1-dihydro-1,1,1-triacetoxy-1,2-benziodooxol-3(1H)-one and the like, and the oxidizing agent can be used at 1 to 5 mole equivalent based on the compound represented by the general formula (XXII).
  • reaction temperature is 0 to 50° C.
  • reaction time is 0.5 to 24 hours.
  • the resulting compound represented by the general formula (XXVIII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a compound represented by the general formula (XXX) can be synthesized by condensing the compound represented by the general formula (XXVIII) with an organophosphorus compound represented by the general formula (XXIX) in the presence of a base.
  • organophosphorus compound represented by the general formula (XXIX) can be used at 1 to 5 mole equivalent based on the compound represented by the general formula (XXVIII).
  • reaction solvent examples include tetrahydrofuran, diethyl ether, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, liquid ammonia and the like.
  • Examples of the base include lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, potassium tert-butoxide, n-butyllithium, lithiumhexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, sodium amide and the like.
  • the base can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XXVIII).
  • reaction temperature is ⁇ 70 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (XXX) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Carboxylic acid represented by the general formula (XXXI) can be synthesized by hydrolyzing the compound represented by the general formula (XXX).
  • Lithium hydroxide, sodium hydroxide, potassium hydroxide or the like can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XXX).
  • reaction solvent examples include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or by mixing.
  • reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 24 hours.
  • the resulting compound represented by the general formula (XXXI) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • An amide compound represented by the general formula (I-l) can be synthesized by condensing the carboxylic acid represented by the general formula (XXXI) with an amine compound represented by the general formula (XIX) in the presence of a condensing agent.
  • the compound represented by the general formula (XIX) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXI).
  • reaction solvent examples include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • Examples of a condensing agent include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyl diimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent.
  • 1-Hydroxybenzotriazole or the like may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of a base include triethylamine, N-morpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or mixing.
  • the base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXXI).
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-l) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a compound represented by the general formula (XXXII) can be synthesized by the method described in Reference Examples 4 to 7 described later, and a method similar thereto.
  • a compound represented by the general formula (XXXIII) can be synthesized by condensing an alcohol represented by the general formula (XXXII) with phthalimide in the presence of an azo compound and a trivalent phosphorus compound.
  • Phthalimide can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (XXXII).
  • reaction solvent examples include tetrahydrofuran, diethyl ether, acetonitrile and the like.
  • azo compound examples include diethyl azo dicarboxylate, diisopropyl azo dicarboxylate and the like, and the azo compound can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (XXXII).
  • trivalent phosphorus compound examples include triphenylphosphine, tributylphosphine and the like, and the trivalent phosphorus compound can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (XXXII).
  • reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • An example of a reaciton time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (XXXIII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • An amine compound represented by the general formula (XXXIV) can be synthesized by treating the compound represented by the general formula (XXXIII) with a hydrazine hydrate.
  • the hydrazine hydrate can be used at 1.0 to 5 mole equivalent baased on the compound represented by the general formula (XXXIII).
  • Example of a reaction solvent include methanol, ethanol, dichloromethane, N,N-dimethylformamide and the like.
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 24 hours.
  • the resulting compound represented by the general formula (XXXIV) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • An amide compound represented by the general formula (I-m) can be synthesized by condensing an amine compound represented by the general formula (XXXIV) with carboxylic acid represented by the general formula (XXXV) in the presence of a condensing agent.
  • the compound represented by the general formula (XXXV) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXIV).
  • reaction solvent examples include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • the condensing agent examples include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXIV). 1-Hydroxybenzotriazole or the like may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of the base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone or by mixing.
  • the base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXXIV).
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-m) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • An amide compound represented by the general formula (XXXVI) can be synthesized by condensing carboxylic acid represented by the general formula (XVIII) with N,O-dimethylhydroxylamine hydrochloride in the presence of a condensing agent.
  • N,O-dimethylhydroxylamine hydrochloride can be used at 0.5 to 3 mole equivalent based on the compound represented by the general formula (XVIII).
  • reaction solvent examples include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like, and these can be used alone, or by mixing.
  • the condensing agent examples include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyldiimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (XVIII). 1-Hydroxybenzotriazole or the like may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of a base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these may be used alone, or by mixing.
  • the base can be used at 0.05 to 3 mole equivalent based on the compound represented by the general formula (XVIII).
  • reaction temperature is 0 to 80° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (XXXVI) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a compound represented by the general formula (I-n) can be synthesized by reacting the amide compound represented by the general formula (XXXVI) with an organometalic compound represented by the general formula (XXXVII).
  • the compound represented by the general formula (XXXVII) can be used at 1 to 3 mole equivalent based on the amide compound represented by the general formula (XXXVI).
  • reaction solvent examples include diethylether, tetrahydrofuran and the like.
  • reaction temperature is ⁇ 70 to 50° C.
  • reaction time is 0.5 to 24 hours.
  • the resulting compound represented by the general formula (I-n) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a compound represented by the general formula (I-o) can be synthesized by reducing the compound represented by the general formula (I-n) with hydrogen:
  • reaction solvent examples include methanol, ethanol, ethyl acetate, tetrahydrofuran, N,N-dimethylformamide and the like.
  • Examples of a metal catalyst include 5% palladium-carbon, 10% palladium-carbon, platinum oxide, chlorotris(triphenylphosphine)rehodium (I), and the metal catalyst can be used at 0.01 to 0.5 weight percent based on the compound represented by the general formula (I-n).
  • An example of a hydrogen pressure is 1 to 50 atm.
  • reaction temperature is 20° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the genral formula (I-o) can be isolated and purified by the known means (e.g. chlomatography, recrystallization etc.).
  • An oxime compound represented by the general formula (I-p) can be synthesized by reacting ketone represented by the general formula (I-n) or (I-o) with a compound represented by the general formula (XXXVIII):
  • the compound represented by the general formula (XXXVIII) can be used at 0.5 to 3 mole equivalent based on the ketone represented by the general formula (I-n) or (I-o). Hydrochloride or sulfate of the compound represented by the general formula (XXXVIII) may be used.
  • reaction solvent examples include methanol, ethanol, isopropanol, butanol, water and the like, and these can be used alone, or by mixing.
  • a base such as triethylamine, and a salt such as sodium acetate, potassium acetate and the like may be used at 0.5 to 5 mole equivalent based on the ketone represented by the general formula (I-n) or (I-o).
  • reaction temperature is 0 to 80° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-p) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • An alcohol represented by the general formula (I-q) can be synthesized by reducing the compound represented by the general formula (I-n) or (I-o) in the presence of a reducing agent:
  • reaction solvent examples include diethyl ether, tetrahydrofuran, toluene, ethanol and the like, and these can be used alone, or by mixing.
  • the reducing agent examples include sodium borohydride, lithium borohydride, lithium aluminum hydride, diisopropyl aluminum hydride and the like and the reducing agent can be used at 0.5 to 6 mole equivalent based on the compound represented by the general formula (I-n) or (I-o).
  • reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by general formula (I-q) can be isolated and purified by the known means (e.g. chromatography, a recrystallization etc.).
  • the compound represented by the general formula (XXXIX) can be synthesized by the method described in JP-A No. 62-258342, and a method similar thereto.
  • a compound represented by the general formula (XXXX) can be synthesized by condensing the compound represented by the general formula (II) and the organophosphorus compound represented by the general formula (XXXIX) in the presence of a base, followed by treatment with an acid.
  • organophosphorus compound represented by the general formula (XXXIX) can be used at 1 to 5 mole equivalent based on the compound represented by the general formula (II).
  • reaction solvent examples include tetrahydrofuran, diethyl ether, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, liquid ammonia and the like.
  • Examples of the base include lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, potassium tert-butoxide, n-butyllithium, lithiumhexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, sodium amide and the like.
  • the base can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (II).
  • reaction temperature is ⁇ 70 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • Examples of an acid used in treatment with an acid include p-toluenesulfonic acid, benzenesulfonic acid, hydrochloric acid, sulfuric acid and the like, and the acid can be used at 0.1 to 10 mole equivalent based on the compound represented by (II).
  • reaction solvent examples include methanol, ethanol, toluene, water and the like, and these can be used alone, or by mixing.
  • reaction temperature 20 to 100° C.
  • reaction time is 0.5 to 24 hours.
  • the resulting compound represented by the general formula (XXXX) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.)
  • Carboxylic acid represented by the general formula (XXXXI) can be synthesized by hydrolyzing the compound represented by the general formula (XXXX).
  • Lithium hydroxide, sodium hydroxide, potassium hydroxide or the like can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XXXX).
  • reaction solvent examples include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or by mixing.
  • reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 24 hours.
  • the resulting compound represented by the general formula (XXXXI) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • An amide compound represented by the general formula (I-r) can be synthesized by condencing carboxylic acid represented by the general formula (XXXXI) with an amine compound represented by the general formula (XIX) in the presence of a condensing agent.
  • the compound represented by the general formula (XIX) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXXI).
  • reaction solvent examples include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • the condensing agent examples include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyldiimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxyalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXXI). 1-Hydroxybenzotriazole or the like may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of the base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or by mixing.
  • the base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXXXI).
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-r) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • An alcohol represented by the general formula (XXXXII) can be synthesized by reducing the compound represented by the general formula (XXXX) in the presence of a reducing agent.
  • reaction solvent examples include diethyl ether, tetrahydrofuran, toluene, ethanol and the like, and these can be used alone, or by mixing.
  • reducing agent examples include sodium borohydride and the like, and the reducing agent can be used at 0.5 to 6 mole equivalent based on the compound represented by the general formula (XXXX).
  • reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (XXXXII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Carboxylic acid represented by the general formula (XXXXIII) can be synthesized by hydrolyzing the compound represented by the general formula (XXXXII).
  • Lithium hydroxide, sodium hydroxide, potassium hydroxide or the like can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XXXXII).
  • reaction solvent examples include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or by mixing.
  • reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 24 hours.
  • the resulting compound represented by the general formula (XXXXIII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • An amide compound represented by the general formula (I-s) can be synthesized by condensing carboxylic acid represented by the general formula (XXXXIII) with an amine compound represented by the general formula (XIX) in the presence of a condensing agent.
  • the compound represented by the general formula (XIX) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXXIII).
  • reaction solvent examples include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • the condensing agent examples include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyldiimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXXIII). 1-Hydroxybenzotriazole or the like may be used at 0.5 to 2 mole equivalent as a condensation assistant.
  • Examples of a base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or by mixing.
  • the base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXXXIII).
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-s) can be isolated and purified by the known means (e.g. chromatography, recrystallization).
  • a compound represented by the general formula (XXXXV) can be synthesized by reacting the compound represented by the general formula (XXXXII) and the compound represented by the general formula (XXXXIV) in the presence of a base.
  • the compound represented by the general formula (XXXXIV) can be used at 1 to 5 mole equivalent based on the compound represented by the general formula (XXXXII).
  • reaction solvent examples include tetrahydrofuran, diethyl ether, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide and the like.
  • Examples of the base include lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, potassium tert-butoxide, n-butyllithium, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide and the like.
  • the base can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XXXXII).
  • reaction temperature is ⁇ 70 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (XXXXV) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Carboxylic acid represented by the general formula (XXXXVI) can be synthesized by hydrolyzing the compound represented by the general formula (XXXXV).
  • Lithium hydroxide, sodium hydroxide, potassium hydroxide or the like can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XXXXV).
  • reaction solvent examples include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or by mixing.
  • reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 24 hours.
  • the resulting compound represented by the general formula (XXXXVI) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.)
  • An amide compound represented by the general formula (I-t) can be synthesized by condensing the carboxylic acid represented by the general formula (XXXXVI) with an amine compound represented by the general formula (XIX) in the presence of a condensing agent.
  • the compound represented by the general formula (XIX) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXXVI).
  • reaction solvent examples include methylene chloride, tetrahydrofuran, N,N-dimethylformamide etc.
  • the condensing agent examples include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyldiimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXXVI). 1-Hydroxybenzotriazole may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of a base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or by mixing.
  • the base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXXXVI).
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-t) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a compound represented by the general formula (XXXXVIII) can be synthesized by condensing the compound represented by the general formula (II) and the compound represented by the general formula (XXXXVII) in the presence of a base.
  • the compound represented by the general formula (XXXXVII) can be used at 1 to 5 mole equivalent based on the compound represented by the general formula (II).
  • reaction solvent examples include tetrahydrofuran, diethyl ether, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide and the like.
  • Examples of the base include sodium hydride, potassium hydride, sodium methoxide, potassium tert-butoxide, n-butyllithium, lithium diisopropylamine, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide and the like.
  • the base can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (II).
  • reaction temperature is ⁇ 100 to 20° C.
  • reaction time is 0.5 to 24 hours.
  • the resulting compound represented by the general formula (XXXXVIII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Carboxylic acid represented by the general formula (XXXXIX) can be synthesized by hydrolyzing the compound represented by the general formula (XXXXVIII).
  • Lithium hydroxide, sodium hydroxide, potassium hydroxide or the like can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XXXXVIII).
  • reaction solvent examples include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or by mixing.
  • reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 24 hours.
  • the compound represented by the resulting general formula (XXXXIX) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • An amide compound represented by the general formula (I-u) can be synthesized by condensing carboxylic acid represented by the general formula (XXXXIX) with an amine compound represented by the general formula (XIX) in the presence of a condensing agent.
  • the compound represented by the general formula (XIX) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXXIX).
  • reaction solvent examples include methylene chloride, tetrahydrofuran, N,N-dimethylformamide etc.
  • the condensing agent examples include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyldiimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXXIX). 1-Hydroxybenzotriazole may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of a base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or by mixing.
  • the base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXXXIX).
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-u) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a compound represented by the general formula (L) can be synthesized by treating the compound represented by the general formula (XVII-a) with a base.
  • a base such as lithium diisopropylamide, lithium hexamethyldisilazide, n-butyllithium, potassium tert-butoxide, 1,8-diazabicyclo[5.4.0]undec-7-ene and the like can be used at 0.1 to 10 mole equivalent based on the compound represented by the general formula (XVII-a).
  • reaction solvent examples include tetrahydrofuran, diethyl ether, toluene and the like.
  • reaction temperature is ⁇ 70 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (L) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Carboxylic acid represented by the general formula (L1) can be synthesized by hydrolyzing the compound represented by the general formula (L).
  • Lithium hydroxide, sodium hydroxide, potassium hydroxide or the like can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (L).
  • reaction solvent examples include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or by mixing.
  • reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 24 hours.
  • the resulting compound represented by the general formula (LI) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • An amide compound represented by the general formula (I-v) can be synthesized by condensing the carboxylic acid represented by the general formula (LI) with an amine compound represented by the general formula (XIX) in the presence of a condensing agent.
  • the compound represented by the general formula (XIX) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (LI).
  • reaction solvent examples include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • the condensing agent examples include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-2-ethylcarbodiimide hydrochloride, N,N′-carbonyldiimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like.
  • the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (LI).
  • 1-Hydroxybenzotriazole or the like may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of a base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or by mixing.
  • the base can be used as 0.05 to 2 mole equivalent based on the compound represented by the general formula (LI).
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-v) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a compound represented by the general formula (I-w) can be synthesized by condensing the aldehyde represented by the general formula (LII) with an organophosphorus compound represented by the general formula (LIII) or (LIV) in the presence of a base:
  • the compound represented by the general formula (XXXII) can be synthesized by the method described in Reference Example 10 described later, and a method similar thereto.
  • the organophosphorus compound represented by the general formula (LIII) and (LIV) can be synthesized by the method described in New Experimental Chemistry Course 14, Maruzen Co. Ltd., (1977), and a method similar thereto.
  • organophosphorus compound represented by the general formula (LIII) or (LIV) can be used at 1 to 5 mole equivalent based on the compound represented by the general formula (LII).
  • reaction solvent examples include tetrahydrofuran, diethyl ether, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, liquid ammonia and the like.
  • Examples of the base include lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, potassium tert-butoxide, n-butyllithium, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, sodium amide and the like.
  • the base can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (LII).
  • reaction temperature is ⁇ 70 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-w) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a compound represented by the general formula (I-x) can be synthesized by reducing the compound represented by the general formula (I-w) with hydrogen in the presence of a metal catalyst:
  • reaction solvent examples include methanol, ethanol, ethyl acetate, tetrahydrofuran, N,N-dimethylformamide and the like.
  • Examples of a metal catalyst include 5% palladium-carbon, 10% palladium-carbon, platinum oxide, chlorotris(triphenylphosphine)rohodium (I).
  • the metal catalyst can be used at 0.01 to 0.5 weight % based on the compound represented by the general formula (I-a).
  • An example of a hydrogen atom is 1 to 50 atm.
  • reaction temperature is 20° C. to a refluxing temperature of a solvent.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-x) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a compound represented by the general formula (I-y) can be synthesized by reductively condensing the compound represented by the general formula (II) and the compound represented by the general formula (LV):
  • the compound represented by the general formula (LV) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (II).
  • reaction solvent examples include 1,2-dichloroethane, tetrahydrofuran and the like.
  • reducing agent examples include sodium triacetoxyborohydride and the like, and the reducing agent can be used at 0.5 to 6 mole equivalent based on the general formula (II).
  • reaction temperature is 0 to 80° C.
  • acetic acid or the like as an acid can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (II).
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-y) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a compound represented by the general formula (LVIII) can be synthesized by condensing the compound represented by the general formula (LVI) and the compound represented by the general formula (LVII) in the presence of a base.
  • the compound represented by the general formula (LVII) can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (LVI).
  • reaction solvent examples include tetrahydrofuran, diethyl ether, acetonitrile, methylene chloride, chloroform, toluene, water and the like, and these can be used alone, or by mixing.
  • Examples of the base include sodium hydroxide, potassium hydroxide, sodium bicarbonate, sodium carbonate, potassium carbonate, sodium hydride, potassium hydride, triethylamine, morpholine, N-methylmorpholine and the like.
  • the base can be used at 1.0 to 5 mole based on the compound represented by the general formula (LVI).
  • reaction temperature is ⁇ 10 to 50° C.
  • reaction time is 0.5 to 24 hours.
  • the resulting compound represented by the general formula (LVIII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Carboxylic acid represented by the general formula (LIX) can be synthesized by hydrolyzing the compound represented by the general formula (LVIII).
  • Lithium hydroxide, sodium hydroxide, potassium hydroxide or the like can be used at 1.0 to 5 mole equivalent can be used based on the compound represented by the general formula (LVIII).
  • reaction solvent examples include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or by mixing.
  • reaction time is 0.5 to 24 hours.
  • the resulting compound represented by the general formula (LIX) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • An amide compound represented by the general formula (I-z) can be synthesized by condensing the carboxylic acid represented by the general formula (LIX) with an amide compound represented by the general formula (XIX) in the presence of a condensing agent.
  • the compound represented by the general formula (XIX) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (LIX).
  • reaction solvent examples include methylene chloride, tetrahydrofuran, N,N-dimethylformamide, N,N-dimethylacetamide, 1,3-dimethyl-2-imidazolidinone, N-methyl-2-pyrrolidone and the like.
  • the condensing agent examples include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyldiimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (LIX). 1-Hydroxybenzotriazole or the like may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of a base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or by mixing.
  • the base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (LIX).
  • reaction temperature is 0 to 100° C.
  • reaction time is 0.5 to 72 hours.
  • the resulting compound represented by the general formula (I-z) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • a 1 is the nitrogen-containing aromatic monocyclic group or the nitrogen-containing aromatic fused cyclic group having at least one of protected hydroxy and/or protected amino and, further, optionally substituted with other group, or the nitrogen-containing aromatic monocyclic group or the nitrogen-containing aromatic fused cyclic group containing —NH— in the ring, and in which other ring constituting atoms may be substituted with a substituent other than protected hydroxy and protected amino
  • the protecting group can be deprotected under the normally used reaction conditions (e.g. the method described in T. W. Green et al., Protective Groups in Organic Synthesis, Second Edition, John Wiley & Sons (1991)).
  • the present compound contains an optical isomer, a steric isomer, a positional isomer, and a rotational isomer, these are also included as the present compound, and can be obtained as a single product, respectively, by the known per se synthesizing procedure, and the separating procedure.
  • an optical isomer is present in the present compound
  • an optical isomer resolved from the compound is also included in the present compound.
  • the optical isomer can be produced by the known per se method. Specifically, an optical isomer is obtained by optically resolving a final racemate mixture using an optically active synthetic intermediate, or according to a conventional method.
  • the known per se method for example, a fractionation recrystallization method, a chiral column method, and a diastereomer method which are described in detail below, are used.
  • a salt is formed between a racemate and an optically active compound (e.g. (+)-mandelic acid), ( ⁇ )-mandelic acid, (+)-tartaric acid, ( ⁇ )-tartaric acid, (+)-1-phenethylamine, ( ⁇ )-1-phenethylamine, cinchonine, ( ⁇ )-cinchonidine, brucine etc.), this is separated by a fractionation recrystallization method and, if desired, a neutralization step is performed, thereby, a free optical isomar is obtained.
  • a method of separating a racemate or a salt thereof by applying it to a column for separating an optical isomar chiral column
  • optical isomers are separated by adding a mixture of optical isomers to a chiral column such as ENANTIO-OVM (manufactured by Tosoh Corporation) and CHIRAL series manufactured by Daicel, and developing the column with water, various buffers (e.g. phosphate buffer), or an organic solvent (e.g. ethanol, methanol, isopropanol, acetonitrile, trifluoroacetic acid, diethylamine, etc) alone or as a mixed solution.
  • a chiral column such as CP-Chirasil-Dex CB (manufactured by GL Sciences).
  • a method of converting a mixture of racemates into a mixture of diastereomers by a chemical reaction with an optically active reagent converting this into a single substance via a conventional separation means (e.g. fractionation recrystallization, chromatography method etc.), and cutting off an optically active reagent site by chemical treatment such as a hydrolysis reaction to obtain an optical isomer.
  • a conventional separation means e.g. fractionation recrystallization, chromatography method etc.
  • a hydrolysis reaction e.g.
  • MTPA [ ⁇ -methoxy- ⁇ -(trifluoromethyl)phenylacetic acid], ( ⁇ )-methoxyacetic acid etc.) to a condensation reaction.
  • diastereomers of an amide form and an ester form are obtained, respectively, by subjecting the compound and optically active amine or an alcohol reagent to a condensation reaction. Separated diastereomers are converted into optical isomers of the original compound by subjecting to acid hydrolysis or basic hydrolysis reaction.
  • a pharmaceutically acceptable salt can be used, and examples of the basic addition salt include alkali metal salts such as sodium salt, potassium salt etc.; alkaline earth metal salts such as calcium salt, magnesium salt etc.; ammonium salts; trimethylamine salt, triethylamine salt; aliphatic amine salts such as dicyclohexylamine salt, ethanolamine salt, diethanol amine salt, triethanolamine salt, procaine salt etc.; aralkylamine salts such as N,N-dibenzylethylenediamine etc.; heterocyclic aromatic amine salts such as pyridine salt, picoline salt, quinoline salt, isoquinoline salt etc.; quaternary ammonium salts such as tetramethylammonium salt, tetraethylammonium salt, benzyltrimethylammonium salt, benzyltriethylammonium salt, benzyltributylammmonium salt, methyl
  • the acid addition salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, carbonate, bicarbonate, perchlorate etc.; organic acid salts such as oxalate, acetate, propionate, lactate, maleate, fumarate, tartarate, malate, citrate, ascorbate etc.; sulfonates such as methanesulfonate, isethionate, benzenesulfonate, p-toluenesulfonate etc.; acidic amino acids such as aspartate, glutamate etc.
  • inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, carbonate, bicarbonate, perchlorate etc.
  • organic acid salts such as oxalate, acetate, propionate, lactate, maleate, fumarate, tartarate, malate, citrate, ascorbate etc.
  • the compound (I) may be a solvate of water, acetonitrile, acetone, ethyl acetate, methanol, ethanol and the like.
  • the solvation number of solvates of the present compound can usually vary depending on a synthesis method, a purification method and the crystallization condition, and for example, is in a range of 0.5 to 5 molecules per one molecule of the compound.
  • the following compounds are particularly preferable.
  • (CR a R b )w is (CH 2 ) 2 or (CH 2 ) 3
  • (CR c R d )t is CH 2 or CHMe
  • a compound in which a combination of A 1 , A 2 and X (A 1 , A 2 , X) is the following in the following formula (1) to (7), or a pharmaceutically acceptable salt, or a solvate thereof is also a preferable aspect of the present invention.
  • Ms represents methanesulfonyl
  • Me represents methyl
  • iPr isopropyl
  • (A 1 , A 2 , X) (a1, b1, X1), (a1, b1, X2), (a1, b1, X3), (a1, b1, X4), (a1, b1, X5), (a1, b1, X6), (a1, b1, X7), (a1, b1, X8), (a1, b1, X9), (a1, b1, X10), (a1, b1, X11), (a1, b1, X12), (a1, b1, X13), (a1, b1, X14), (a1, b1, X15), (a1, b1, X16), (a1, b1, X17), (a1, b1, X18), (a1, b2, X1), (a1, b2, X2), (a1, b2, X3), (a1, b2, X4), (a1, b2, X5), (a1, b2, X6), (a
  • the compound (I) Since the compound (I) has high affinity for the NMDA receptor, particularly, NR1/NR2B receptor, and has high subtype selectivity, and high selectivity for other receptor, it can be a medicament with the reduced side effect (e.g. influence on motion function).
  • the compound (I) also has an advantage that stability is high, oral absorbability is high, good bioavailability is exhibited, clearance is low, brain transferability is high, a half life is long, a non-protein binding rate is high, drug efficacy sustainability is high, and/or the liver enzyme inhibiting activity is low.
  • the compound (I) can be orally or parenterally administered to an animal including a human, as a medicament, particularly, as a preventive/remedy for various central diseases resulting from the NMDA receptor, particularly the NR1/NR2B receptor (e.g. cerebral stroke, cerebral infarction, brain trauma, chronic neurodegenerative diseases), or as an analgesic for cancer pain.
  • a dosage form include granules, tablets, capsules, injectables and the like.
  • various additives for example, excipients, disintegrating agents, binders, lubricants, stabilizers, coloring agents, and coating agents can be used.
  • a dose is different depending on an age, a weight and condition of a subject, and an administration method, and is not particularly limited, but usually, is about 1 mg to about 5000 mg in the case of oral administration, and about 0.1 mg to about 1000 mg in the case of parenteral administration, per adult one day.
  • a melting point described in the text is an uncorrected value.
  • 1 H-NMR was measured in a solvent of deuterium chloroform (CDCl 3 ) or deuterium dimethyl sulfoxide (DMSO-d 6 ) using tetramethylsilane as an internal standard.
  • a ⁇ value is expressed in ppm, and a binding constant (J) is expressed in Hz.
  • s means singlet
  • d means doublet
  • t means triplet
  • q means quartet
  • m means multiplet
  • br means broad
  • brs means broad singlet.
  • 2-Amino-5-nitrophenol 22 (22.20 g, 144 mmol) was dissolved in THF (100 ml), and the interior of the system was replaced with a nitrogen gas, and cooled with an ice bath.
  • a suspension (100 ml) of 1,1′-carbonyldiimidazole (28.03 g, 173 mmol) in THF was added in portions at 0 to 5° C., and the mixture was stirred at room temperature for 15 hours.
  • the solvent was distilled off under reduced pressure, water (144 ml) was added to the residue, this was cooled with an ice bath, 2 mol/L hydrochloric acid (144 ml, 288 mmol) was added, and the mixture was stirred at room temperature for 3 hours.
  • the precipitated solid was collected by filtration, washed with water, and dried to obtain Compound 23 (25.81 g, yield 99%).
  • the filtrate was extracted with chloroform-methanol (9:1 mixed solution), washed with water, and dried with anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform-methanol) to obtain 66 mg of a solid.
  • the resulting solids were combined, purified by silica gel column chromatography (chloroform-methanol) and, further, recrystallized from methanol to obtain Compound (I-7) (244 mg yield 56%).
  • the filtrate was extracted with chloroform, and dried with anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (acetonitrile-chloroform) and, further, recrystallized from acetone-isopropanol to obtain 121 mg of a solid.
  • the resulting solids were combined, purified by silica gel column chromatography (chloroform-methanol) and, further, recrystallizaed with ethyl acetate-methanol-isopropanol to obtain Compound (I-7) (153 mg, yield 27%).
  • 5-bromo-2-tert-butoxypyridine 400 mg, 1.74 mmol was dissolved in THF (8 ml), and the solution was cooled to ⁇ 78° C. with a dry ice-acetone bath.
  • a 2.6 M n-butyllitium-hexane solution (0.72 ml, 1.86 mmol) was added dropwise, the mixture was stirred at ⁇ 78° C. for 30 minutes, a solution of Compound 42 (415 mg, 1.16 mmol) in THF (4 ml) was added, and the mixture was stirred at ⁇ 78° C. for 1 hour, and at ⁇ 40° C. for 5 hours.
  • Ifenprodil which is an antagonist specific for a NR1/NR2B subtype receptor as a ligand, an experiment of competition between a receptor and a test compound was performed.
  • a brain was isolated after decapitation, and a cerebral cortex was fractionated.
  • the cerebral cortex was homogenized with a 20-fold amount of an ice-cooled 50 mM Tris/HCl buffer (pH 7.4), and the homogenate was centrifuged at 4° C. and 27,500 ⁇ g for 10 minutes. The resulting precipitate was suspended in the same buffer, and this was again centrifuged. This operation was repeated for three times, the resulting precipitate was suspended in a buffer, and this was stored at ⁇ 80° C. Immediately before an experiment, the frozen suspension was thawed at room temperature, this was centrifuged at 4° C.
  • DMSO as a solvent was used and, for measuring a non-specific binding amount, 100 ⁇ M Ifenprodil was used.
  • GBR-12909 was added in order to block binding of [ 3 H]-Ifenprodil to non-polyamine-sensitive site. After incubation, a bound form and a free form were separated using Whatman GF/C filter (manufactured by Whatman), and the filter was washed with 2.5 ml ice-cooled buffer four times. The filter was immersed in liquid scintillation (Cryasol I, manufactured by Nacalai tesque), and radioactivity (dpm) was measured with a liquid scintillation counter.
  • a binding inhibition rate (%) was obtained by the following equation, and a dose at which binding is inhibited 50% (IC 50 ) was calculated.
  • An IC 50 value of a test substance is shown in Table 42.
  • a formula of GBR-12909 (vanoxerine) is shown below.
  • Binding inhibition rate (%) 100 ⁇ [(binding amount in the presence of test compound ⁇ non-specific binding amount)/(total binding amount ⁇ non-specific binding amount)] ⁇ 100
  • the following compounds showed 1050 of 0.1 ⁇ M or lower.
  • a complementary DNA (c DNA) of a mouse NMDA receptor subunit was transiently introduced into a HEK293 cell and, after 1 day from introduction, change in a glutamic acid/glycine-induced intracelluar Ca amount was measured using a Ca ion reactive fluorescent coloring matter.
  • the HEK293 cell was cultured, and passaged using a modified Dulbecco's Eagle medium (DMEM, low glucose).
  • DMEM Dulbecco's Eagle medium
  • the HEK293 cell (20,000/well) was seeded on a 96-well plate, a NR1 subunit and a NR2B subunit of the NMDA receptor incorporated into the pcDNA3.1 plasmid were transiently introduced into a cell, and the subunits were co-expressed.
  • An introduction amount of a DNA was 0.025 ⁇ g in the case of the NR1 subunit, and 0.075 ⁇ g in the case of NR2B subunit per well.
  • cell death was inhibited using 50 ⁇ M of the NMDA receptor antagonist MK-801.
  • Krebs/Ringer/Hepes buffer (KRH, Ca: 5 mM) was used.
  • the NMDA receptor antagonist MK-801 was washed out using the KRH buffer, and a Ca ion indication fluorescent coloring matter Fluo-3/AM was made to be taken into the cell.
  • Ca ion influx was induced with 20 ⁇ M glutamic acid/2 ⁇ M glycine. Change in a fluorescent amount due to Ca ion influx into the cell was measured at excitation of 480 nm using a fluorescent imaging system FDSS 3000.
  • test compound exhibits the antagonism of the NMDA receptor, Ca ion influx into the cell is reduced, a fluorescent amount is reduced.
  • a Ca ion influx inhibition rate (%) was obtained by the following equation, and a dose at which influx is inhibited 50% (IC 50 ) was calculated.
  • An IC 50 value of the test substance is shown in Table 43.
  • Ca ion influx inhibition rate (%) 100 ⁇ [(fluorescent amount in the presence of test compound ⁇ background fluorescent amount)/(total fluorescent amount ⁇ background fluorescent)] ⁇ 100
  • the present invention is usefull as an analgesic and/or nerve protecting agent, which exhibits specific antagonism for a glutamic acid receptor of a central nervous cell, particularly, NR1/NR2B receptor being one kind of NMDA receptors, and has little side effect on motion function (abnormal sensation) and mental symptom (schizophrenia).

Abstract

It was found out that the nitrogen-containing heterocyclic derivative represented by the formula (I) specifically binds to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist.
A compound represented by:
Figure US20110172415A1-20110714-C00001
wherein Z is N or CR1, A1 is a nitrogen-containing aromatic monocyclic group which is optionally substituted, a nitrogen-containing aromatic fused cyclic group which is optionally substituted etc., A2 is an aromatic hydrocarbon cyclic group or an aromatic heterocyclic group, each optionally having a substituent, R1, R2, Ra, Rb, Rc and Rd are each independently hydrogen, hydroxy, etc., w is 2 or 3, t is 1 or 2, X is —(CR3R4)m-, —CO(CR3R4)n-, —CONR5(CR3R4)n- etc., m is an integer of 1 to 4, n is an integer of 0 to 4, R3 and R4 are each independently hydrogen, halogen, hydroxy etc., and R5 is hydrogen or lower alkyl,
or a pharmaceutically acceptable salt, or a solvate thereof.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a Division of application Ser. No. 12/278412, filed Aug. 6, 2008, which is a U.S. National Stage of PCT/JP2007/053166, filed Feb. 21, 2007, which applications are incorporated herein by reference.
  • TECHNICAL FIELD
  • The present invention relates to a nitrogen-containing heterocycle derivative useful as a drug such as an analgesic and the like, which exhibits the specific antagonism to a glutamic acid receptor of a central nervous cell, particularly, an NR1/NR2B receptor which is one kind of NMDA receptors and, preferably, has little side effect on the motion function (e.g.: abnormal sensation) and mental symptom (e.g.: schizophrenia).
  • BACKGROUND ART
  • An amino acid such as L-glutamic acid and L-aspartic acid is important as a neurotransmitter in a central nervous system for activating a nerve cell. However, excessive accumulation of these excitatory amino acids outside a cell is thought to cause loss of nerve and motion functions seen in various cerebro-neurological diseases such as Parkinson's disease, senile dementia, Huntington's chorea, and epilepsia, as well as at anoxia, ischemia, hypoglycemia state, or head or spinal cord damage.
  • It is known that the activity of the excitatory amino acid on a central nervous cell acts via a glutamic acid receptor present on a nerve cell, and a glutamic acid receptor antagonist is thought to be useful as a remedy for the aforementioned diseases and symptoms, and for example, as an anti-epileptic drug, a preventive for ischemic brain injury, or a drug for anti-Parkinsonism.
  • The NMDA receptor which is one kind of glutamic acid receptors is composed of two subunits of NR1 and NR2, and there are further 4 kinds (NR2A, 2B, 2C, 2D) of subfamilies in the NR2 subunit. It is said that the NR1/NR2A receptor is exclusively involved in memory formation or learning acquisition, and the NR1/NR2B receptor is involved in transmission of neurodegenerative cell death or pain at ischemia. Therefore, a drug exhibiting high affinity for the NR1/NR2B receptor has a high possibility that it becames an effective analgesic having little side effect.
  • Compounds similar to the present compounds are described in the Patent Literature 1 to 20 and non-Patent Literature 1, but the compound related to the present invention is described in none of them.
    • [Patent Literature 1]
    • International Publication WO 03/057688
    • [Patent Literature 2]
    • International Publication WO 02/068409
    • [Patent Literature 3]
    • International Publication WO 02/080928
    • [Patent Literature 4]
    • International Publication WO 02/40466
    • [Patent Literature 5]
    • Japanese Patent Appliction Laid-Open (JP-A) No. 11-147872
    • [Patent Literature 6]
    • JP-A No. 1-079151
    • [Patent Literature 7]
    • JP-A No. 2-169569
    • [Patent Literature 8]
    • International Publication WO 2003/076420
    • [Patent Literature 9]
    • International Publication WO 2003/010159
    • [Patent Literature 10]
    • International Publication WO 2006/010968
    • [Patent Literature 11]
    • International Publication WO 2006/010964
    • [Patent Literature 12]
    • International Publication WO 2003/053366
    • [Patent Literature 13]
    • International Publication WO 03/084948
    • [Patent Literature 14]
    • International Publication WO 2002/051806
    • [Patent Literature 15]
    • International Publication WO 2001/007436
    • [Patent Literature 16]
    • International Publication WO 86/00899
    • [Patent Literature 17]
    • Switzerland Patent Application Publication No. CH460016
    • [Patent Literature 18]
    • Switzerland Patent Application Publication No. CH460017
    • [Patent Literature 19]
    • U.S. Pat. No. 3,538,089
    • [Non-Patent Literature 1]
    • Farmaco 1989, vol. 44, No. 5, p. 227-255
    DISCLOSURE OF THE INVENTION Problems to be Solved in the Invention
  • An object of the present invention is to provide a NMDA receptor antagonist which is highly active and, more preferably, exhibits high affinity for a subtype, particularly a NR1/NR2B receptor, particularly an analgesic for cancer pain or the like.
  • Means to Solve the Problems
  • The present invention provides the following.
    • (1) A compound represented by the formula (I):
  • Figure US20110172415A1-20110714-C00002
  • wherein Z is N or CR1;
    • A1 is a nitrogen-containing aromatic monocyclic group which is optionally substituted, or a nitrogen-containing aromatic fused cyclic group which is optionally substituted,
    • the nitrogen-containing aromatic monocyclic group or the nitrogen-containing aromatic fused cyclic group satisfies at least one of the following conditions:
    • i) the group has at least one group selected from optionally substituted hydroxy, optionally protected amino and optionally substituted aminooxy, and
    • ii) the group contains —NH— in the ring;
    • A2 is an aromatic hydrocarbon cyclic group which is optionally substituted, or an aromatic heterocyclic group which is optionally substituted;
    • R1 and R2 are each independently hydrogen, hydroxy or lower alkyl, or R1 and R2 may be taken together to form a single bond;
    • Ra, Rb, Rc and Rd are each independently hydrogen or lower alkyl and, when there are a plurality of Ras, a plurality of Rbs, a plurality of Rcs or a plurality of Rds, they may be different from each other;
    • w is 2 or 3;
    • t is 0 or 2;
    • X is:
    • —(CR3R4)m-,
    • —CO(CR3R4)n-,
    • —(CR3R4)mCO—,
    • —CONR5(CR3R4)n-,
    • —NR5CO(CR3R4)n-,
    • —(CR3R4)mNR5CO—,
    • —NR5CONR6(CR3R4)n-,
    • —C(═N—OR7)(CR3R4)n-,
    • —(CR8R9)rO(CR3R4)n-,
    • —(CR8R9)rS(CR3R4)n-,
    • —(CR8R9)rSO(CR3R4)n-,
    • —(CR8R9)rSO2(CR3R4)n-,
    • —CR9═N—O(CR3R4)n-,
    • —C(═O)O(CR3R4)n-,
    • —(CR3R4)mC(═N—OR7)-,
    • —CH(OR8)(CR3R4)n-,
    • —(CR3R4)mCH(OR8)—,
    • —NR5COCO(CR3R4)n-,
    • —(CR3R4)mNR5COCO—,
    • —COCONR5(CR3R4)n-,
    • —NR5COCH(OR8)(CR3R4)n-,
    • —CH(OR8)(CR3R4)nNR5CO—,
    • —NR5(CR3R4)mCO—,
    • -A3-(CR3R4)n-,
    • —(CR3R4)m-A3-,
    • -A3-CR10═CR11(CR3R4)n-,
    • —CR10═CR11(CR3R4)n-A3-,
    • -A3-NR6(CR3R4)n-,
    • —(CR3R4)nNR6-A3- or
    • —NR6(CR3R4)m-A3-,
    • further, X may be
    • —CONR5(CR3R4)m-NR6—,
    • —(CR3R4)mCONR5—,
    • —(CR3R4)mNR5CONR6—,
    • —CO(CR3R4)mNR5—, or
    • -A3-(CR3R4)mNR6— when Z is CR1—;
    • m is an integer of 1 to 4;
    • n and r are an integer of 0 to 4;
    • A3 is an aromatic hydrocarbon cyclic group which is optionally substituted, an aromatic heterocyclic group which is optionally substituted, or a non-aromatic heterocyclic group which is optionally substituted;
    • R3 and R4 are each independently hydrogen, halogen, hydroxy, optionally substituted lower alkyl, or optionally substituted lower alkoky, when there are plurality of R3s and R4s, respectively, they may be different from each other;
    • R5, R6, R7, R8, R9, R10 and R11 are each independently hydrogen or lower alkyl, and
    • when m or n is 1 or more, R1 may be taken together with R3 on CR3R4 adjacent to a carbon atom to which R1 binds, to form a single bond, or a pharmaceutically acceptable salt, or a solvate thereof.
    • (1′) A compound represented by the formula (I):
  • Figure US20110172415A1-20110714-C00003
  • wherein Z is N or CR1;
    • A1 is a nitrogen-containing aromatic monocyclic group which is optionally substituted, or a nitrogen-containing aromatic fused cyclic group which is optionally substituted, the nitrogen-containing aromatic monocyclic group or the nitrogen-containing aromatic fused cyclic group satisfies at least one of the following conditions:
    • i) the group has at least one group selected from optionally protected hydroxy, optionally protected amino and optionally substituted aminooxy, and
    • ii) the group contains —NH— in the ring;
    • A2 is an aromatic hydrocarbon cyclic group which is optionally substituted or an aromatic heterocyclic group which is optionally substituted;
    • R1 and R2 are each independently hydrogen, hydroxy or lower alkyl, or R1 and R2 may be taken together to form a single bond;
    • Ra, Rb, Rc and Rd are each independently hydrogen or lower alkyl and, when there are a plurality of Ras, a plurality of Rbs, a plurality of Rcs or a plurality of Rds, they may be different, respectively;
    • w is 2 or 3;
    • t is 1 or 2;
    • X is —(CR3R4)m-, —CO(CR3R4)n-, —(CR3R4)nCO—, —CONR5(CR3R4)n-, —CONR5(CR3R4)m-NR6—, —(CR3R4)nCONR5—, —NR5CO(CR3R4)n-, —(CR3R4)nNR5CO—, —NR5CONR6(CR3R4)n-, —(CR3R4)nNR5CONR6—, —C(═N—OR7)(CR3R4)n-, —(CR8R9)rO(CR3R4)n-, —(CR8R9)rS(CR3R4)n-, —(CR8R9)rSO(CR3R4)n-, —(CR8R9)rSO2(CR3R4)n-, —CR9═N—O (CR3R4)n-, —C(═O)O(CR3R4)n-, —(CR3R4)nC(═N—OR7)—, —CH(OR8)(CR3R4)n-, —(CR3R4)nCH(OR8)—, —NR5COCO(CR3R4)n-, —(CR3R4)nNR5COCO—, —COCONR5(CR3R4)n-, —NR5COCH(OR8)(CR3R4)n-, —CH(OR8)(CR3R4)nNR5CO—, -A3-(CR3R4)n-, —(CR3R4)n-A3-, -A3-CR10═CR11(CR3R4)n-, —CR10═CR11(CR3R4)n-A3-, -A3-(CR3R4)nNR6—, -A3-NR6(CR3R4)n-, —(CR3R4)nNR6-A3- or —NR6(CR3R4)n-A3-;
    • m is an integer of 1 to 4;
    • n and r are an integer of 0 to 4;
    • A3 is an aromatic hydrocarbon cyclic group which is optionally substituted, an aromatic heterocyclic group which is optionally substituted, or a non-aromatic heterocyclic group which is optionally substituted;
    • R3 and R4 are each independently, hydrogen, halogen, hydroxy, optionally substituted lower alkyl, or optionally substituted lower alkoxy and, where there are a plurality of Ras and R4s, respectively, they may be different from each other;
    • R5, R6, R7, R8, R9, R10 and R11 are each independently hydrogen or lower alkyl;
    • when m or n is 1 or more, R1 may be take together with R3 on CR3R4 adjacent to a carbon atom to which R1 binds to form a single bond, or a pharmaceutically acceptable salt, or a solvate thereof.
    • (1″) a compound represented by the formula (I);
  • Figure US20110172415A1-20110714-C00004
  • wherein Z is N or CR1;
    • A1 is a nitrogen-containing aromatic monocyclic group having at least one of optionally protected hydroxy, optionally protected amino or optionally substituted aminooxy, and further optionally substituted with other group or a nitrogen-containing aromatic fused cyclic group having at least one of optionally protected hydroxy, optionally protected amino or optionally substituted aminooxy, and further optionally substituted with other group, or
    • a nitrogen-containing aromatic monocyclic group containing —NH— in the ring, in which other ring constituting atoms may be substituted with a substituent other than optionally protected hydroxy, optionally protected amino, and optionally substituted aminooxy or a nitrogen-containing aromatic fused cyclic group containing —NH— in the ring, in which other ring constituting atoms may be substituted with a substituent other than optionally protected hydroxy, optionally protected amino, and optionally substituted aminooxy;
    • A2 is an aromatic hydrocarbon group which is optionally substituted, or an aromatic heterocyclic group which is optionally substituted;
    • R1 and R2 are each independently hydrogen, hydroxy or lower alkyl, or R1 and R2 may be taken together to form a single bond;
    • Ra, Rb, Rc and Rd are each independently hydrogen or lower alkyl and, when there are a plurality of Ras, a plurality of Rbs, a plurality of Rcs, or a plurality of Rds, they may be different respectively;
    • w is 2 or 3;
    • t is 1 or 2;
    • X is —(CR3R4)m-, —CO(CR3R4)n-, —(CR3R4)nCO—, —CONR5(CR3R4)n-, —(CR3R4)nCONR5—, —NR5CO(CR3R4)n-, —(CR3R4)nNR5CO—, —NR5CONR6(CR3R4)n-, —(CR3R4)nNR5CONR6—, —C(═N—OR7)(CR3R4)n-, —(CR3R4)nC(═N—OR7)—, —CH(OR8)(CR3R4)n-, —(CR3R4)nCH(OR8)—, —NR5COCO(CR3R4)n-, —(CR3R4)nNR5COCO—, —COCONR5(CR3R4)n-, —NR5COCH(OR8)(CR3R4)n-, —CH(OR8)(CR3R4)nNR5CO—, -A3-(CR3R4)n-, —(CR3R4)n-A3-, -A3-CR10═CR11(CR3R4)n-, —CR10═CR11(CR3R4)n-A3, -A3-(CR3R4)nNR6— or —NR6(CR3R4)n-A3-;
    • m is an integer of 1 to 4;
    • n is an integer of 0 to 4;
    • A3 is:
  • Figure US20110172415A1-20110714-C00005
  • wherein a broken line indicates the presence or the absence of a bond and Rx is hydrogen or lower alkyl;
    • R3 and R4 are each independently hydrogen, halogen, hydroxy, optionally substituted lower alkyl, or optionally substituted lower alkoxy and, when there are a plurality of Ras and R4s, they may be different each other;
    • R5, R6, R7, R8, R9, R10 and R11 are each independently hydrogen or lower alkyl;
    • when m or n is 1 or more, R1 may be taken together with R3 on CR3R4 adjacent to carbon atom to which R1 binds, to form a single bond, or pharmaceutically acceptable salt, or a solvate thereof.
    • (1′″) A compound represented by the formula (I′):
  • Figure US20110172415A1-20110714-C00006
  • wherein Z is N or CR1;
    • A1 is a nitrogen-containing aromatic monocyclic group having at least one of optionally protected hydroxy, optionally protected amino or optionally substituted aminooxy, and further optionally substituted with other group or a nitrogen-containing aromatic fused cyclic group having at least one of optionally protected hydroxy, optionally protected amino or optionally substituted aminooxy, and further optionally substituted with other group, or
    • a nitrogen-containing aromatic monocyclic group containing —NH— in the ring, in which other ring constituting atoms may be substituted with a substituent other than optionally protected hydroxy, optionally protected amino and optionally substituted aminooxy or a nitrogen-containing aromatic fused cyclic group containing —NH— in the ring, in which other ring constituting atoms may be substituted with a substituent other than optionally protected hydroxy, optionally protected amino and optionally substituted aminooxy;
    • A2 is an aromatic hydrocarbon cyclic group which is optionally substituted, or an aromatic heterocyclic group which is optionally substituted;
    • R1 and R2 are each independently hydrogen, hydroxy or lower alkyl, or R1 and R2 may be taken together to form a single bond;
    • X is —(CR3R4)m-, —CO(CR3R4)n-, —(CR3R4)nCO—, —CONR5(CR3R4)n-, —(CR3R4)nCONR5—, —NR5CO(CR3R4)n-, —(CR3R4)nNR5CO—, —NR5CONR6(CR3R4)n-, —(CR3R4)nNR5CONR6—, —C(═N—OR7)(CR3R4)n-, —(CR3R4)nC(═N—OR7)−, —CH(OR8)(CR3R4)n-, —(CR3R4)nCH(OR8)—, —NR5COCO(CR3R4)n-, —(CR3R4)nNR5COCO—, —COCONR5(CR3R4)n-, —NR5COCH(OR8)(CR3R4)n-, —CH(OR8)(CR3R4)nNR5CO—, -A3-(CR3R4)n-, —(CR3R4)n-A3-, -A3-CR10═CR11(CR3R4)n-, -CR10═CR11(CR3R4)n-A3-, -A3-(CR3R4)nNR6— or —NR6(CR3R4)n-A3-;
    • m is an integer of 1 to 4;
    • n is an integer of 0 to 4;
    • A3 is
  • Figure US20110172415A1-20110714-C00007
  • wherein a broken line indicates the presence or the absence of a bond and Rx is hydrogen or lower alkyl;
    • R3 and R4 are each independently hydrogen, halogen, hydroxy, optionally substituted lower alkyl or optionally substituted lower alkoxy and, when there are a plurality of Ras and R4s, they may be different from each other, R5, R6, R7, R8, R9, R10 and R11 are each independently hydrogen or lower alkyl;
    • when m or n is 1 or more, R1 may be taken together with R3 on CR3R4 adjacent to carbon atom to which R1 binds, to form a single bond, or a pharmaceutically acceptable salt, or a solvate thereof.
    • (2) The compound according to (1), (1′) or (1″), wherein w is 2 or 3, and t is 1, or a pharmaceutically acceptable salt, or a solvate thereof.
    • (3) The compound according to (1), (1′), or (1″), (1′″) or (2), wherein X is —(CR3R4)m-, —CO(CR3R4)n-, —CONR5(CR3R4)n-, —(CR3R4)mCONR5—, —NR5CO(CR3R4)n-, —(CR3R4)mNR5CO—, —NR5CONR6(CR3R4)n-, —C(═N—OR7)(CR3R4)n-, —CH(OR8)(CR3R4)n-, —NR5COCO(CR3R4)n-, —NR5COCH(OR8)(CR3R4)n-, —NR5(CR3R4)mCO—, -A3-(CR3R4)n-, -A3-CR10═CR11(CR3R4)n- or -A3-(CR3R4)nNR6—, or a pharmaceutically acceptable salt, or a solvate thereof.
    • (4) The compound according to (1), (1′), (1″), (1′″), (2) or (3), wherein A1 is pyridyl substituted with at least hydroxy, quinolyl substituted with at least hydroxy, benzoxazolyl substituted with at least hydroxy, benzimidazolyl substituted with at least hydroxy, pyridyl substituted with at least optionally protected amino, imidazolyl in which ring constituting atoms other than —NH— may be substituted, pyrrolyl in which ring constituting atoms other than —NH— may be substituted, pyrazolyl in which ring constituting atoms other than —NH— may be substituted, benzpyrazolyl in which ring constituting atoms other than —NH— may be substituted, benzimidazolyl in which ring constituting atoms other than —NH— may be substituted, or indolyl in which ring constituting atoms other than —NH— may be substituted, or a pharmaceutically acceptable salt, or a solvate thereof.
    • (5) The compound according to (1), (1′), (1″), (1′″), (2) or (3), wherein A1 is:
  • Figure US20110172415A1-20110714-C00008
  • or a pharmaceutically acceptable salt, or a solvate thereof.
    • (6) The compound according to any one of (1) to (5), (1′), (1″) and (1′″), wherein X is —CO(CHR3)n-, —CONH(CHR3)n-, —NHCO(CHR3)n-, —NHCONH(CHR3)n-, —NHCOCO(CHR3)n- or —NR5(CR3R4)mCO— or a pharmaceutically acceptable salt, or a solvate thereof.
    • (7) The compound according to any one of (1) to (5), (1′), (1″) and (1′″), wherein X is —CO(CHR3)2—, —CONHCHR3—, —CONH(CHR3)2—, —NHCOCHR3—, —NHCO(CHR3)2—, —NHCONH—, —NHCOCO— or —NHCH2CO— or a pharmaceutically acceptable salt, or a solvate thereof.
    • (8) The compound according to any one of (1) to (7), (1′), (1″) and (1′″), wherein Z is CR1, R1 and R2 are each independently hydrogen or hydroxy, or R1 and R2 are taken together to form a single bond and, when m or n is 1 or more, R1 is taken together with R3 on CR3R4 adjacent to a carbon atom to which R1 binds, to form a single bond, or a pharmaceutically acceptable salt, or a solvate thereof.
    • (9) The compound according to any one of (1) to (7), (1′), (1″) and (1′″), wherein Z is N, or a pharmaceutically acceptable salt, or a solvate thereof.
    • (10) The compound according to any one of (1) to (9), (1), (1″) and (1′″), wherein A2 is phenyl optionally substituted with one or more groups selected from halogen, cyano, lower alkyl, halogeno lower alkyl, lower alkoxy and halogeno lower alkoxy or pyridyl optionally substituted with one or more groups selected from halogen, cyano, lower alkyl, halogeno lower alkyl, lower alkoxy and halogeno lower alkoxy, or a pharmaceutically acceptable salt, or a solvate thereof.
    • (11) The compound according to any one of (1) to (10), (1′), (1″) and (1′″), wherein A2 is para-substituted phenyl, meta and para-di-substituted phenyl or meta and para-tri-substituted phenyl(3,4,5-tri-substituted phenyl), or a pharmaceutically acceptable salt, or a solvate thereof.
    • (12) A pharmaceutical composition containing the compound according to any one of (1) to (11), (1′), (1″) and (1′″), or a pharmaceutically acceptable salt, or a solvate thereof.
    • (13) The pharmaceutical composition according to (12), which has the NMDA receptor antagonism.
    • (14) The pharmaceutical composition according to (13), which has the NR1/NR2B receptor antagonism.
    • (15) A method of alleviating pain, or a method of treating migraine, cerebral stroke, head trauma, Alzheimer's diseases, Parkinson's disease, tinnitus, epilepsia, Huntington's disease, motion disorder or alcoholism, comprising administering the compound as defined in any one of (1) to (11), (1′), (1″) and (1′″).
    • (16) Use of the compound as defined in any one of (1) to (11), (1′), (1″) and (1′″), for producing an analgesic, or a remedy for migraine, cerebral stroke, head trauma, Alzheimer's diseases, Parkinson's disease, tinnitus, epilepsia, Huntington's disease, motion disorder or alcoholism.
    EFFECT OF THE INVENTION
  • The present compound is not only used in treating neurodegeneration such as cerebral stroke and cerebral trauma, but also is useful as an analgesic (e.g. cancer pain analgesic) having little side effect.
  • BEST MODE FOR CARRYING OUT THE INVENTION
  • Herein, the “optionally protected hydoxy” includes, for example, hydroxy optionally protected with a protecting group selected from lower alkyl (methyl, tert-butyl etc.), aryl lower alkyl (triphenylmethyl, benzyl etc.), tri lower alkylsilyl (trimethylsilyl, tert-butyldimethylsilyl, triethylsilyl, triisopropylsilyl etc.), lower alkyldiarylsilyl (tert-butyldiphenylsilyl etc.), triaryl lower alkylsilyl (tribenzylsilyl etc.), lower alkoxy lower alkyl (methoxymethyl, 1-ethoxyethyl, 1-methyl-1-methoxymethyl etc.), lower alkoxy lower alkoxy lower alkyl (methoxyethoxymethyl etc.), lower alkylthio lower alkyl (methylthiomethyl etc.), tetrahydropyranyl (tetrahydropyran-2-yl, 4-methoxytetrahydropyran-4-yl etc.), tetrahydrothiopyranyl (tetrahydrothiopyran-2-yl etc.), tetrahydrofuranyl (tetrahydrofuran-2-yl etc.), tetrahydrothiofuranyl (tetrahydrothiofuran-2-yl etc.), aryl lower alkoxy lower alkyl (benzyloxymethyl etc.), lower alkylsulfonyl, arylsulfonyl, lower alkylarylsulfonyl (p-toluenesulfonyl etc.) and acyl. A preferable protecting group is lower alkyl, aryl lower alkyl or lower alkylsulfonyl.
  • The “optionally protected amino” includes, for example, amino optionally protected with a protecting group selected from lower alkoxycarbonyl (tert-butyloxycarbonyl etc.), lower alkenyloxycarbonyl (vinyloxycarbonyl, allyloxycarbonyl etc.), halogeno lower alkoxycarbonyl (2-iodinated ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl etc.), aryl lower alkoxycarbonyl (benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, phenyloxycarbonyl etc.), tri lower alkylsilyl (trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl etc.), diazo, acyl (formyl, acetyl, pivaloyl, benzoyl etc.), halogeno acyl (trifluoroacetyl etc.), lower alkylsulfonyl (methanesulfonyl etc.), halogeno lower alkylsulfonyl (trifluoroethanesulfonyl etc.), arylsulfonyl, lower alkylarylsulfonyl (toluenesulfonyl, 4-tert-butylbenzenesulfonyl etc.), aryl lower alkyl (triphenylmethyl etc.). A preferable protecting group is acyl or lower alkylsulfonyl.
  • Examples of a substituent of the “optionally substituted aminooxy” include lower alkyl and acyl.
  • The “nitrogen-containing aromatic monocyclic group” includes a 5- to 6-membered aromatic cyclic group having at least one N in the ring and, further, optionally having O or S, such as:
  • Figure US20110172415A1-20110714-C00009
  • The “nitrogen-containing aromatic fused cyclic group” includes:
    • a) a group in which one or two aromatic ring(s) or non-aromatic ring(s) (preferably, benzene ring or aromatic hetero ring” is (are) fused to a 5- to 6-membered aromatic cyclic group having at least one N in the ring and, further, optionally having O or S, and
    • b) a group in which one or two benzene ring(s) or aromatic hetero ring(s) is (are) fused to a 5- to 7-membered non-aromatic cyclic group having at least one N in the ring and, further, optionally having O or S, preferably a).
  • Examples include:
  • Figure US20110172415A1-20110714-C00010
    Figure US20110172415A1-20110714-C00011
  • A bond may be present on any ring.
  • The “nitrogen-containing aromatic monocyclic group which is optionally substituted, or nitrogen-containing aromatic fused cyclic group which is optionally substituted”, and the “nitrogen-containing aromatic monocyclic group or the nitrogen-containing aromatic fused cyclic group having at least one of optionally protected hydroxy, optionally protected amino or optionally substituted aminooxy and, further optionally substituted with other group” satisfying the condition of “i) having at least one group selected from optionally protected hydroxy, optionally protected amino and optionally substituted aminooxy” includes the “nitrogen-containing aromatic monocyclic group” having at least one group selected from optionally protected hydroxy, optionally protected amino and optionally substituted aminooxy on the ring and, further, optionally substituted with one or more groups selected from Substituent group α, and the “nitrogen-containing aromatic fused cyclic group” having at least one group selected from optionally protected hydroxy, optionally protected amino and optionally substituted aminooxy on the ring and, further, optionally substituted with one or more groups selected from Substituent group α.
  • Herein, the Substituent group α is a group consisting of halogen, lower alkyl, halogeno lower alkyl, lower alkoxy, halogeno lower alkoxy, acyl, acyloxy, lower alkylamino, carboxy, lower alkoxycarbonyl, cyano and nitro.
  • The “pyridyl substituted with at least hydroxy”, the “quinolyl substituted with at least hydroxy”, the “benzoxyazolyl substituted with at least hydroxy” and the “benzimidazolyl substituted with at least hydroxy” include pyridyl, quinolyl, benzoxazolyl and benzimidazolyl having at least one hydroxy as a substituent and, optionally substituted with 1 or more groups selected from Substituent group α, respectively. Examples are 6-hydroxypyridin-3-yl, 2-hydroxypyridin-3-yl, 6-hydroxy-4-methyl-pyridin-3-yl, 4-acetyl-2-hydroxy-benzoxazol-6-yl.
  • The “pyridyl substituted with at least optionally protected amino” includes pyridyl having at least one amino or protected amino as a substituent and, further, optionally substituted with 1 or more groups selected from Substituent group α.
  • The “nitrogen-containing aromatic monocyclic group which is optionally substituted, or the nitrogen-containing aromatic fused cyclic group which is optionally substituted” and the “nitrogen-containing aromatic monocyclic group or the nitrogen-containing aromatic fused cyclic group containing —NH— in the ring, and in which other ring constituting atoms may be substituted with a substituent other than optionally protected hydroxy, optionally protected amino and optionally substituted aminooxy” satisfying the condition of “ii) containing —NH— in the ring” includes groups containing a —NH— group in the ring among the “nitrogen-containing aromatic monocyclic group” and the “nitrogen-containing aromatic fused cyclic group”.
  • Examples are as follows:
  • Figure US20110172415A1-20110714-C00012
  • A bond may be present on any ring, and arbitrary ring constituting atoms other than —NH— may be substituted with one or more groups selected from Substituent group β.
  • Herein, Substituent group β is halogen, lower alkyl, halogeno lower alkyl, acyl, carboxy, lower alkoxycarbonyl, cyano and nitro.
  • The “imidazolyl in which ring constituting atoms other than —NH— may be substituted”, the “pyrrolyl in which ring constituting atoms other than —NH— may be substituted”, the “pyrazolyl in which ring constituting atoms other than —NH— may be substituted”, the “benzpyrazolyl in which ring constituting atoms other than —NH— may be substituted”, the “benzimidazolyl in which ring constituting atoms other than —NH— may be substituted” and the “indolyl in which ring constituting atoms other than —NH— may be substituted” include imidazolyl, pyrrolyl, pyrazolyl, benzpyrazolyl, benzimidazolyl and indolyl in which arbitrary ring constituting atoms other than —NH— may be substituted with 1 or more groups selected from Substituent group β, respectively.
  • The “aromatic hydrocarbon cyclic group” includes phenyl, naphthyl, phenanthryl and the like.
  • Examples of a substituent of the “aromatic hydrocarbon cyclic group which is optionally substituted” include halogen, hydroxy, lower alkyl, halogeno lower alkyl, lower alkoxy, halogeno lower alkoxy, lower alkylsulfonyloxy, halogeno lower alkylsulfonyloxy, acyl, acyloxy, amino, lower alkylamino, acylamino, nitro, cyano, carboxy, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, aromatic hydrocarbon cyclic group optionally substituted with 1 or more groups selected from Substituent group γ, arylthio optionally substituted with one or more groups selected from Substituent group γ, aryloxy optionally substituted with one or more groups selected from Substituent group γ, arylamino optionally substituted with one or more groups selected from Substituent group γ, arylsulfonyloxy optionally substituted with one or more groups selected from Substituent group γ.
  • Herein, the Substituent group γ is a group consisting of halogen, hydroxy, lower alkyl, halogeno lower alkyl, lower alkoxy, halogeno lower alkoxy, acyl, acyloxy, amino, lower alkylamino, acylamino, carboxy, lower alkoxycarbonyl, cyano and nitro.
  • A preferable example of the “aromatic hydrocarbon cyclic group which is optionally substituted” is phenyl substituted at a para-position or phenyl substituted at a meta-position and a para-position, and a substituent is preferably halogen and/or halogeno lower alkyl.
  • An aryl part of the “arylsulfonyl”, the “arylsulfonyloxy”, the “aryloxy”, the “arylthio”, the “arylamino”, the “aryl lower alkyl”, the “lower alkyldiarylsilyl”, the “triaryl lower alkylsilyl”, the “aryl lower alkoxy lower alkyl”, the “lower alkylarylsulfonyl”, or the “aryl lower alkoxycarbonyl” is the same as that of the “aromatic hydrocarbon cyclic group”. Preferable is phenyl.
  • The “aromatic heterocyclic group” includes a 5- to 6-membered aromatic monocyclic group containing 1 to 4 hetero atom(s) selected from the group consisting of N, O and S (e.g. pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, tetrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, thiadiazolyl, furyl and thienyl), and an aromatic fused cyclic group (e.g. indolyl, isoindolyl, indolizidinyl, benzimidazolyl, benzpyrazolyl, indazolyl, cinnolinyl, phthalazinyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzisothiazolyl, benzthiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl, triazolopyridyl, imidathiazolyl, pyrazinopyridazinyl, quinazolinyl, quinolyl, isoquinolyl, quinoxalinyl, purinyl, pteridinyl, naphthyridinyl and pyrazinopyridazinyl etc.).
  • The “non-aromatic heterocyclic group” include a 5- to 6-membered aromatic monocyclic group containing 1 to 4 hetero atom(s) selected from the group consisting of N, O and S (e.g. thiranyl, oxylanyl, azetidinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, tetrahydrofuryl, dihydrofuryl, oxazolinyl, oxazolidinyl, isoxazolinyl, isoxazolidinyl, oxadiazolinyl, oxathiolanyl, dioxolanyl, dioxolyl, tetrahydrothienyl, dihydrothienyl, thiazolinyl, thiazolidinyl, isothiazolinyl, isothiazolidinyl, tetrahydropyranyl, thianyl, piperidinyl, dioxanyl, piperadinyl, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, dihydropyridyl etc.).
  • Particularly, the “aromatic hydrocarbon cyclic group”, the “aromatic heterocyclic group” and the “non-aromatic heterocyclic group” in A3 include a divalent group of the “aromatic hydrocarbon cyclic group”, the “aromatic heterocyclic group” and the “non-aromatic heterocyclic group”. A bond may be present at any possible position and, specifically, examples include the following groups:
  • Figure US20110172415A1-20110714-C00013
  • wherein a broken line indicates the presence or the absence of the bond, and Rx is hydrogen or lower alkyl
  • A substituent of the “aromatic heterocyclic group which is optionally substituted” and the “non-aromatic heterocyclic group which is optionally substituted” is the same as that of the “aromatic hydrocarbon cyclic group which is optionally substituted”.
  • A preferable example of the “aromatic heterocyclic group which is optionally substituted” in A2 is optionally substituted pyridyl, and examples of a preferable substituent include halogen, halogeno lower alkyl, lower alkoxy, halogeno lower alkoxy and the like.
  • The “halogen” includes F, Cl, Br and I.
  • A lower alkyl part and a halogen part of the “halogeno lower alkyl”, the “halogeno lower alkoxy”, the “halogeno lower alkoxycarbonyl”, the “halogenoacyl”, “halogeno lower alkylsulfonyl”, and the “halogeno lower alkylsulfonyloxy” are the same as the “halogen”.
  • The “lower alkyl” includes a linear or branched alkyl of a carbon number of 1 to 10, preferably a carbon number of 1 to 6, further preferably a carbon number of 1 to 3, and examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl and n-decyl. Particularly preferable is methyl or ethyl.
  • Examples of a substituent of the “optionally substituted lower alkyl” include halogen, hydroxy, lower alkoxy, halogeno lower alkoxy, acyl, acyloxy, amino, lower alkylamino, acylamino, carboxy, lower alkoxycarbonyl, cyano, nitro and the like, and a preferable example of substituted lower alkyl is trihalogeno lower alkyl and the like.
  • A lower alkyl part of the “halogeno lower alkyl”, the “lower alkoxy lower alkyl”, the “lower alkoxy lower alkoxy lower alkyl”, the “lower alkylthio lower alkyl”, the “aryl lower alkoxy lower alkyl”, the “lower alkoxy”, the “halogeno lower alkoxy”, the “lower alkoxycarbonyl”, the “halogeno lower alkoxycarbonyl”, the “aryl lower alkoxycarbonyl”, the “lower alkylcarbamoyl”, the “lower alkylsulfonyl”, the “lower alkylarylsulfonyl”, the “lower alkylsulfonyloxy”, “halogeno lower alkylsulfonyl”, the “halogeno lower alkylsulfonyloxy”, the “lower alkylamino”, the “aryl lower alkyl”, the “tri lower alkkylsilyl”, the “lower alkyldiarylsilyl”, and the “triaryl lower alkylsilyl” is the same as the “lower alkyl”.
  • A substituent of the “optionally substituted lower alkoxy” is the same as the substituent of the “optionally substituted lower alkyl”.
  • The “lower alkenyl” includes a linear or branched alkenyl of a carbon number of 2 to 10, preferably a carbon number of 2 to 8, further preferably a carbon number of 3 to 6, having one or more double bonds at an arbitrary position. Specifically, examples include vinyl, allyl, propenyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl and decenyl.
  • A lower alkenyl part of the “lower alkenyloxycarbonyl” is the same as the “lower alkenyl”.
  • The “acyl” includes aliphatic acyl and aroyl of a carbon number of 1 to 7. Specifically, examples include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, pivaloyl, hexanoyl, acryloyl, propionyl, methacryloyl, crotonolyl and benzoyl.
  • An acyl part of the “acyloxy”, the “acylamino” and the “halogeno acyl” is the same as the “acyl”.
  • The case that “R1 and R2 are taken together to form a single bond” means that
  • Figure US20110172415A1-20110714-C00014
  • The case that “when m or n is 1 or more, R1 is taken together with R3 on CR3R4 adjacent to a carbon atom to which R1 binds” means that
  • Figure US20110172415A1-20110714-C00015
  • wherein Xa is —CO—, —CONR5—, —NR5CO—, —NR5CONR6—, —C(═N—OR7)—, —(CR8R9)rO—, —(CR8R9)rS—, —(CR8R9)rSO—, —(CR8R9)rSO2—, —CR9═N—O—, —C(═O)O—, —CH(OR8)—, —NR5COCO—, —COCONR5—, —NR5COCH(OR8)—, -A3-, -A3NR6— or -A3-CR10═CR11—, and other symbols are as defined above.
  • The present compound (I) is not limited to a specified isomer, but includes all possible isomers and racemates. For example, a tautomer is included as follows.
  • Figure US20110172415A1-20110714-C00016
  • A general method of synthesizing the present compound will be shown below, but the method is not limited to the present synthesizing method.
  • A Method: Synthesis of (I-a) from (II)
  • A compound represented by the general formula (I-a) can be synthesized by condensing ketone represented by the general formula (II) and an organophosphorus compound represented by the general formula (III) or (IV) in the presence of a base:
  • Figure US20110172415A1-20110714-C00017
  • wherein X1 is optionally substituted lower alkenylene, or -A3-(CR3R4)s, s is an integer of 0 to 3, Z is a chlorine atom or a bromine atom, a wave line indicates a cis or trans form, and other respective symbols are as defined above.
  • The ketone represented by the general formula (II) can be synthesized by the method described in Reference Examples 8 to 9 described later, and a method similar thereto. And, the organophosphorus compound represented by the general formula (III) and (IV) can be synthesized by the method described in New Experimental Chemistry Course 14, MARUZEN Co., Ltd (1977), or a method similar thereto.
  • The organophosphorus compound represented by the general formula (III) or (IV) can be used at 1 to 5 mole equivalent based on the compound represented by the general formula (II).
  • Examples of a reaction solvent include tetrahydrofuran, diethyl ether, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, liquid ammonia and the like.
  • Examples of the base include lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, potassium tert-butoxide, n-butyllithium, lithiumhexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, sodium amide and the like. The base can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (II).
  • An example of a reaction temperature is −70 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-a) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • B Method: Synthesis of (Pb) from (I-a)
  • A compound represented by the general formula (I-b) can be synthesized by reducing a compound represented by the general formula (I-a) with hydrogen in the presence of a metal catalyst:
  • Figure US20110172415A1-20110714-C00018
  • wherein each symbol is as defined above.
  • Examples of the reaction solvent include methanol, ethanol, ethyl acetate, tetrahydrofuran, N,N-dimethylformamide and the like.
  • Examples of the metal catalyst include 5% palladium-carbon, 10% palladium-carbon, platinum oxide, chlorotris(triphenylphosphine)rhodium (I). The metal catalyst can be used at 0.01 to 0.5 weight percent based on the compound represented by the general formula (I-a).
  • An example of a hydrogen pressure is 1 to 50 atm.
  • An example of a reaction temperature is 20° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-b) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • C Method: Synthesis of (I-c) from (II)
  • A compound represented by the general formula (I-c) can be synthesized by reacting the ketone represented by the general formula (II) with an organometallic compound represented by the general formula (V):
  • Figure US20110172415A1-20110714-C00019
  • wherein X2 is optionally substituted lower alkenylene, or -A3-(CR3R4)n, L1 is lithium, MgCl, MgBr or MgI, and other respective symbols are as defied above.
  • The compound represented by the general formula (V) can be used at 1 to 3 mole equivalent based on the ketone represented by the general formula (II).
  • An example of a reaction solvent is diethyl ether, tetrahydrofuran and the like.
  • An example of a reaction temperature is −70 to 50° C.
  • An example of a reaction time is 0.5 to 24 hours.
  • The resulting compound represented by the general formula (I-c) can be isolated and purified by the known method (e.g. chromatography, recrystallization etc.).
  • D Method: Synthesis of (I-d) from Compound (VI):
  • Figure US20110172415A1-20110714-C00020
  • wherein R13 is C1-4 alkyl, and other respective symbols are as defined above.
  • Compounds represented by the general formulas (VI) and (VII) can be synthesized by the method described in Reference Example 11 described later, and a method similar thereto.
  • Synthesis of (VII) from (VI)
  • Carboxylic acid represented by the general formula (VII) can be synthesized by hydrolyzing the compound represented by the general formula (VI).
  • Lithium hydroxide, sodium hydroxide or potassium hydroxide can be used at 1 to 5 mole equivalent based on the compound represented by the general formula (VI).
  • Examples of a reaction solvent include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and they can be used alone or in combination.
  • An example of a reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 24 hours.
  • The resulting compound represented by the general formula (VII) can be isolated and purified by the known method (e.g. chromatography, recrystallization etc.).
  • Synthesis of (I-d) from (VII)
  • An amide compound represented by the general formula (I-d) can be synthesized by condensing carboxylic acid represented by the general formula (VII) and an amine compound represented by the general formula (VIII) in the presence of a condensing agent.
  • The compound represented by the general formula (VIII) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (VII).
  • Examples of a reaction solvent include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • Examples of the condensing agent include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyldiimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (VII). 1-Hydroxybenzotriazole may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of the base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or in combination. The base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (VII).
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-d) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • E Method: Synthesis of (I-e) from Compound (VII):
  • Figure US20110172415A1-20110714-C00021
  • wherein respective symbols are as defined above.
  • An alcohol represented by the general formula (IX) can be synthesized by the method described in Reference Examples 1 to 7 described later, and a method similar thereto.
  • Synthesis of (X) from (IX)
  • A compound represented by the general formula (X) can be synthesized by condensing the alcohol represented by the general formula (IX) and phthalimide in the presence of an azo compound and a trivalent phosphorus compound.
  • The phthalimide can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (IX).
  • Examples of a reaction solvent include tetrahydrofuran, diethyl ether, acetonitrile and the like.
  • Examples of the azo compound include diethyl azodicarboxylate, diisopropyl azodicarboxylate and the like, and the azo compound can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (IX).
  • Examples of the trivalent phosphorus compound include triphenylphosphine, tributylphosphine and the like, and the trivalent phosphorus compound can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (IX).
  • An example of a reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (X) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (XI) from (X)
  • An amine compound represented by the general formula (XI) can be synthesized by treating the compound represented by the general formula (XI) with hydrazine hydrate.
  • The hydrazine hydrate can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (X).
  • Examples of the reaction solvent include methanol, ethanol, dichloromethane, N,N-dimethylformamide and the like.
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 24 hours.
  • The resulting compound represented by the general formula (XI) can be isolated and purified by the known means (e.g. chromatography, recrystalization etc.).
  • Synthesis of (I-e) from (XI)
  • An amide compound represented by the general formula (I-e) can be synthesized by condensing the amine compound represented by the general formula (XII) with carboxylic acid represented by the general formula (X) in the presence of a condensing agent.
  • The compound represented by the general formula (X) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XII).
  • Examples of a reaction solvent include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • Examples of the condensing agent include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XII). 1-Hydroxybenzotriazole may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of the base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and they may be used alone, or in combination. The base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XI).
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-e) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • F Method: Synthesis of (I-f) from Compound (XI)
  • A compound represented by the general formula (I-f) can be synthesized by reacting the amine represented by the general formula (XI) with isocyanate represented by the general formula (XIII) or carbamate represented by (XIV):
  • Figure US20110172415A1-20110714-C00022
  • wherein R14 is phenyl, or 4-nitrophenyl, and other respective symbols are as defined above.
  • The compound represented by the general formula (XIII) or (XIV) can be used at 0.5 to 3 mole equivalent based on the compound represented by the general formula (XI).
  • Examples of a reaction solvent include methylene chloride, 1,2-dichloroethane, toluene, acetonitrile, tetrahydrofuran and the like.
  • If necessary, amine such as triethylamine, diisopropylethylamine and the like can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XII).
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-f) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • G Method: Syntheis of (I-g) from Compound (II):
  • Figure US20110172415A1-20110714-C00023
  • wherein X3 is (CR3R4)s; other respective symbols are as defined above.
    Synthesis of (XVII) from (II)
  • A compound represented by the general formula (XVII) can be synthesized by condensing the ketone represented by the general formula (II) with an organophosphorus compound represented by the general formula (XV) or (XVI) in the presence of a base.
  • The organophosphorus compound represented by the general formula (XV) or (XVI) can be used at 1 to 5 mole equivalent based on the compound represented by the general formula (II).
  • Examples of a reaction solvent include tetrahyrofuran, diethyl ether, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, liquid ammonia and the like.
  • Examples of the base include lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, potassium tert-butoxide, n-butyllithium, lithiumhexamethyldisilazide, sodium hexaethyldisilazide, potassium hexamethyldisilazide, sodium amide and the like. The base can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (II).
  • An example of a reaction temperature is −70 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (XVII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (XVIII) from (XVII)
  • Carboxylic acid represented by the general formula (XVIII) can be synthesized by hydrolyzing the compound represented by the general formula (XVII).
  • Lithium hydroxide, sodium hydroxide, potassium hydroxide or the like can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XVII).
  • Examples of a reaction solvent include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or in combination.
  • An example of a reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 24 hours.
  • The resulting compound represented by the general formula (XVIII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (I-g) from (XVIII)
  • An amide compound represented by the general formula (I-g) can be synthesized by condensing carboxylic acid represented by the general formula (XVIII) with an amine compound represented by the general formula (XIX) in the presence of a condensing agent.
  • The compound represented by the general formula (XIX) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XVIII).
  • Examples of the reaction solvent include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • Examples of the condensing agent include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyldiimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XVIII). 1-Hydroxybenzotriazole may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of the base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or in combination. The base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XVIII).
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-g) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • H Method: Synthesis of (I-h) from Compound (XVII):
  • Figure US20110172415A1-20110714-C00024
  • wherein respective symbols are as defined above.
    Synthesis of (XX) from (XVII)
  • A compound represented by the general formula (XX) can be synthesized by reducing the compound represented by the general formula (XVII) with hydrogen in the presence of a metal catalyst.
  • Examples of a reaction solvent include methanol, ethanol, ethyl acetate, tetrahydrofuran, N,N-dimethylformamide and the like.
  • Examples of the metal catalyst include 5% palladium-carbon, 10% palladium-carbon, platinum oxide, chlorotris(triphenylphosphine)rhodium (I) and the like, and the metal catalyst can be used at 0.01 to 0.5 weight percent based on the compound represented by the general formula (VXII).
  • An example of a hydrogen pressure is 1 atm to 50 atm.
  • An example of a reaction temperature is 20° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (XX) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (XXI) from (XX)
  • Carboxylic acid represented by the general formula (XXI) can be synthesized by hydrolyzing the compound represented by the general formula (XXI).
  • Lithium hydroxide, sodium hydroxide, potassium hydroxide, and the like can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XX).
  • Examples of a reaction solvent include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or in combination.
  • An example of a reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 24 hours.
  • The resulting compound represented by the general formula (XXI) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (I-h) from (XXI)
  • An amide compound represented by the general formula (I-h) can be synthesized by condensing carboxylic acid represented by the general formula (XXI) with an amine compound represented by the general formula (XIX) in the presence of a condensing agent.
  • The compound represented by the general formula (XIX) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXI).
  • Examples of a reaction solvent include methylene chloride, tetrahydrofuran, N,N-dimetylformamide and the like.
  • Examples of the condensing agent include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonylimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXI). 1-Hydroxybenzotriazole may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of the base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone or in combination. The base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXI).
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-h) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • I Method: Synthesis of (I-i) from Compound (XVII-a) or (XX-a):
  • Figure US20110172415A1-20110714-C00025
  • wherein X4 is (CR3R4)v, v is an integer of 0 to 2, a broken line indicates the presence or the absence of a bond, and other symbols are as defined above.
    Synthesis of (XXII) from (XVII-a) or (XX-a)
  • An alcohol represented by the general formula (XXII) can be synthesized by reducing a compound represented by the general formula (XVII-a) or (XX-a) in the presence of a reducing agent.
  • Examples of a reaction solvent include diethyl ether, tetrahydrofuran, toluene, ethanol and the like, and these can be used alone, or in combination.
  • Examples of the reducing agent include sodium borohydride, lithium borohydride, lithium aluminum borohydride, diisobutyl aluminum hydride and the like, and the reducing agent can be used at 0.5 to 6 mole equivalent based on the compound represented by the general formula (XVII-a) or (XX-a).
  • An example of a reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (XXII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (XXIII) from (XXII)
  • A compound represented by the general formula (XXIII) can be synthesized by condensing an alcohol represented by the general formula (XXII) with phthalimide in the presence of an azo compound and a trivalent phosphorus compound.
  • The phthalimide can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (XXII).
  • Examples of a reaction solvent include tetrahydrofuran, diethyl ether, acetonitrile and the like.
  • Examples of the azo compound include diethyl azodicarboxylate, diisopropyl azo dicarboxylate, and the like, and the azo compound can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (XXII).
  • Examples of the trivalent phosphorus compound include triphenylphosphine, tributylphosphine and the like, and the trivalent phosphorus compound can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (XXII).
  • An example of a reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (XXIII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (XXIV) from (XXIII)
  • An amine compound represented by the general formula (XXIV) can be synthesized by treating the compound represented by the general formula (XXIII) with hydrazine hydrate.
  • The hydrazine hydrate can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XXIII).
  • Examples of a reaction solvent include methanol, ethanol, dichloromethane, N,N-dimethylformamide and the like.
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 24 hours.
  • The resulting compound represented by the general formula (XXIV) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (I-i) from (XXIV)
  • An amide compound represented by the general formula (I-i) can be synthesized by condensing the amine compound represented by the general formula (XXIV) with carboxylic acid represented by the general formula (XII) in the presence of a condensing agent.
  • The compound represented by the general formula (XII) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXIV).
  • Examples of a reaction solvent include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • Examples of the condensing agent include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarobodiimide hydrochloride, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXIV). 1-Hydroxybenzotriazole may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of the base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or in combination. The base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXIV).
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-i) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • J Method: Synthesis of (I-j) from Compound (XXIV)
  • A compound represented by the general formula (I-j) can be synthesized by reacting amine represented by the general formula (XXIV) with isocyanate represented by the general formula (XIII) or carbamate represented by (XIV):
  • Figure US20110172415A1-20110714-C00026
  • wherein respective symbols are as defined above.
  • The compound represented by the general formula (XIII) or (XIV) can be used at 0.5 to 3 mole equivalent based on the compound represented by the general formula (XXIV).
  • Examples of a reaction solvent include methylene chloride, 1,2-dichloroethane, toluene, acetonitrile, tetrahydrofuran and the like.
  • If necessary, amine such as triethylamine, diisopropylethylamine and the like can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXV).
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-j) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • K Method: Synthesis of (I-k) from Compound (XXII):
  • Figure US20110172415A1-20110714-C00027
  • wherein L2 is a halogen atom, C1-4 alkylsulfonyloxy, C6-9 alylsulfonyloxy, and other respective symbols are as defined above.
    Synthesis of (XXV) from (XXII)
  • A compound represented by the general formula (XXV) can be synthesized by reacting the compound represented by the general formula (XXII) with a halogenating agent, alkylsulfonyl chloride or arylsulfonyl chloride.
  • Examples of a reaction solvent include acetonitrile, methylene chloride, tetrahydrofuran, toluene, N,N-dimethylformamide and the like.
  • Examples of the halogenating agent include carbon tetrachloride/triphenhylphosphine, carbon tetrabromide/triphenylphosphine, and carbon tetrachloride or carbon tetrabromide can be used at 0.5 to 4 mole equivalent, and triphenylphosphine can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXII).
  • Examples of the alkylsulfonyl chloride and the arylsulfonyl chloride include methanesulfonyl chloride benzenesulfonyl chloride, toluenesulfonyl chloride and the like, and it can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXX). Thereupon, as the base, triethylamine or the like can be used at 1 to 6 mole equivalent based on the compound represented by the general formula (XXII).
  • An example of a reaction temperature is 20° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (XXV) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (XXVI) from (XXV)
  • A cyan compound represented by the general formula (XXVI) can be synthesized by reacting the compound represented by the general formula (XXV) with a cyanidating agent.
  • Examples of a reaction solvent include methylene chloride, tetrahydrofulan, N,N-dimethylformamide, dimethyl sulfoxide and the like, and these can be used alone, or in combination.
  • Examples of the cyanidating agent include sodium cyanide, potassium cyanide, tetrabutylammonium cyanide, tetramethylammonium cyanide and the like, and the cyanidating agent can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (XXV).
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (XXVI) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (XXVII) from (XXVI)
  • Carboxylic acid represented by the general formula (XXVII) can be synthesized by hydrolyzing the compound represented by the general formula (XXVI).
  • Sodium hydroxide, potassium hydroxide or the like can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XXVI).
  • Examples of a reaction solvent include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or in combination.
  • An example of a reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 48 hours.
  • The resulting compound represented by the general formula (XXVII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (I-k) from (XXVII)
  • An amide compound represented by the general formula (I-k) can be synthesized by condensing carboxylic acid represented by the general formula (XXVII) with an amine compound represented by the general formula (XIX) in the presence of a condensing agent.
  • The compound represented by the general formula (XIX) can be used at 0.5 to 2 mole based on the compound represented by the general formula (XXVII).
  • Examples of a reaction solvent include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • Examples of the condensing agent include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyldimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXVII). 1-Hydroxybenzotriazole or the like may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of a base include triethylamine, N-methylmorpholine, 4-dimethyl aminopyridine and the like, and they can be used alone, or by mixing. The base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXVII).
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-k) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • L Method: Synthesis of (I-l) from Compound (XXII):
  • Figure US20110172415A1-20110714-C00028
  • wherein respective symbols are as defined above.
    Synthesis of (XXVIII) from (XXII)
  • A compound represented by the general formula (XXVIII) can be synthesized by reacting the compound represented by the general formula (XXII) with an oxidizing agent.
  • Examples of a reaction solvent include ethyl acetate, methylene chloride, dimethyl sulphoxide and the like.
  • Examples of the oxidizing agent include 1-hydroxy-1,2-benziodooxol-3(1H)-one 1-oxide, 1,1-dihydro-1,1,1-triacetoxy-1,2-benziodooxol-3(1H)-one and the like, and the oxidizing agent can be used at 1 to 5 mole equivalent based on the compound represented by the general formula (XXII).
  • An example of a reaction temperature is 0 to 50° C.
  • An example of a reaction time is 0.5 to 24 hours.
  • The resulting compound represented by the general formula (XXVIII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (XXX) from (XXVIII)
  • A compound represented by the general formula (XXX) can be synthesized by condensing the compound represented by the general formula (XXVIII) with an organophosphorus compound represented by the general formula (XXIX) in the presence of a base.
  • The organophosphorus compound represented by the general formula (XXIX) can be used at 1 to 5 mole equivalent based on the compound represented by the general formula (XXVIII).
  • Examples of a reaction solvent include tetrahydrofuran, diethyl ether, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, liquid ammonia and the like.
  • Examples of the base include lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, potassium tert-butoxide, n-butyllithium, lithiumhexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, sodium amide and the like. The base can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XXVIII).
  • An example of a reaction temperature is −70 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (XXX) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (XXXI) from (XXX)
  • Carboxylic acid represented by the general formula (XXXI) can be synthesized by hydrolyzing the compound represented by the general formula (XXX).
  • Lithium hydroxide, sodium hydroxide, potassium hydroxide or the like can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XXX).
  • Examples of a reaction solvent include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or by mixing.
  • An example of a reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 24 hours.
  • The resulting compound represented by the general formula (XXXI) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (I-l) from (XXXI)
  • An amide compound represented by the general formula (I-l) can be synthesized by condensing the carboxylic acid represented by the general formula (XXXI) with an amine compound represented by the general formula (XIX) in the presence of a condensing agent.
  • The compound represented by the general formula (XIX) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXI).
  • Examples of a reaction solvent include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • Examples of a condensing agent include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyl diimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent. 1-Hydroxybenzotriazole or the like may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of a base include triethylamine, N-morpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or mixing. The base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXXI).
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-l) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • M Method: Synthesis of (I-m) from Compound (XXXII):
  • Figure US20110172415A1-20110714-C00029
  • wherein respecting symbols are as defined above.
  • A compound represented by the general formula (XXXII) can be synthesized by the method described in Reference Examples 4 to 7 described later, and a method similar thereto.
  • Synthesis of (XXXIII) from (XXXII)
  • A compound represented by the general formula (XXXIII) can be synthesized by condensing an alcohol represented by the general formula (XXXII) with phthalimide in the presence of an azo compound and a trivalent phosphorus compound.
  • Phthalimide can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (XXXII).
  • Examples of a reaction solvent include tetrahydrofuran, diethyl ether, acetonitrile and the like.
  • Examples of the azo compound include diethyl azo dicarboxylate, diisopropyl azo dicarboxylate and the like, and the azo compound can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (XXXII).
  • Examples of the trivalent phosphorus compound include triphenylphosphine, tributylphosphine and the like, and the trivalent phosphorus compound can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (XXXII).
  • An example of a reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • An example of a reaciton time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (XXXIII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (XXXIV) from (XXXIII)
  • An amine compound represented by the general formula (XXXIV) can be synthesized by treating the compound represented by the general formula (XXXIII) with a hydrazine hydrate.
  • The hydrazine hydrate can be used at 1.0 to 5 mole equivalent baased on the compound represented by the general formula (XXXIII).
  • Example of a reaction solvent include methanol, ethanol, dichloromethane, N,N-dimethylformamide and the like.
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 24 hours.
  • The resulting compound represented by the general formula (XXXIV) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (I-m) from (XXXIV)
  • An amide compound represented by the general formula (I-m) can be synthesized by condensing an amine compound represented by the general formula (XXXIV) with carboxylic acid represented by the general formula (XXXV) in the presence of a condensing agent.
  • The compound represented by the general formula (XXXV) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXIV).
  • Examples of a reaction solvent include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • Examples of the condensing agent include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXIV). 1-Hydroxybenzotriazole or the like may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of the base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone or by mixing. The base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXXIV).
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-m) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • N Method: Synthesis of (I-n) from Compound (XVIII):
  • Figure US20110172415A1-20110714-C00030
  • wherein respective symbols are as defined above.
    Synthesis of (XXXVI) from (XVIII)
  • An amide compound represented by the general formula (XXXVI) can be synthesized by condensing carboxylic acid represented by the general formula (XVIII) with N,O-dimethylhydroxylamine hydrochloride in the presence of a condensing agent.
  • N,O-dimethylhydroxylamine hydrochloride can be used at 0.5 to 3 mole equivalent based on the compound represented by the general formula (XVIII).
  • Examples of a reaction solvent include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like, and these can be used alone, or by mixing.
  • Examples of the condensing agent include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyldiimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (XVIII). 1-Hydroxybenzotriazole or the like may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of a base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these may be used alone, or by mixing. The base can be used at 0.05 to 3 mole equivalent based on the compound represented by the general formula (XVIII).
  • An example of a reaction temperature is 0 to 80° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (XXXVI) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (I-n) from (XXXVI)
  • A compound represented by the general formula (I-n) can be synthesized by reacting the amide compound represented by the general formula (XXXVI) with an organometalic compound represented by the general formula (XXXVII).
  • The compound represented by the general formula (XXXVII) can be used at 1 to 3 mole equivalent based on the amide compound represented by the general formula (XXXVI).
  • Examples of a reaction solvent include diethylether, tetrahydrofuran and the like.
  • An example of a reaction temperature is −70 to 50° C.
  • An example of a reaction time is 0.5 to 24 hours.
  • The resulting compound represented by the general formula (I-n) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • O Method: Synthesis of (I-o) from (I-n)
  • A compound represented by the general formula (I-o) can be synthesized by reducing the compound represented by the general formula (I-n) with hydrogen:
  • Figure US20110172415A1-20110714-C00031
  • wherein respective symbols are as defined above.
  • Examples of a reaction solvent include methanol, ethanol, ethyl acetate, tetrahydrofuran, N,N-dimethylformamide and the like.
  • Examples of a metal catalyst include 5% palladium-carbon, 10% palladium-carbon, platinum oxide, chlorotris(triphenylphosphine)rehodium (I), and the metal catalyst can be used at 0.01 to 0.5 weight percent based on the compound represented by the general formula (I-n).
  • An example of a hydrogen pressure is 1 to 50 atm.
  • An example of a reaction temperature is 20° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the genral formula (I-o) can be isolated and purified by the known means (e.g. chlomatography, recrystallization etc.).
  • P Method: Synthesis of (I-p) from Compound (I-n) or (I-o)
  • An oxime compound represented by the general formula (I-p) can be synthesized by reacting ketone represented by the general formula (I-n) or (I-o) with a compound represented by the general formula (XXXVIII):
  • Figure US20110172415A1-20110714-C00032
  • wherein respective symbols are as defined above.
  • The compound represented by the general formula (XXXVIII) can be used at 0.5 to 3 mole equivalent based on the ketone represented by the general formula (I-n) or (I-o). Hydrochloride or sulfate of the compound represented by the general formula (XXXVIII) may be used.
  • Examples of a reaction solvent include methanol, ethanol, isopropanol, butanol, water and the like, and these can be used alone, or by mixing.
  • A base such as triethylamine, and a salt such as sodium acetate, potassium acetate and the like may be used at 0.5 to 5 mole equivalent based on the ketone represented by the general formula (I-n) or (I-o).
  • An example of a reaction temperature is 0 to 80° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-p) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Q Method: Synthesis of (I-q) from Compound (I-n) or (I-o)
  • An alcohol represented by the general formula (I-q) can be synthesized by reducing the compound represented by the general formula (I-n) or (I-o) in the presence of a reducing agent:
  • Figure US20110172415A1-20110714-C00033
  • wherein respective symbols are as defined above.
  • Examples of a reaction solvent include diethyl ether, tetrahydrofuran, toluene, ethanol and the like, and these can be used alone, or by mixing.
  • Examples of the reducing agent include sodium borohydride, lithium borohydride, lithium aluminum hydride, diisopropyl aluminum hydride and the like and the reducing agent can be used at 0.5 to 6 mole equivalent based on the compound represented by the general formula (I-n) or (I-o).
  • An example of a reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by general formula (I-q) can be isolated and purified by the known means (e.g. chromatography, a recrystallization etc.).
  • R Method: Synthesis of (I-r) from Compound (II):
  • Figure US20110172415A1-20110714-C00034
  • wherein respective symbols are as defined above.
  • The compound represented by the general formula (XXXIX) can be synthesized by the method described in JP-A No. 62-258342, and a method similar thereto.
  • Synthesis of (XXXX) from (II)
  • A compound represented by the general formula (XXXX) can be synthesized by condensing the compound represented by the general formula (II) and the organophosphorus compound represented by the general formula (XXXIX) in the presence of a base, followed by treatment with an acid.
  • The organophosphorus compound represented by the general formula (XXXIX) can be used at 1 to 5 mole equivalent based on the compound represented by the general formula (II).
  • Examples of a reaction solvent include tetrahydrofuran, diethyl ether, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, liquid ammonia and the like.
  • Examples of the base include lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, potassium tert-butoxide, n-butyllithium, lithiumhexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, sodium amide and the like. The base can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (II).
  • An example of a reaction temperature is −70 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • Examples of an acid used in treatment with an acid include p-toluenesulfonic acid, benzenesulfonic acid, hydrochloric acid, sulfuric acid and the like, and the acid can be used at 0.1 to 10 mole equivalent based on the compound represented by (II).
  • Examples of a reaction solvent include methanol, ethanol, toluene, water and the like, and these can be used alone, or by mixing.
  • An example of a reaction temperature is 20 to 100° C.
  • An example of a reaction time is 0.5 to 24 hours.
  • The resulting compound represented by the general formula (XXXX) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.)
  • Synthesis of (XXXXI) from (XXXX)
  • Carboxylic acid represented by the general formula (XXXXI) can be synthesized by hydrolyzing the compound represented by the general formula (XXXX).
  • Lithium hydroxide, sodium hydroxide, potassium hydroxide or the like can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XXXX).
  • Examples of a reaction solvent include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or by mixing.
  • An example of a reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 24 hours.
  • The resulting compound represented by the general formula (XXXXI) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (I-r) from (XXXXI)
  • An amide compound represented by the general formula (I-r) can be synthesized by condencing carboxylic acid represented by the general formula (XXXXI) with an amine compound represented by the general formula (XIX) in the presence of a condensing agent.
  • The compound represented by the general formula (XIX) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXXI).
  • Examples of a reaction solvent include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • Examples of the condensing agent include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyldiimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxyalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXXI). 1-Hydroxybenzotriazole or the like may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of the base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or by mixing. The base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXXXI).
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • When ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride or the like is used as the condensing agent, a reaction time can be shortened.
  • The resulting compound represented by the general formula (I-r) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • S Method: Synthesis of (I-s) from Compound (XXXX):
  • Figure US20110172415A1-20110714-C00035
  • wherein respective symbols are as defined above.
    Synthesis of (XXXXII) from (XXXX)
  • An alcohol represented by the general formula (XXXXII) can be synthesized by reducing the compound represented by the general formula (XXXX) in the presence of a reducing agent.
  • Examples of a reaction solvent include diethyl ether, tetrahydrofuran, toluene, ethanol and the like, and these can be used alone, or by mixing.
  • Examples of the reducing agent include sodium borohydride and the like, and the reducing agent can be used at 0.5 to 6 mole equivalent based on the compound represented by the general formula (XXXX).
  • An example of a reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (XXXXII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (XXXXIII) from (XXXXII)
  • Carboxylic acid represented by the general formula (XXXXIII) can be synthesized by hydrolyzing the compound represented by the general formula (XXXXII).
  • Lithium hydroxide, sodium hydroxide, potassium hydroxide or the like can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XXXXII).
  • Examples of a reaction solvent include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or by mixing.
  • An example of a reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 24 hours.
  • The resulting compound represented by the general formula (XXXXIII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (I-s) from (XXXXIII)
  • An amide compound represented by the general formula (I-s) can be synthesized by condensing carboxylic acid represented by the general formula (XXXXIII) with an amine compound represented by the general formula (XIX) in the presence of a condensing agent.
  • The compound represented by the general formula (XIX) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXXIII).
  • Examples of a reaction solvent include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • Examples of the condensing agent include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyldiimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXXIII). 1-Hydroxybenzotriazole or the like may be used at 0.5 to 2 mole equivalent as a condensation assistant.
  • Examples of a base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or by mixing. The base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXXXIII).
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-s) can be isolated and purified by the known means (e.g. chromatography, recrystallization).
  • T Method: Synthesis of (I-t) from Compound (XXXXII):
  • Figure US20110172415A1-20110714-C00036
  • wherein respective symbols are as defined above.
    Synthesis of (XXXXV) from (XXXXII)
  • A compound represented by the general formula (XXXXV) can be synthesized by reacting the compound represented by the general formula (XXXXII) and the compound represented by the general formula (XXXXIV) in the presence of a base.
  • The compound represented by the general formula (XXXXIV) can be used at 1 to 5 mole equivalent based on the compound represented by the general formula (XXXXII).
  • Examples of a reaction solvent include tetrahydrofuran, diethyl ether, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide and the like.
  • Examples of the base include lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, potassium tert-butoxide, n-butyllithium, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide and the like. The base can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XXXXII).
  • An example of a reaction temperature is −70 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (XXXXV) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (XXXXVI) from (XXXXV)
  • Carboxylic acid represented by the general formula (XXXXVI) can be synthesized by hydrolyzing the compound represented by the general formula (XXXXV).
  • Lithium hydroxide, sodium hydroxide, potassium hydroxide or the like can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XXXXV).
  • Examples of a reaction solvent include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or by mixing.
  • An example of a reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 24 hours.
  • The resulting compound represented by the general formula (XXXXVI) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.)
  • Synthesis of (I-t) from (XXXXVI)
  • An amide compound represented by the general formula (I-t) can be synthesized by condensing the carboxylic acid represented by the general formula (XXXXVI) with an amine compound represented by the general formula (XIX) in the presence of a condensing agent.
  • The compound represented by the general formula (XIX) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXXVI).
  • Examples of a reaction solvent include methylene chloride, tetrahydrofuran, N,N-dimethylformamide etc.
  • Examples of the condensing agent include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyldiimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXXVI). 1-Hydroxybenzotriazole may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of a base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or by mixing. The base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXXXVI).
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-t) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • U Method: Synthesis of (I-u) from Compound (II):
  • Figure US20110172415A1-20110714-C00037
  • wherein respective symbols are as defined above.
    Synthesis of (XXXXVIII) from (II)
  • A compound represented by the general formula (XXXXVIII) can be synthesized by condensing the compound represented by the general formula (II) and the compound represented by the general formula (XXXXVII) in the presence of a base.
  • The compound represented by the general formula (XXXXVII) can be used at 1 to 5 mole equivalent based on the compound represented by the general formula (II).
  • Examples of a reaction solvent include tetrahydrofuran, diethyl ether, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide and the like.
  • Examples of the base include sodium hydride, potassium hydride, sodium methoxide, potassium tert-butoxide, n-butyllithium, lithium diisopropylamine, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide and the like. The base can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (II).
  • An example of a reaction temperature is −100 to 20° C.
  • An example of a reaction time is 0.5 to 24 hours.
  • The resulting compound represented by the general formula (XXXXVIII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (XXXXIX) from (XXXXVIII)
  • Carboxylic acid represented by the general formula (XXXXIX) can be synthesized by hydrolyzing the compound represented by the general formula (XXXXVIII).
  • Lithium hydroxide, sodium hydroxide, potassium hydroxide or the like can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (XXXXVIII).
  • Examples of a reaction solvent include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or by mixing.
  • An example of a reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 24 hours.
  • The compound represented by the resulting general formula (XXXXIX) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (I-u) from (XXXXIX)
  • An amide compound represented by the general formula (I-u) can be synthesized by condensing carboxylic acid represented by the general formula (XXXXIX) with an amine compound represented by the general formula (XIX) in the presence of a condensing agent.
  • The compound represented by the general formula (XIX) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXXIX).
  • Examples of a reaction solvent include methylene chloride, tetrahydrofuran, N,N-dimethylformamide etc.
  • Examples of the condensing agent include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyldiimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (XXXXIX). 1-Hydroxybenzotriazole may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of a base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or by mixing. The base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (XXXXIX).
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-u) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • V Method: Synthesis of (I-v) from Compound (XVII-a):
  • Figure US20110172415A1-20110714-C00038
  • wherein respective symbols are as defined above.
    Synthesis of (L) from (XVII-a)
  • A compound represented by the general formula (L) can be synthesized by treating the compound represented by the general formula (XVII-a) with a base.
  • A base such as lithium diisopropylamide, lithium hexamethyldisilazide, n-butyllithium, potassium tert-butoxide, 1,8-diazabicyclo[5.4.0]undec-7-ene and the like can be used at 0.1 to 10 mole equivalent based on the compound represented by the general formula (XVII-a).
  • Examples of a reaction solvent include tetrahydrofuran, diethyl ether, toluene and the like.
  • An example of a reaction temperature is −70 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (L) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (LI) from (L)
  • Carboxylic acid represented by the general formula (L1) can be synthesized by hydrolyzing the compound represented by the general formula (L).
  • Lithium hydroxide, sodium hydroxide, potassium hydroxide or the like can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (L).
  • Examples of a reaction solvent include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or by mixing.
  • An example of a reaction temperature is 0° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 24 hours.
  • The resulting compound represented by the general formula (LI) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (I-v) from (LI)
  • An amide compound represented by the general formula (I-v) can be synthesized by condensing the carboxylic acid represented by the general formula (LI) with an amine compound represented by the general formula (XIX) in the presence of a condensing agent.
  • The compound represented by the general formula (XIX) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (LI).
  • Examples of a reaction solvent include methylene chloride, tetrahydrofuran, N,N-dimethylformamide and the like.
  • Examples of the condensing agent include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-2-ethylcarbodiimide hydrochloride, N,N′-carbonyldiimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like. The condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (LI). 1-Hydroxybenzotriazole or the like may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of a base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or by mixing. The base can be used as 0.05 to 2 mole equivalent based on the compound represented by the general formula (LI).
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-v) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • W Method: Synthesis from (I-w) from Compound (LII)
  • A compound represented by the general formula (I-w) can be synthesized by condensing the aldehyde represented by the general formula (LII) with an organophosphorus compound represented by the general formula (LIII) or (LIV) in the presence of a base:
  • Figure US20110172415A1-20110714-C00039
  • wherein respective symbols are as defined above.
  • The compound represented by the general formula (XXXII) can be synthesized by the method described in Reference Example 10 described later, and a method similar thereto. The organophosphorus compound represented by the general formula (LIII) and (LIV) can be synthesized by the method described in New Experimental Chemistry Course 14, Maruzen Co. Ltd., (1977), and a method similar thereto.
  • The organophosphorus compound represented by the general formula (LIII) or (LIV) can be used at 1 to 5 mole equivalent based on the compound represented by the general formula (LII).
  • Examples of a reaction solvent include tetrahydrofuran, diethyl ether, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, liquid ammonia and the like.
  • Examples of the base include lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, potassium tert-butoxide, n-butyllithium, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, sodium amide and the like. The base can be used at 1.0 to 5 mole equivalent based on the compound represented by the general formula (LII).
  • An example of a reaction temperature is −70 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-w) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • X Method: Synthesis of (I-x) from Compound (I-w)
  • A compound represented by the general formula (I-x) can be synthesized by reducing the compound represented by the general formula (I-w) with hydrogen in the presence of a metal catalyst:
  • Figure US20110172415A1-20110714-C00040
  • wherein respective symbols are as defined above.
  • Examples of a reaction solvent include methanol, ethanol, ethyl acetate, tetrahydrofuran, N,N-dimethylformamide and the like.
  • Examples of a metal catalyst include 5% palladium-carbon, 10% palladium-carbon, platinum oxide, chlorotris(triphenylphosphine)rohodium (I). The metal catalyst can be used at 0.01 to 0.5 weight % based on the compound represented by the general formula (I-a).
  • An example of a hydrogen atom is 1 to 50 atm.
  • An example of a reaction temperature is 20° C. to a refluxing temperature of a solvent.
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-x) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Y Method: Synthesis of (I-y) from Compound (II)
  • A compound represented by the general formula (I-y) can be synthesized by reductively condensing the compound represented by the general formula (II) and the compound represented by the general formula (LV):
  • Figure US20110172415A1-20110714-C00041
  • wherein respective symbols are as defined above.
  • The compound represented by the general formula (LV) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (II).
  • Examples of a reaction solvent include 1,2-dichloroethane, tetrahydrofuran and the like.
  • Examples of the reducing agent include sodium triacetoxyborohydride and the like, and the reducing agent can be used at 0.5 to 6 mole equivalent based on the general formula (II).
  • An example of a reaction temperature is 0 to 80° C.
  • If necessary, acetic acid or the like as an acid can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (II).
  • An example of a reaction time is 0.5 to 72 hours.
  • The resulting compound represented by the general formula (I-y) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Z Method: Synthesis of (I-z) from Compound (LVI):
  • Figure US20110172415A1-20110714-C00042
  • wherein respective symbols are as defined above.
    Synthesis of (LVIII) from (LVI)
  • A compound represented by the general formula (LVIII) can be synthesized by condensing the compound represented by the general formula (LVI) and the compound represented by the general formula (LVII) in the presence of a base.
  • The compound represented by the general formula (LVII) can be used at 1 to 3 mole equivalent based on the compound represented by the general formula (LVI).
  • Examples of a reaction solvent include tetrahydrofuran, diethyl ether, acetonitrile, methylene chloride, chloroform, toluene, water and the like, and these can be used alone, or by mixing.
  • Examples of the base include sodium hydroxide, potassium hydroxide, sodium bicarbonate, sodium carbonate, potassium carbonate, sodium hydride, potassium hydride, triethylamine, morpholine, N-methylmorpholine and the like. The base can be used at 1.0 to 5 mole based on the compound represented by the general formula (LVI).
  • An example of a reaction temperature is −10 to 50° C.
  • An example of a reaction time is 0.5 to 24 hours.
  • The resulting compound represented by the general formula (LVIII) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (LIX) from (LVIII)
  • Carboxylic acid represented by the general formula (LIX) can be synthesized by hydrolyzing the compound represented by the general formula (LVIII).
  • Lithium hydroxide, sodium hydroxide, potassium hydroxide or the like can be used at 1.0 to 5 mole equivalent can be used based on the compound represented by the general formula (LVIII).
  • Examples of a reaction solvent include methanol, ethanol, propanol, isopropanol, butanol, water and the like, and these can be used alone, or by mixing.
  • An example of a reaction time is 0.5 to 24 hours.
  • The resulting compound represented by the general formula (LIX) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • Synthesis of (I-z) from (LIX)
  • An amide compound represented by the general formula (I-z) can be synthesized by condensing the carboxylic acid represented by the general formula (LIX) with an amide compound represented by the general formula (XIX) in the presence of a condensing agent.
  • The compound represented by the general formula (XIX) can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (LIX).
  • Examples of a reaction solvent include methylene chloride, tetrahydrofuran, N,N-dimethylformamide, N,N-dimethylacetamide, 1,3-dimethyl-2-imidazolidinone, N-methyl-2-pyrrolidone and the like.
  • Examples of the condensing agent include dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N′-carbonyldiimidazole, ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride and the like, and the condensing agent can be used at 0.5 to 2 mole equivalent based on the compound represented by the general formula (LIX). 1-Hydroxybenzotriazole or the like may be used as a condensation assistant at 0.5 to 2 mole equivalent.
  • Examples of a base include triethylamine, N-methylmorpholine, 4-dimethylaminopyridine and the like, and these can be used alone, or by mixing. The base can be used at 0.05 to 2 mole equivalent based on the compound represented by the general formula (LIX).
  • An example of a reaction temperature is 0 to 100° C.
  • An example of a reaction time is 0.5 to 72 hours.
  • When ethyl chlorocarbonate, isobutyl chlorocarbonate, thionyl chloride, oxalyl chloride or the like is used as the condensing agent, a reaction time can be shortened.
  • The resulting compound represented by the general formula (I-z) can be isolated and purified by the known means (e.g. chromatography, recrystallization etc.).
  • In addition, when A1 is the nitrogen-containing aromatic monocyclic group or the nitrogen-containing aromatic fused cyclic group having at least one of protected hydroxy and/or protected amino and, further, optionally substituted with other group, or the nitrogen-containing aromatic monocyclic group or the nitrogen-containing aromatic fused cyclic group containing —NH— in the ring, and in which other ring constituting atoms may be substituted with a substituent other than protected hydroxy and protected amino, the protecting group can be deprotected under the normally used reaction conditions (e.g. the method described in T. W. Green et al., Protective Groups in Organic Synthesis, Second Edition, John Wiley & Sons (1991)).
  • When the present compound contains an optical isomer, a steric isomer, a positional isomer, and a rotational isomer, these are also included as the present compound, and can be obtained as a single product, respectively, by the known per se synthesizing procedure, and the separating procedure. For example, when an optical isomer is present in the present compound, an optical isomer resolved from the compound is also included in the present compound. The optical isomer can be produced by the known per se method. Specifically, an optical isomer is obtained by optically resolving a final racemate mixture using an optically active synthetic intermediate, or according to a conventional method.
  • As the optical resolution method, the known per se method, for example, a fractionation recrystallization method, a chiral column method, and a diastereomer method which are described in detail below, are used.
  • 1) Fractionation Recrystallization Method
  • A salt is formed between a racemate and an optically active compound (e.g. (+)-mandelic acid), (−)-mandelic acid, (+)-tartaric acid, (−)-tartaric acid, (+)-1-phenethylamine, (−)-1-phenethylamine, cinchonine, (−)-cinchonidine, brucine etc.), this is separated by a fractionation recrystallization method and, if desired, a neutralization step is performed, thereby, a free optical isomar is obtained.
  • 2) Chiral Column Method
  • A method of separating a racemate or a salt thereof by applying it to a column for separating an optical isomar (chiral column). For example, in the case of liquid chromatography, optical isomers are separated by adding a mixture of optical isomers to a chiral column such as ENANTIO-OVM (manufactured by Tosoh Corporation) and CHIRAL series manufactured by Daicel, and developing the column with water, various buffers (e.g. phosphate buffer), or an organic solvent (e.g. ethanol, methanol, isopropanol, acetonitrile, trifluoroacetic acid, diethylamine, etc) alone or as a mixed solution. Alternatively, for example, in the case of gas chromatography, optical isomers are separated using a chiral column such as CP-Chirasil-Dex CB (manufactured by GL Sciences).
  • 3) Diastereomer Method
  • A method of converting a mixture of racemates into a mixture of diastereomers by a chemical reaction with an optically active reagent, converting this into a single substance via a conventional separation means (e.g. fractionation recrystallization, chromatography method etc.), and cutting off an optically active reagent site by chemical treatment such as a hydrolysis reaction to obtain an optical isomer. For example, when the present compound has hydroxy or primary or secondary amino in a molecure, diastereomers of an ester form and an amide form can be obtained, resepectively, by subjecting the compound and an optically active organic acid (e.g. MTPA [α-methoxy-α-(trifluoromethyl)phenylacetic acid], (−)-methoxyacetic acid etc.) to a condensation reaction. On the other hand, when the present compound has a carboxylic acid group, diastereomers of an amide form and an ester form are obtained, respectively, by subjecting the compound and optically active amine or an alcohol reagent to a condensation reaction. Separated diastereomers are converted into optical isomers of the original compound by subjecting to acid hydrolysis or basic hydrolysis reaction.
  • As a salt of the present compound, a pharmaceutically acceptable salt can be used, and examples of the basic addition salt include alkali metal salts such as sodium salt, potassium salt etc.; alkaline earth metal salts such as calcium salt, magnesium salt etc.; ammonium salts; trimethylamine salt, triethylamine salt; aliphatic amine salts such as dicyclohexylamine salt, ethanolamine salt, diethanol amine salt, triethanolamine salt, procaine salt etc.; aralkylamine salts such as N,N-dibenzylethylenediamine etc.; heterocyclic aromatic amine salts such as pyridine salt, picoline salt, quinoline salt, isoquinoline salt etc.; quaternary ammonium salts such as tetramethylammonium salt, tetraethylammonium salt, benzyltrimethylammonium salt, benzyltriethylammonium salt, benzyltributylammmonium salt, methyltrioctylammonium salt, tetrabutylammonium salt etc.; basic amino acid salts such as arginine salt, lysine salt etc.
  • Examples of the acid addition salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, carbonate, bicarbonate, perchlorate etc.; organic acid salts such as oxalate, acetate, propionate, lactate, maleate, fumarate, tartarate, malate, citrate, ascorbate etc.; sulfonates such as methanesulfonate, isethionate, benzenesulfonate, p-toluenesulfonate etc.; acidic amino acids such as aspartate, glutamate etc.
  • The compound (I) may be a solvate of water, acetonitrile, acetone, ethyl acetate, methanol, ethanol and the like. And, the solvation number of solvates of the present compound can usually vary depending on a synthesis method, a purification method and the crystallization condition, and for example, is in a range of 0.5 to 5 molecules per one molecule of the compound.
  • Among the present compound (I), the following compounds are particularly preferable.
  • In the formula (I), (CRaRb)w is (CH2)2 or (CH2)3, and (CRcRd)t is CH2 or CHMe,
    • 1) a compound in which A1 is pyridyl substituted with at least hydroxy, benzoxazolyl substituted with at least hydroxy, benzimidazolyl substituted with at least hydroxy, pyridyl substituted with at least optionally protected amino, imidazolyl in which ring constituting atoms other than —NH— may be substituted, pyrrolyl in which ring constituting atoms other than —NH— may be substituted, pyrazolyl in which ring constituting atoms other than —NH— may be substituted, or benzimidazolyl in which ring constituting atoms other than —NH— may be substituted (hereinafter, A1 being a1),
    • 2) a compound in which A1 is hydroxypyridyl, hydroxybenzoxazolyl, hydroxybenzimidazolyl, benzpyrazolyl, benzimidazolyl, unsubstituted imidazolyl, unsubstituted pyrrolyl, unsubstituted pyrazolyl, or unsubstituted benzimidazolyl (hereinafter, A1 being a2),
    • 3) a compound in which A1 is hydroxypyridyl, hydroxybenzoxazolyl, hydroxybenzimidazolyl, unsubstituted imidazolyl, unsubstituted pyrazolyl, or unsubstituted pyrrolyl (hereinafter, A1 being a3),
    • 4) a compound in which A1 is hydroxybenzoxazolyl (hereinafter, A1 being a4),
    • 5) a compound in which X is —(CHR3)m-, —CO(CHR3)n-, —CONH(CHR3)n-, —NHCO(CHR3)n-, —NHCONH—, —NHCOCO— or —NH(CHR3)mCO— (each R3 may be different), Z is N or CR1, R1 and R2 are each independently hydrogen, hydroxy or methyl, or R1 and R2 may be taken together to form a single bond, when m or n is 1 or more, R1 may be taken together with R3 on CR3R4 adjacent to a carbon atom to which R1 binds, to form a single bond (when Z is N, R1 is absent, the same hereinafter) (hereinafter, X, R1 and R2 being xr1),
    • 6) a compound in which X is —CO(CHR3)n-, —CONH(CHR3)n-, —NHCO(CHR3)n-, —NHCOCO— or —NH(CHR3)mCO—, Z is N or CR1, R1 is hydrogen or hydroxy, and R2 is hydrogen or methyl (hereinafter, X being xr2),
    • 7) a compound in which X is —CO(CHR3)n-, —CONH(CHR3)n- or —NHCO(CHR3)n-, Z is CR1, and R1 and R2 are taken together to form a single bond, (hereinafter, X being xr3),
    • 8) a compound in which X is —CO(CHR3)n-, —CONH(CHR3)n- or —NHCO(CHR3)n-, Z is CR1, R1 is taken together with R3 on CR3R4 adjacent to a carbon atom to which R1 binds, to form a single bond, and R2 is hydrogen (hereinafter, X being xr4),
    • 9) a compound in which X is —CO(CHR3)3—, —CONH(CHR3)2—, —NHCO(CHR3)2—, —NHCOCO— or —NHCHR3CO—, R3 is hydrogen or methyl (each R3 may be different), Z is N or CR1, R1 is hydrogen or hydroxy, and R2 is hydrogen or methyl (hereinafter, X being xr5),
    • 10) a compound in which X is —CO(CHR3)3—, —CONH(CHR3)2— or —NHCO(CHR3)2—, R3 is hydrogen or methyl (each R3 may be different), Z is CR1, and R1 and R2 are taken together to form a single bond (hereinafter, X being xr6),
    • 11) a compound in which X is —CO(CHR3)3—, —CONH(CHR3)2— or —NHCO(CHR3)2—, R3 is hydrogen or methyl (each R3 may be different), Z is CR1, R1 is taken together with R3 on CR3R4 adjacent to a carbon atom to which R1 binds, to form a single bond, and R3 is hydrogen (hereinafter, X being xr7),
    • 12) a compound in which X is —CO(CHR3)3—, —CONH(CHR3)2—, —NHCO(CHR3)2—, —NHCOCO— or —NHCHR3CO—, R3 is hydrogen or methyl (each R3 may be different), Z is N or CH, and R2 is hydrogen (hereinafter, X being xr8),
    • 13) a compound in which X is —CO(CHR3)3—, —CONH(CHR3)2—, —NHCO(CHR3)2—, —NHCOCO— or —NHCHR3CO—, R3 is hydrogen or methyl (each R3 may be different), and Z is CR1 or N (hereinafter, X being xr9),
    • 14) a compound in which A2 is phenyl optionally substituted with one or more groups selected from halogen, cyano, lower alkyl, halogeno lower alkyl, lower alkoxy and halogeno lower alkoxy or pyridyl optionally substituted with one or more groups selected from halogen, cyano, lower alkyl, halogeno lower alkyl, lower alkoxy and halogeno lower alkoxy (hereinafter, A2 being a5),
    • 15) a compound in which A2 is phenyl substituted with one or more groups selected from halogen, C1-C3 alkyl, halogeno C1-C3 alkyl, C1-C3 alkoxy and halogeno C1-C3 alkoxy or pyridyl optionally substituted with one or more groups selected from halogen, C1-C3 alkyl, halogeno C1-C3 alkyl, C1-C3 alkoxy and halogeno C1-C3 alkoxy (hereinafter, A2 being a6),
    • 16) a compound in which A2 is phenyl substituted with one or more groups selected from halogen, C1-C3 alkyl, halogeno C1-C3 alkyl, C1-C3 alkoxy and halogeno C1-C3 alkoxy at a para-position or pyridyl substituted with one or more groups selected from halogen, C1-C3 alkyl, halogeno C1-C3 alkyl, C1-C3 alkoxy and halogeno C1-C3 alkoxy at a para-position (hereinafter, A2 being a7),
    • 17) a compound in which A2 is phenyl substituted with one or more groups selected from halogen, C1-C3 alkyl, halogeno C1-C3 alkyl, C1-C3 alkoxy and halogeno C1-C3 alkoxy at a meta-position and a para-position (hereinafter, A2 being a8),
    • 18) a compound is which a combination of A1, X, R1, R2 and A2 (A1, xr, A2) is the following:
  • (A1,xr,
  • A2)=(a1,xr1,a5),(a1,xr1,a6),(a1,xr1,a7),(a1,xr1,a8),(a1,xr2,a5),(a1,xr2, a6),(a1, xr2,a7),(a1,xr2,a8),(a1,xr3,a5),(a1,xr3,a6),(a1,xr3,a7),(a1,xr3,a8),(a1,xr4,a5), (a1,xr4,a6),(a1,xr4,a7),(a1,xr4,a8),(a1,xr5,a5),(a1,xr5,a6),(a1,xr5,a7),(a1,xr5, a8),(a1,xr6,a5),(a1,xr6,a6),(a1,xr6,a7),(a1,xr6,a8),(a1,xr7,a5),(a1,xr7,a6),(a1, xr7,a7),(a1,xr7,a8),(a1,xr8,a5),(a1,xr8,a6),(a1,xr8,a7),(a1,xr8,a8),(a1,xr9,a5), (a1,xr9,a6),(a1,xr9,a7),(a1,xr9,a8),
  • (a2,xr1,a5),(a2,xr1,a6),(a2,xr1,a7),(a2,xr1,a8),(a2,xr2,a5),(a2,xr2,a6),(a2,xr2, a7),(a2,xr2,a8),(a2,xr3,a5),(a2,xr3,a6),(a2,xr3,a7),(a2,xr4,a5),(a2,xr4,a6),(a2, xr4,a7),(a2,xr4,a8),(a2,xr5,a5),(a2,xr5,a6),(a2,xr5,a7),(a2,xr5,a8),(a2,xr6,a5), (a2,xr6,a6),(a2,xr6,a7),(a2,xr6,a8),(a2,xr7,a5),(a2,xr7,a6),(a2,xr7,a7),(a2,xr7, a8),(a2,xr8,a5),(a2,xr8,a6),(a2,xr8,a7),(a2,xr8,a8),(a2,xr9,a5),(a2,xr9,a6),(a2, xr9,a7),(a2,xr9,a8),
  • (a3,xr1,a5),(a3,xr1,a6),(a3,xr1,a7),(a3,xr1,a8),(a3,xr2,a5),(a3,xr2,a6),(a3,xr2, a7),(a3,xr2,a8),(a3,xr3,a5),(a3,xr3,a6),(a3,xr3,a7),(a3,xr3,a8),(a3,xr4,a5),(a3, xr4,a6),(a3,xr4,a7),(a3,xr4,a8),(a3,xr5,a5),(a3,xr5,a6),(a3,xr5,a7),(a3,xr5,a8), (a3,xr6,a5),(a3,xr6,a6),(a3,xr6,a7),(a3,xr6,a8),(a3,xr7,a5),(a3,xr7,a6),(a3,xr7, a7),(a3,xr7,a8),(a3,xr8,a5),(a3,xr8,a6),(a3,xr8,a7),(a3,xr8,a8),(a3,xr9,a5),(a3, xr9,a6),(a3,xr9,a7),(a3,xr9,a8),
  • (a4,xr1,a5),(a4,xr1,a6),(a4,xr1,a7),(a4,xr1,a8),(a4,xr2,a5),(a4,xr2,a6),(a4,xr2, a7),(a4,xr2,a8),(a4,xr3,a5),(a4,xr3,a6),(a4,xr3,a7),(a4,xr3,a8),(a4,xr4,a5),(a4, xr4,a6),(a4,xr4,a7),(a4,xr4,a8),(a4,xr5,a5),(a4,xr5,a6),(a4,xr5,a7),(a4,xr5,a8), (a4,xr6,a5),(a4,xr6,a6),(a4,xr6,a7),(a4,xr6,a8),(a4,xr7,a5),(a4,xr7,a6),(a4,xr7, a7),(a4,xr7,a8),(a4,xr8,a5),(a4,xr8,a8),(a4,xr8,a7),(a4,xr8,a8),(a4,xr9,a5),(a4, xr9,a6),(a4,xr9,a7),(a4,xr9,a8)
  • In the formula (I) or (I′),
    • 16) a compound in which A1 is pyridyl having at least one of optionally protected hydroxy, and optionally protected amino, —X— is —CONH(CHR3)n-, —NHCO(CHR3)n- or —NHCOCO—, and n is 2 or more,
    • 17) a compound in which A1 is benzoxazolyl having at least one of optionally protected hydroxy and optionally protected amino or benzoimidazolyl having at least one of optionally protected hydroxy and optionally protected amino, and X is —CONH(CHR3)n-, —NR5CO(CR3R4)n-, —NR5CONR6— or —NHCOCO—, or a pharmaceutically acceptable salt, or a solvate thereof.
  • A compound in which a combination of A1, A2 and X (A1, A2, X) is the following in the following formula (1) to (7), or a pharmaceutically acceptable salt, or a solvate thereof is also a preferable aspect of the present invention.
  • Figure US20110172415A1-20110714-C00043
  • TABLE 1
    A1
    Figure US20110172415A1-20110714-C00044
    a7
    Figure US20110172415A1-20110714-C00045
    Figure US20110172415A1-20110714-C00046
    a8
    Figure US20110172415A1-20110714-C00047
    Figure US20110172415A1-20110714-C00048
    a9
    Figure US20110172415A1-20110714-C00049
    Figure US20110172415A1-20110714-C00050
    a10
    Figure US20110172415A1-20110714-C00051
    Figure US20110172415A1-20110714-C00052
    a11
    Figure US20110172415A1-20110714-C00053
    Figure US20110172415A1-20110714-C00054
    a12
    Figure US20110172415A1-20110714-C00055
  • TABLE 2
    A2
    b1
    Figure US20110172415A1-20110714-C00056
    b2
    Figure US20110172415A1-20110714-C00057
    b3
    Figure US20110172415A1-20110714-C00058
    b4
    Figure US20110172415A1-20110714-C00059
    b5
    Figure US20110172415A1-20110714-C00060
    b6
    Figure US20110172415A1-20110714-C00061
    b7
    Figure US20110172415A1-20110714-C00062
    b8
    Figure US20110172415A1-20110714-C00063
    b9
    Figure US20110172415A1-20110714-C00064
    b10
    Figure US20110172415A1-20110714-C00065
    b11
    Figure US20110172415A1-20110714-C00066
    b12
    Figure US20110172415A1-20110714-C00067
    b13
    Figure US20110172415A1-20110714-C00068
    b14
    Figure US20110172415A1-20110714-C00069
    b15
    Figure US20110172415A1-20110714-C00070
    b16
    Figure US20110172415A1-20110714-C00071
    b17
    Figure US20110172415A1-20110714-C00072
    b18
    Figure US20110172415A1-20110714-C00073
    b19
    Figure US20110172415A1-20110714-C00074
    b20
    Figure US20110172415A1-20110714-C00075
    b21
    Figure US20110172415A1-20110714-C00076
    b22
    Figure US20110172415A1-20110714-C00077
    b23
    Figure US20110172415A1-20110714-C00078
    b24
    Figure US20110172415A1-20110714-C00079
    b25
    Figure US20110172415A1-20110714-C00080
    b26
    Figure US20110172415A1-20110714-C00081
    b27
    Figure US20110172415A1-20110714-C00082
  • TABLE 3
    X X
    X1 COCH2CH2 X10 NHCOCH2CH2
    X2 COCH2CH2CH2 X11 NHCOCH(OH)
    X3* COCH2CH2CH═ X12 NHCOCO
    X4 CONHCH2 X13* NHCOCH═
    X5 CONHCH2CH2 X14* NHCOCF═
    X6 CONHCH(Me)CH2 X15 NHCONH
    X7 CONHCH2CH(Me) X16
    Figure US20110172415A1-20110714-C00083
    X8 NHCO X17
    Figure US20110172415A1-20110714-C00084
    X9 NHCOCH2 X18 NHCH2CO
    *Only the case of (1)
  • In table, Ms represents methanesulfonyl, Me represents methyl, and iPr represents isopropyl.
  • (A1, A2, X)=(a1, b1, X1), (a1, b1, X2), (a1, b1, X3), (a1, b1, X4), (a1, b1, X5), (a1, b1, X6), (a1, b1, X7), (a1, b1, X8), (a1, b1, X9), (a1, b1, X10), (a1, b1, X11), (a1, b1, X12), (a1, b1, X13), (a1, b1, X14), (a1, b1, X15), (a1, b1, X16), (a1, b1, X17), (a1, b1, X18), (a1, b2, X1), (a1, b2, X2), (a1, b2, X3), (a1, b2, X4), (a1, b2, X5), (a1, b2, X6), (a1, b2, X7), (a1, b2, X8), (a1, b2, X9), (a1, b2, X10), (a1, b2, X11), (a1, b2, X12), (a1, b2, X13), (a1, b2, X14), (a1, b2, X15), (a1, b2, X16), (a1, b2, X17), (a1, b2, X18), (a1, b3, X1), (a1, b3, X2), (a1, b3, X3), (a1, b3, X4), (a1, b3, X5), (a1, b3, X6), (a1, b3, X7), (a1, b3, X8), (a1, b3, X9), (a1, b3, X10), (a1, b3, X11), (a1, b3, X12), (a1, b3, X13), (a1, b3, X14), (a1, b3, X15), (a1, b3, X16), (a1, b3, X17), (a1, b3, X18), (a1, b4, X1), (a1, b4, X2), (a1, b4, X3), (a1, b4, X4), (a1, b4, X5), (a1, b4, X6), (a1, b4, X7), (a1, b4, X8), (a1, b4, X9), (a1, b4, X10), (a1, b4, X11), (a1, b4, X12), (a1, b4, X13), (a1, b4, X14), (a1, b4, X15), (a1, b4, X16), (a1, b4, X17), (a1, b4, X18), (a1, b5, X1), (a1, b5, X2), (a1, b5, X3), (a1, b5, X4), (a1, b5, X5), (a1, b5, X6), (a1, b5, X7), (a1, b5, X8), (a1, b5, X9), (a1, b5, X10), (a1, b5, X11), (a1, b5, X12), (a1, b5, X13), (a1, b5, X14), (a1, b5, X15), (a1, b5, X16), (a1, b5, X17), (a1, b5, X18), (a1, b6, X1), (a1, b6, X2), (a1, b6, X3), (a1, b6, X4), (a1, b6, X5), (a1, b6, X6), (a1, b6, X7), (a1, b6, X8), (a1, b6, X9), (a1, b6, X10), (a1, b6, X11), (a1, b6, X12), (a1, b6, X13), (a1, b6, X14), (a1, b6, X15), (a1, b6, X16), (a1, b6, X17), (a1, b6, X18), (a1, b7, X1), (a1, b7, X2), (a1, b7, X3), (a1, b7, X4), (a1, b7, X5), (a1, b7, X6), (a1, b7, X7), (a1, b7, X8), (a1, b7, X9), (a1, b7, X10), (a1, b7, X11), (a1, b7, X12), (a1, b7, X13), (a1, b7, X14), (a1, b7, X15), (a1, b7, X16), (a1, b7, X17), (a1, b7, X18), (a1, b8, X1), (a1, b8, X2), (a1, b8, X3), (a1, b8, X4), (a1, b8, X5), (a1, b8, X6), (a1, b8, X7), (a1, b8, X8), (a1, b8, X9), (a1, b8, X10), (a1, b8, X11), (a1, b8, X12), (a1, b8, X13), (a1, b8, X14), (a1, b8, X15), (a1, b8, X16), (a1, b8, X17), (a1, b8, X18), (a1, b9, X1), (a1, b9, X2), (a1, b9, X3), (a1, b9, X4), (a1, b9, X5), (a1, b9, X6), (a1, b9, X7), (a1, b9, X8), (a1, b9, X9), (a1, b9, X10), (a1, b9, X11), (a1, b9, X12), (a1, b9, X13), (a1, b9, X14), (a1, b9, X15), (a1, b9, X16), (a1, b9, X17), (a1, b9, X18), (a1, b10, X1), (a1, b10, X2), (a1, b10, X3), (a1, b10, X4), (a1, b10, X5), (a1, b10, X6), (a1, b10, X7), (a1, b10, X8), (a1, b10, X9), (a1, b10, X10), (a1, b10, X11), (a1, b10, X12), (a1, b10, X13), (a1, b10, X14), (a1, b10, X15), (a1, b10, X16), (a1, b10, X17), (a1, b10, X18), (a1, b11, X1), (a1, b11, X2), (a1, b11, X3), (a1, b11, X4), (a1, b11, X5), (a1, b11, X6), (a1, b11, X7), (a1, b11, X8), (a1, b11, X9), (a1, b11, X10), (a1, b11, X11), (a1, b11, X12), (a1, b11, X13), (a1, b11, X14), (a1, b11, X15), (a1, b11, X16), (a1, b11, X17), (a1, b11, X18), (a1, b12, X1), (a1, b12, X2), (a1, b12, X3), (a1, b12, X4), (a1, b12, X5), (a1, b12, X6), (a1, b12, X7), (a1, b12, X8), (a1, b12, X9), (a1, b12, X10), (a1, b12, X11), (a1, b12, X12), (a1, b12, X13), (a1, b12, X14), (a1, b12, X15), (a1, b12, X16), (a1, b12, X17), (a1, b12, X18), (a1, b13, X1), (a1, b13, X2), (a1, b13, X3), (a1, b13, X4), (a1, b13, X5), (a1, b13, X6), (a1, b13, X7), (a1, b13, X8), (a1, b13, X9), (a1, b13, X10), (a1, b13, X11), (a1, b13, X12), (a1, b13, X13), (a1, b13, X14), (a1, b13, X15), (a1, b13, X16), (a1, b13, X17), (a1, b13, X18), (a1, b14, X1), (a1, b14, X2), (a1, b14, X3), (a1, b14, X4), (a1, b14, X5), (a1, b14, X6), (a1, b14, X7), (a1, b14, X8), (a1, b14, X9), (a1, b14, X10), (a1, b14, X11), (a1, b14, X12), (a1, b14, X13), (a1, b14, X14), (a1, b14, X15), (a1, b14, X16), (a1, b14, X17), (a1, b14, X18), (a1, b15, X1), (a1, b15, X2), (a1, b15, X3), (a1, b15, X4), (a1, b15, X5), (a1, b15, X6), (a1, b15, X7), (a1, b15, X8), (a1, b15, X9), (a1, b15, X10), (a1, b15, X11), (a1, b15, X12), (a1, b15, X13), (a1, b15, X14), (a1, b15, X15), (a1, b15, X16), (a1, b15, X17), (a1, b15, X18), (a1, b16, X1), (a1, b16, X2), (a1, b16, X3), (a1, b16, X4), (a1, b16, X5), (a1, b16, X6), (a1, b16, X7), (a1, b16, X8), (a1, b16, X9), (a1, b16, X10), (a1, b16, X11), (a1, b16, X12), (a1, b16, X13), (a1, b16, X14), (a1, b16, X15), (a1, b16, X16), (a1, b16, X17), (a1, b16, X18), (a1, b17, X1), (a1, b17, X2), (a1, b17, X3), (a1, b17, X4), (a1, b17, X5), (a1, b17, X6), (a1, b17, X7), (a1, b17, X8), (a1, b17, X9), (a1, b17, X10), (a1, b17, X11), (a1, b17, X12), (a1, b17, X13), (a1, b17, X14), (a1, b17, X15), (a1, b17, X16), (a1, b17, X17), (a1, b17, X18), (a1, b18, X1), (a1, b18, X2), (a1, b18, X3), (a1, b18, X4), (a1, b18, X5), (a1, b18, X6), (a1, b18, X7), (a1, b18, X8), (a1, b18, X9), (a1, b18, X10), (a1, b18, X11), (a1, b18, X12), (a1, b18, X13), (a1, b18, X14), (a1, b18, X15), (a1, b18, X16), (a1, b18, X17), (a1, b18, X18), (a1, b19, X1), (a1, b19, X2), (a1, b19, X3), (a1, b19, X4), (a1, b19, X5), (a1, b19, X6), (a1, b19, X7), (a1, b19, X8), (a1, b19, X9), (a1, b19, X10), (a1, b19, X11), (a1, b19, X12), (a1, b19, X13), (a1, b19, X14), (a1, b19, X15), (a1, b19, X16), (a1, b19, X17), (a1, b19, X18), (a1, b20, X1), (a1, b20, X2), (a1, b20, X3), (a1, b20, X4), (a1, b20, X5), (a1, b20, X6), (a1, b20, X7), (a1, b20, X8), (a1, b20, X9), (a1, b20, X10), (a1, b20, X11), (a1, b20, X12), (a1, b20, X13), (a1, b20, X14), (a1, b20, X15), (a1, b20, X16), (a1, b20, X17), (a1, b20, X18), (a1, b21, X1), (a1, b21, X2), (a1, b21, X3), (a1, b21, X4), (a1, b21, X5), (a1, b21, X6), (a1, b21, X7), (a1, b21, X8), (a1, b21, X9), (a1, b21, X10), (a1, b21, X11), (a1, b21, X12), (a1, b21, X13), (a1, b21, X14), (a1, b21, X15), (a1, b21, X16), (a1, b21, X17), (a1, b21, X18), (a1, b22, X1), (a1, b22, X2), (a1, b22, X3), (a1, b22, X4), (a1, b22, X5), (a1, b22, X6), (a1, b22, X7), (a1, b22, X8), (a1, b22, X9), (a1, b22, X10), (a1, b22, X11), (a1, b22, X12), (a1, b22, X13), (a1, b22, X14), (a1, b22, X15), (a1, b22, X16), (a1, b22, X17), (a1, b22, X18), (a1, b23, X1), (a1, b23, X2), (a1, b23, X3), (a1, b23, X4), (a1, b23, X5), (a1, b23, X6), (a1, b23, X7), (a1, b23, X8), (a1, b23, X9), (a1, b23, X10), (a1, b23, X11), (a1, b23, X12), (a1, b23, X13), (a1, b23, X14), (a1, b23, X15), (a1, b23, X16), (a1, b23, X17), (a1, b23, X18), (a1, b24, X1), (a1, b24, X2), (a1, b24, X3), (a1, b24, X4), (a1, b24, X5), (a1, b24, X6), (a1, b24, X7), (a1, b24, X8), (a1, b24, X9), (a1, b24, X10), (a1, b24, X11), (a1, b24, X12), (a1, b24, X13), (a1, b24, X14), (a1, b24, X15), (a1, b24, X16), (a1, b24, X17), (a1, b24, X18), (a1, b25, X1), (a1, b25, X2), (a1, b25, X3), (a1, b25, X4), (a1, b25, X5), (a1, b25, X6), (a1, b25, X7), (a1, b25, X8), (a1, b25, X9), (a1, b25, X10), (a1, b25, X11), (a1, b25, X12), (a1, b25, X13), (a1, b25, X14), (a1, b25, X15), (a1, b25, X16), (a1, b25, X17), (a1, b25, X18), (a1, b26, X1), (a1, b26, X2), (a1, b26, X3), (a1, b26, X4), (a1, b26, X5), (a1, b26, X6), (a1, b26, X7), (a1, b26, X8), (a1, b26, X9), (a1, b26, X10), (a1, b26, X11), (a1, b26, X12), (a1, b26, X13), (a1, b26, X14), (a1, b26, X15), (a1, b26, X16), (a1, b26, X17), (a1, b26, X18), (a1, b27, X1), (a1, b27, X2), (a1, b27, X3), (a1, b27, X4), (a1, b27, X5), (a1, b27, X6), (a1, b27, X7), (a1, b27, X8), (a1, b27, X9), (a1, b27, X10), (a1, b27, X11), (a1, b27, X12), (a1, b27, X13), (a1, b27, X14), (a1, b27, X15), (a1, b27, X16), (a1, b27, X17), (a1, b27, X18),
  • (a2, b1, X1), (a2, b1, X2), (a2, b1, X3), (a2, b1, X4), (a2, b1, X5), (a2, b1, X6), (a2, b1, X7), (a2, b1, X8), (a2, b1, X9), (a2, b1, X10), (a2, b1, X11), (a2, b1, X12), (a2, b1, X13), (a2, b1, X14), (a2, b1, X15), (a2, b1, X16), (a2, b1, X17), (a2, b1, X18), (a2, b2, X1), (a2, b2, X2), (a2, b2, X3), (a2, b2, X4), (a2, b2, X5), (a2, b2, X6), (a2, b2, X7), (a2, b2, X8), (a2, b2, X9), (a2, b2, X10), (a2, b2, X11), (a2, b2, X12), (a2, b2, X13), (a2, b2, X14), (a2, b2, X15), (a2, b2, X16), (a2, b2, X17), (a2, b2, X18), (a2, b3, X1), (a2, b3, X2), (a2, b3, X3), (a2, b3, X4), (a2, b3, X5), (a2, b3, X6), (a2, b3, X7), (a2, b3, X8), (a2, b3, X9), (a2, b3, X10), (a2, b3, X11), (a2, b3, X12), (a2, b3, X13), (a2, b3, X14), (a2, b3, X15), (a2, b3, X16), (a2, b3, X17), (a2, b3, X18), (a2, b4, X1), (a2, b4, X2), (a2, b4, X3), (a2, b4, X4), (a2, b4, X5), (a2, b4, X6), (a2, b4, X7), (a2, b4, X8), (a2, b4, X9), (a2, b4, X10), (a2, b4, X11), (a2, b4, X12), (a2, b4, X13), (a2, b4, X14), (a2, b4, X15), (a2, b4, X16), (a2, b4, X17), (a2, b4, X18), (a2, b5, X1), (a2, b5, X2), (a2, b5, X3), (a2, b5, X4), (a2, b5, X5), (a2, b5, X6), (a2, b5, X7), (a2, b5, X8), (a2, b5, X9), (a2, b5, X10), (a2, b5, X11), (a2, b5, X12), (a2, b5, X13), (a2, b5, X14), (a2, b5, X15), (a2, b5, X16), (a2, b5, X17), (a2, b5, X18), (a2, b6, X1), (a2, b6, X2), (a2, b6, X3), (a2, b6, X4), (a2, b6, X5), (a2, b6, X6), (a2, b6, X7), (a2, b6, X8), (a2, b6, X9), (a2, b6, X10), (a2, b6, X11), (a2, b6, X12), (a2, b6, X13), (a2, b6, X14), (a2, b6, X15), (a2, b6, X16), (a2, b6, X17), (a2, b6, X18), (a2, b7, X1), (a2, b7, X2), (a2, b7, X3), (a2, b7, X4), (a2, b7, X5), (a2, b7, X6), (a2, b7, X7), (a2, b7, X8), (a2, b7, X9), (a2, b7, X10), (a2, b7, X11), (a2, b7, X12), (a2, b7, X13), (a2, b7, X14), (a2, b7, X15), (a2, b7, X16), (a2, b7, X17), (a2, b7, X18), (a2, b8, X1), (a2, b8, X2), (a2, b8, X3), (a2, b8, X4), (a2, b8, X5), (a2, b8, X6), (a2, b8, X7), (a2, b8, X8), (a2, b8, X9), (a2, b8, X10), (a2, b8, X11), (a2, b8, X12), (a2, b8, X13), (a2, b8, X14), (a2, b8, X15), (a2, b8, X16), (a2, b8, X17), (a2, b8, X18), (a2, b9, X1), (a2, b9, X2), (a2, b9, X3), (a2, b9, X4), (a2, b9, X5), (a2, b9, X6), (a2, b9, X7), (a2, b9, X8), (a2, b9, X9), (a2, b9, X10), (a2, b9, X11), (a2, b9, X12), (a2, b9, X13), (a2, b9, X14), (a2, b9, X15), (a2, b9, X16), (a2, b9, X17), (a2, b9, X18), (a2, b10, X1), (a2, b10, X2), (a2, b10, X3), (a2, b10, X4), (a2, b10, X5), (a2, b10, X6), (a2, b10, X7), (a2, b10, X8), (a2, b10, X9), (a2, b10, X10), (a2, b10, X11), (a2, b10, X12), (a2, b10, X13), (a2, b10, X14), (a2, b10, X15), (a2, b10, X16), (a2, b10, X17), (a2, b10, X18), (a2, b11, X1), (a2, b11, X2), (a2, b11, X3), (a2, b11, X4), (a2, b11, X5), (a2, b11, X6), (a2, b11, X7), (a2, b11, X8), (a2, b11, X9), (a2, b11, X10), (a2, b11, X11), (a2, b11, X12), (a2, b11, X13), (a2, b11, X14), (a2, b11, X15), (a2, b11, X16), (a2, b11, X17), (a2, b11, X18), (a2, b12, X1), (a2, b12, X2), (a2, b12, X3), (a2, b12, X4), (a2, b12, X5), (a2, b12, X6), (a2, b12, X7), (a2, b12, X8), (a2, b12, X9), (a2, b12, X10), (a2, b12, X11), (a2, b12, X12), (a2, b12, X13), (a2, b12, X14), (a2, b12, X15), (a2, b12, X16), (a2, b12, X17), (a2, b12, X18), (a2, b13, X1), (a2, b13, X2), (a2, b13, X3), (a2, b13, X4), (a2, b13, X5), (a2, b13, X6), (a2, b13, X7), (a2, b13, X8), (a2, b13, X9), (a2, b13, X10), (a2, b13, X11), (a2, b13, X12), (a2, b13, X13), (a2, b13, X14), (a2, b13, X15), (a2, b13, X16), (a2, b13, X17), (a2, b13, X18), (a2, b14, X1), (a2, b14, X2), (a2, b14, X3), (a2, b14, X4), (a2, b14, X5), (a2, b14, X6), (a2, b14, X7), (a2, b14, X8), (a2, b14, X9), (a2, b14, X10), (a2, b14, X11), (a2, b14, X12), (a2, b14, X13), (a2, b14, X14), (a2, b14, X15), (a2, b14, X16), (a2, b14, X17), (a2, b14, X18), (a2, b15, X1), (a2, b15, X2), (a2, b15, X3), (a2, b15, X4), (a2, b15, X5), (a2, b15, X6), (a2, b15, X7), (a2, b15, X8), (a2, b15, X9), (a2, b15, X10), (a2, b15, X11), (a2, b15, X12), (a2, b15, X13), (a2, b15, X14), (a2, b15, X15), (a2, b15, X16), (a2, b15, X17), (a2, b15, X18), (a2, b16, X1), (a2, b16, X2), (a2, b16, X3), (a2, b16, X4), (a2, b16, X5), (a2, b16, X6), (a2, b16, X7), (a2, b16, X8), (a2, b16, X9), (a2, b16, X10), (a2, b16, X11), (a2, b16, X12), (a2, b16, X13), (a2, b16, X14), (a2, b16, X15), (a2, b16, X16), (a2, b16, X17), (a2, b16, X18), (a2, b17, X1), (a2, b17, X2), (a2, b17, X3), (a2, b17, X4), (a2, b17, X5), (a2, b17, X6), (a2, b17, X7), (a2, b17, X8), (a2, b17, X9), (a2, b17, X10), (a2, b17, X11), (a2, b17, X12), (a2, b17, X13), (a2, b17, X14), (a2, b17, X15), (a2, b17, X16), (a2, b17, X17), (a2, b17, X18), (a2, b18, X1), (a2, b18, X2), (a2, b18, X3), (a2, b18, X4), (a2, b18, X5), (a2, b18, X6), (a2, b18, X7), (a2, b18, X8), (a2, b18, X9), (a2, b18, X10), (a2, b18, X11), (a2, b18, X12), (a2, b18, X13), (a2, b18, X14), (a2, b18, X15), (a2, b18, X16), (a2, b18, X17), (a2, b18, X18), (a2, b19, X1), (a2, b19, X2), (a2, b19, X3), (a2, b19, X4), (a2, b19, X5), (a2, b19, X6), (a2, b19, X7), (a2, b19, X8), (a2, b19, X9), (a2, b19, X10), (a2, b19, X11), (a2, b19, X12), (a2, b19, X13), (a2, b19, X14), (a2, b19, X15), (a2, b19, X16), (a2, b19, X17), (a2, b19, X18), (a2, b20, X1), (a2, b20, X2), (a2, b20, X3), (a2, b20, X4), (a2, b20, X5), (a2, b20, X6), (a2, b20, X7), (a2, b20, X8), (a2, b20, X9), (a2, b20, X10), (a2, b20, X11), (a2, b20, X12), (a2, b20, X13), (a2, b20, X14), (a2, b20, X15), (a2, b20, X16), (a2, b20, X17), (a2, b20, X18), (a2, b21, X1), (a2, b21, X2), (a2, b21, X3), (a2, b21, X4), (a2, b21, X5), (a2, b21, X6), (a2, b21, X7), (a2, b21, X8), (a2, b21, X9), (a2, b21, X10), (a2, b21, X11), (a2, b21, X12), (a2, b21, X13), (a2, b21, X14), (a2, b21, X15), (a2, b21, X16), (a2, b21, X17), (a2, b21, X18), (a2, b22, X1), (a2, b22, X2), (a2, b22, X3), (a2, b22, X4), (a2, b22, X5), (a2, b22, X6), (a2, b22, X7), (a2, b22, X8), (a2, b22, X9), (a2, b22, X10), (a2, b22, X11), (a2, b22, X12), (a2, b22, X13), (a2, b22, X14), (a2, b22, X15), (a2, b22, X16), (a2, b22, X17), (a2, b22, X18), (a2, b23, X1), (a2, b23, X2), (a2, b23, X3), (a2, b23, X4), (a2, b23, X5), (a2, b23, X6), (a2, b23, X7), (a2, b23, X8), (a2, b23, X9), (a2, b23, X10), (a2, b23, X11), (a2, b23, X12), (a2, b23, X13), (a2, b23, X14), (a2, b23, X15), (a2, b23, X16), (a2, b23, X17), (a2, b23, X18), (a2, b24, X1), (a2, b24, X2), (a2, b24, X3), (a2, b24, X4), (a2, b24, X5), (a2, b24, X6), (a2, b24, X7), (a2, b24, X8), (a2, b24, X9), (a2, b24, X10), (a2, b24, X11), (a2, b24, X12), (a2, b24, X13), (a2, b24, X14), (a2, b24, X15), (a2, b24, X16), (a2, b24, X17), (a2, b24, X18), (a2, b25, X1), (a2, b25, X2), (a2, b25, X3), (a2, b25, X4), (a2, b25, X5), (a2, b25, X6), (a2, b25, X7), (a2, b25, X8), (a2, b25, X9), (a2, b25, X10), (a2, b25, X11), (a2, b25, X12), (a2, b25, X13), (a2, b25, X14), (a2, b25, X15), (a2, b25, X16), (a2, b25, X17), (a2, b25, X18), (a2, b26, X1), (a2, b26, X2), (a2, b26, X3), (a2, b26, X4), (a2, b26, X5), (a2, b26, X6), (a2, b26, X7), (a2, b26, X8), (a2, b26, X9), (a2, b26, X10), (a2, b26, X11), (a2, b26, X12), (a2, b26, X13), (a2, b26, X14), (a2, b26, X15), (a2, b26, X16), (a2, b26, X17), (a2, b26, X18), (a2, b27, X1), (a2, b27, X2), (a2, b27, X3), (a2, b27, X4), (a2, b27, X5), (a2, b27, X6), (a2, b27, X7), (a2, b27, X8), (a2, b27, X9), (a2, b27, X10), (a2, b27, X11), (a2, b27, X12), (a2, b27, X13), (a2, b27, X14), (a2, b27, X15), (a2, b27, X16), (a2, b27, X17), (a2, b27, X18),
  • (a3, b1, X1), (a3, b1, X2), (a3, b1, X3), (a3, b1, X4), (a3, b1, X5), (a3, b1, X6), (a3, b1, X7), (a3, b1, X8), (a3, b1, X9), (a3, b1, X10), (a3, b1, X11), (a3, b1, X12), (a3, b1, X13), (a3, b1, X14), (a3, b1, X15), (a3, b1, X16), (a3, b1, X17), (a3, b1, X18), (a3, b2, X1), (a3, b2, X2), (a3, b2, X3), (a3, b2, X4), (a3, b2, X5), (a3, b2, X6), (a3, b2, X7), (a3, b2, X8), (a3, b2, X9), (a3, b2, X10), (a3, b2, X11), (a3, b2, X12), (a3, b2, X13), (a3, b2, X14), (a3, b2, X15), (a3, b2, X16), (a3, b2, X17), (a3, b2, X18), (a3, b3, X1), (a3, b3, X2), (a3, b3, X3), (a3, b3, X4), (a3, b3, X5), (a3, b3, X6), (a3, b3, X7), (a3, b3, X8), (a3, b3, X9), (a3, b3, X10), (a3, b3, X11), (a3, b3, X12), (a3, b3, X13), (a3, b3, X14), (a3, b3, X15), (a3, b3, X16), (a3, b3, X17), (a3, b3, X18), (a3, b4, X1), (a3, b4, X2), (a3, b4, X3), (a3, b4, X4), (a3, b4, X5), (a3, b4, X6), (a3, b4, X7), (a3, b4, X8), (a3, b4, X9), (a3, b4, X10), (a3, b4, X11), (a3, b4, X12), (a3, b4, X13), (a3, b4, X14), (a3, b4, X15), (a3, b4, X16), (a3, b4, X17), (a3, b4, X18), (a3, b5, X1), (a3, b5, X2), (a3, b5, X3), (a3, b5, X4), (a3, b5, X5), (a3, b5, X6), (a3, b5, X7), (a3, b5, X8), (a3, b5, X9), (a3, b5, X10), (a3, b5, X11), (a3, b5, X12), (a3, b5, X13), (a3, b5, X14), (a3, b5, X15), (a3, b5, X16), (a3, b5, X17), (a3, b5, X18), (a3, b6, X1), (a3, b6, X2), (a3, b6, X3), (a3, b6, X4), (a3, b6, X5), (a3, b6, X6), (a3, b6, X7), (a3, b6, X8), (a3, b6, X9), (a3, b6, X10), (a3, b6, X11), (a3, b6, X12), (a3, b6, X13), (a3, b6, X14), (a3, b6, X15), (a3, b6, X16), (a3, b6, X17), (a3, b6, X18), (a3, b7, X1), (a3, b7, X2), (a3, b7, X3), (a3, b7, X4), (a3, b7, X5), (a3, b7, X6), (a3, b7, X7), (a3, b7, X8), (a3, b7, X9), (a3, b7, X10), (a3, b7, X11), (a3, b7, X12), (a3, b7, X13), (a3, b7, X14), (a3, b7, X15), (a3, b7, X16), (a3, b7, X17), (a3, b7, X18), (a3, b8, X1), (a3, b8, X2), (a3, b8, X3), (a3, b8, X4), (a3, b8, X5), (a3, b8, X6), (a3, b8, X7), (a3, b8, X8), (a3, b8, X9), (a3, b8, X10), (a3, b8, X11), (a3, b8, X12), (a3, b8, X13), (a3, b8, X14), (a3, b8, X15), (a3, b8, X16), (a3, b8, X17), (a3, b8, X18), (a3, b9, X1), (a3, b9, X2), (a3, b9, X3), (a3, b9, X4), (a3, b9, X5), (a3, b9, X6), (a3, b9, X7), (a3, b9, X8), (a3, b9, X9), (a3, b9, X10), (a3, b9, X11), (a3, b9, X12), (a3, b9, X13), (a3, b9, X14), (a3, b9, X15), (a3, b9, X16), (a3, b9, X17), (a3, b9, X18), (a3, b10, X1), (a3, b10, X2), (a3, b10, X3), (a3, b10, X4), (a3, b10, X5), (a3, b10, X6), (a3, b10, X7), (a3, b10, X8), (a3, b10, X9), (a3, b10, X10), (a3, b10, X11), (a3, b10, X12), (a3, b10, X13), (a3, b10, X14), (a3, b10, X15), (a3, b10, X16), (a3, b10, X17), (a3, b10, X18), (a3, b11, X1), (a3, b11, X2), (a3, b11, X3), (a3, b11, X4), (a3, b11, X5), (a3, b11, X6), (a3, b11, X7), (a3, b11, X8), (a3, b11, X9), (a3, b11, X10), (a3, b11, X11), (a3, b11, X12), (a3, b11, X13), (a3, b11, X14), (a3, b11, X15), (a3, b11, X16), (a3, b11, X17), (a3, b11, X18), (a3, b12, X1), (a3, b12, X2), (a3, b12, X3), (a3, b12, X4), (a3, b12, X5), (a3, b12, X6), (a3, b12, X7), (a3, b12, X8), (a3, b12, X9), (a3, b12, X10), (a3, b12, X11), (a3, b12, X12), (a3, b12, X13), (a3, b12, X14), (a3, b12, X15), (a3, b12, X16), (a3, b12, X17), (a3, b12, X18), (a3, b13, X1), (a3, b13, X2), (a3, b13, X3), (a3, b13, X4), (a3, b13, X5), (a3, b13, X6), (a3, b13, X7), (a3, b13, X8), (a3, b13, X9), (a3, b13, X10), (a3, b13, X11), (a3, b13, X12), (a3, b13, X13), (a3, b13, X14), (a3, b13, X15), (a3, b13, X16), (a3, b13, X17), (a3, b13, X18), (a3, b14, X1), (a3, b14, X2), (a3, b14, X3), (a3, b14, X4), (a3, b14, X5), (a3, b14, X6), (a3, b14, X7), (a3, b14, X8), (a3, b14, X9), (a3, b14, X10), (a3, b14, X11), (a3, b14, X12), (a3, b14, X13), (a3, b14, X14), (a3, b14, X15), (a3, b14, X16), (a3, b14, X17), (a3, b14, X18), (a3, b15, X1), (a3, b15, X2), (a3, b15, X3), (a3, b15, X4), (a3, b15, X5), (a3, b15, X6), (a3, b15, X7), (a3, b15, X8), (a3, b15, X9), (a3, b15, X10), (a3, b15, X11), (a3, b15, X12), (a3, b15, X13), (a3, b15, X14), (a3, b15, X15), (a3, b15, X16), (a3, b15, X17), (a3, b15, X18), (a3, b16, X1), (a3, b16, X2), (a3, b16, X3), (a3, b16, X4), (a3, b16, X5), (a3, b16, X6), (a3, b16, X7), (a3, b16, X8), (a3, b16, X9), (a3, b16, X10), (a3, b16, X11), (a3, b16, X12), (a3, b16, X13), (a3, b16, X14), (a3, b16, X15), (a3, b16, X16), (a3, b16, X17), (a3, b16, X18), (a3, b17, X1), (a3, b17, X2), (a3, b17, X3), (a3, b17, X4), (a3, b17, X5), (a3, b17, X6), (a3, b17, X7), (a3, b17, X8), (a3, b17, X9), (a3, b17, X10), (a3, b17, X11), (a3, b17, X12), (a3, b17, X13), (a3, b17, X14), (a3, b17, X15), (a3, b17, X16), (a3, b17, X17), (a3, b17, X18), (a3, b18, X1), (a3, b18, X2), (a3, b18, X3), (a3, b18, X4), (a3, b18, X5), (a3, b18, X6), (a3, b18, X7), (a3, b18, X8), (a3, b18, X9), (a3, b18, X10), (a3, b18, X11), (a3, b18, X12), (a3, b18, X13), (a3, b18, X14), (a3, b18, X15), (a3, b18, X16), (a3, b18, X17), (a3, b18, X18), (a3, b19, X1), (a3, b19, X2), (a3, b19, X3), (a3, b19, X4), (a3, b19, X5), (a3, b19, X6), (a3, b19, X7), (a3, b19, X8), (a3, b19, X9), (a3, b19, X10), (a3, b19, X11), (a3, b19, X12), (a3, b19, X13), (a3, b19, X14), (a3, b19, X15), (a3, b19, X16), (a3, b19, X17), (a3, b19, X18), (a3, b20, X1), (a3, b20, X2), (a3, b20, X3), (a3, b20, X4), (a3, b20, X5), (a3, b20, X6), (a3, b20, X7), (a3, b20, X8), (a3, b20, X9), (a3, b20, X10), (a3, b20, X11), (a3, b20, X12), (a3, b20, X13), (a3, b20, X14), (a3, b20, X15), (a3, b20, X16), (a3, b20, X17), (a3, b20, X18), (a3, b21, X1), (a3, b21, X2), (a3, b21, X3), (a3, b21, X4), (a3, b21, X5), (a3, b21, X6), (a3, b21, X7), (a3, b21, X8), (a3, b21, X9), (a3, b21, X10), (a3, b21, X11), (a3, b21, X12), (a3, b21, X13), (a3, b21, X14), (a3, b21, X15), (a3, b21, X16), (a3, b21, X17), (a3, b21, X18), (a3, b22, X1), (a3, b22, X2), (a3, b22, X3), (a3, b22, X4), (a3, b22, X5), (a3, b22, X6), (a3, b22, X7), (a3, b22, X8), (a3, b22, X9), (a3, b22, X10), (a3, b22, X11), (a3, b22, X12), (a3, b22, X13), (a3, b22, X14), (a3, b22, X15), (a3, b22, X16), (a3, b22, X17), (a3, b22, X18), (a3, b23, X1), (a3, b23, X2), (a3, b23, X3), (a3, b23, X4), (a3, b23, X5), (a3, b23, X6), (a3, b23, X7), (a3, b23, X8), (a3, b23, X9), (a3, b23, X10), (a3, b23, X11), (a3, b23, X12), (a3, b23, X13), (a3, b23, X14), (a3, b23, X15), (a3, b23, X16), (a3, b23, X17), (a3, b23, X18), (a3, b24, X1), (a3, b24, X2), (a3, b24, X3), (a3, b24, X4), (a3, b24, X5), (a3, b24, X6), (a3, b24, X7), (a3, b24, X8), (a3, b24, X9), (a3, b24, X10), (a3, b24, X11), (a3, b24, X12), (a3, b24, X13), (a3, b24, X14), (a3, b24, X15), (a3, b24, X16), (a3, b24, X17), (a3, b24, X18), (a3, b25, X1), (a3, b25, X2), (a3, b25, X3), (a3, b25, X4), (a3, b25, X5), (a3, b25, X6), (a3, b25, X7), (a3, b25, X8), (a3, b25, X9), (a3, b25, X10), (a3, b25, X11), (a3, b25, X12), (a3, b25, X13), (a3, b25, X14), (a3, b25, X15), (a3, b25, X16), (a3, b25, X17), (a3, b25, X18), (a3, b26, X1), (a3, b26, X2), (a3, b26, X3), (a3, b26, X4), (a3, b26, X5), (a3, b26, X6), (a3, b26, X7), (a3, b26, X8), (a3, b26, X9), (a3, b26, X10), (a3, b26, X11), (a3, b26, X12), (a3, b26, X13), (a3, b26, X14), (a3, b26, X15), (a3, b26, X16), (a3, b26, X17), (a3, b26, X18), (a3, b27, X1), (a3, b27, X2), (a3, b27, X3), (a3, b27, X4), (a3, b27, X5), (a3, b27, X6), (a3, b27, X7), (a3, b27, X8), (a3, b27, X9), (a3, b27, X10), (a3, b27, X11), (a3, b27, X12), (a3, b27, X13), (a3, b27, X14), (a3, b27, X15), (a3, b27, X16), (a3, b27, X17), (a3, b27, X18),
  • (a4, b1, X1), (a4, b1, X2), (a4, b1, X3), (a4, b1, X4), (a4, b1, X5), (a4, b1, X6), (a4, b1, X7), (a4, b1, X8), (a4, b1, X9), (a4, b1, X10), (a4, b1, X11), (a4, b1, X12), (a4, b1, X13), (a4, b1, X14), (a4, b1, X15), (a4, b1, X16), (a4, b1, X17), (a4, b1, X18), (a4, b2, X1), (a4, b2, X2), (a4, b2, X3), (a4, b2, X4), (a4, b2, X5), (a4, b2, X6), (a4, b2, X7), (a4, b2, X8), (a4, b2, X9), (a4, b2, X10), (a4, b2, X11), (a4, b2, X12), (a4, b2, X13), (a4, b2, X14), (a4, b2, X15), (a4, b2, X16), (a4, b2, X17), (a4, b2, X18), (a4, b3, X1), (a4, b3, X2), (a4, b3, X3), (a4, b3, X4), (a4, b3, X5), (a4, b3, X6), (a4, b3, X7), (a4, b3, X8), (a4, b3, X9), (a4, b3, X10), (a4, b3, X11), (a4, b3, X12), (a4, b3, X13), (a4, b3, X14), (a4, b3, X15), (a4, b3, X16), (a4, b3, X17), (a4, b3, X18), (a4, b4, X1), (a4, b4, X2), (a4, b4, X3), (a4, b4, X4), (a4, b4, X5), (a4, b4, X6), (a4, b4, X7), (a4, b4, X8), (a4, b4, X9), (a4, b4, X10), (a4, b4, X11), (a4, b4, X12), (a4, b4, X13), (a4, b4, X14), (a4, b4, X15), (a4, b4, X16), (a4, b4, X17), (a4, b4, X18), (a4, b5, X1), (a4, b5, X2), (a4, b5, X3), (a4, b5, X4), (a4, b5, X5), (a4, b5, X6), (a4, b5, X7), (a4, b5, X8), (a4, b5, X9), (a4, b5, X10), (a4, b5, X11), (a4, b5, X12), (a4, b5, X13), (a4, b5, X14), (a4, b5, X15), (a4, b5, X16), (a4, b5, X17), (a4, b5, X18), (a4, b6, X1), (a4, b6, X2), (a4, b6, X3), (a4, b6, X4), (a4, b6, X5), (a4, b6, X6), (a4, b6, X7), (a4, b6, X8), (a4, b6, X9), (a4, b6, X10), (a4, b6, X11), (a4, b6, X12), (a4, b6, X13), (a4, b6, X14), (a4, b6, X15), (a4, b6, X16), (a4, b6, X17), (a4, b6, X18), (a4, b7, X1), (a4, b7, X2), (a4, b7, X3), (a4, b7, X4), (a4, b7, X5), (a4, b7, X6), (a4, b7, X7), (a4, b7, X8), (a4, b7, X9), (a4, b7, X10), (a4, b7, X11), (a4, b7, X12), (a4, b7, X13), (a4, b7, X14), (a4, b7, X15), (a4, b7, X16), (a4, b7, X17), (a4, b7, X18), (a4, b8, X1), (a4, b8, X2), (a4, b8, X3), (a4, b8, X4), (a4, b8, X5), (a4, b8, X6), (a4, b8, X7), (a4, b8, X8), (a4, b8, X9), (a4, b8, X10), (a4, b8, X11), (a4, b8, X12), (a4, b8, X13), (a4, b8, X14), (a4, b8, X15), (a4, b8, X16), (a4, b8, X17), (a4, b8, X18), (a4, b9, X1), (a4, b9, X2), (a4, b9, X3), (a4, b9, X4), (a4, b9, X5), (a4, b9, X6), (a4, b9, X7), (a4, b9, X8), (a4, b9, X9), (a4, b9, X10), (a4, b9, X11), (a4, b9, X12), (a4, b9, X13), (a4, b9, X14), (a4, b9, X15), (a4, b9, X16), (a4, b9, X17), (a4, b9, X18), (a4, b10, X1), (a4, b10, X2), (a4, b10, X3), (a4, b10, X4), (a4, b10, X5), (a4, b10, X6), (a4, b10, X7), (a4, b10, X8), (a4, b10, X9), (a4, b10, X10), (a4, b10, X11), (a4, b10, X12), (a4, b10, X13), (a4, b10, X14), (a4, b10, X15), (a4, b10, X16), (a4, b10, X17), (a4, b10, X18), (a4, b11, X1), (a4, b11, X2), (a4, b11, X3), (a4, b11, X4), (a4, b11, X5), (a4, b11, X6), (a4, b11, X7), (a4, b11, X8), (a4, b11, X9), (a4, b11, X10), (a4, b11, X11), (a4, b11, X12), (a4, b11, X13), (a4, b11, X14), (a4, b11, X15), (a4, b11, X16), (a4, b11, X17), (a4, b11, X18), (a4, b12, X1), (a4, b12, X2), (a4, b12, X3), (a4, b12, X4), (a4, b12, X5), (a4, b12, X6), (a4, b12, X7), (a4, b12, X8), (a4, b12, X9), (a4, b12, X10), (a4, b12, X11), (a4, b12, X12), (a4, b12, X13), (a4, b12, X14), (a4, b12, X15), (a4, b12, X16), (a4, b12, X17), (a4, b12, X18), (a4, b13, X1), (a4, b13, X2), (a4, b13, X3), (a4, b13, X4), (a4, b13, X5), (a4, b13, X6), (a4, b13, X7), (a4, b13, X8), (a4, b13, X9), (a4, b13, X10), (a4, b13, X11), (a4, b13, X12), (a4, b13, X13), (a4, b13, X14), (a4, b13, X15), (a4, b13, X16), (a4, b13, X17), (a4, b13, X18), (a4, b14, X1), (a4, b14, X2), (a4, b14, X3), (a4, b14, X4), (a4, b14, X5), (a4, b14, X6), (a4, b14, X7), (a4, b14, X8), (a4, b14, X9), (a4, b14, X10), (a4, b14, X11), (a4, b14, X12), (a4, b14, X13), (a4, b14, X14), (a4, b14, X15), (a4, b14, X16), (a4, b14, X17), (a4, b14, X18), (a4, b15, X1), (a4, b15, X2), (a4, b15, X3), (a4, b15, X4), (a4, b15, X5), (a4, b15, X6), (a4, b15, X7), (a4, b15, X8), (a4, b15, X9), (a4, b15, X10), (a4, b15, X11), (a4, b15, X12), (a4, b15, X13), (a4, b15, X14), (a4, b15, X15), (a4, b15, X16), (a4, b15, X17), (a4, b15, X18), (a4, b16, X1), (a4, b16, X2), (a4, b16, X3), (a4, b16, X4), (a4, b16, X5), (a4, b16, X6), (a4, b16, X7), (a4, b16, X8), (a4, b16, X9), (a4, b16, X10), (a4, b16, X11), (a4, b16, X12), (a4, b16, X13), (a4, b16, X14), (a4, b16, X15), (a4, b16, X16), (a4, b16, X17), (a4, b16, X18), (a4, b17, X1), (a4, b17, X2), (a4, b17, X3), (a4, b17, X4), (a4, b17, X5), (a4, b17, X6), (a4, b17, X7), (a4, b17, X8), (a4, b17, X9), (a4, b17, X10), (a4, b17, X11), (a4, b17, X12), (a4, b17, X13), (a4, b17, X14), (a4, b17, X15), (a4, b17, X16), (a4, b17, X17), (a4, b17, X18), (a4, b18, X1), (a4, b18, X2), (a4, b18, X3), (a4, b18, X4), (a4, b18, X5), (a4, b18, X6), (a4, b18, X7), (a4, b18, X8), (a4, b18, X9), (a4, b18, X10), (a4, b18, X11), (a4, b18, X12), (a4, b18, X13), (a4, b18, X14), (a4, b18, X15), (a4, b18, X16), (a4, b18, X17), (a4, b18, X18), (a4, b19, X1), (a4, b19, X2), (a4, b19, X3), (a4, b19, X4), (a4, b19, X5), (a4, b19, X6), (a4, b19, X7), (a4, b19, X8), (a4, b19, X9), (a4, b19, X10), (a4, b19, X11), (a4, b19, X12), (a4, b19, X13), (a4, b19, X14), (a4, b19, X15), (a4, b19, X16), (a4, b19, X17), (a4, b19, X18), (a4, b20, X1), (a4, b20, X2), (a4, b20, X3), (a4, b20, X4), (a4, b20, X5), (a4, b20, X6), (a4, b20, X7), (a4, b20, X8), (a4, b20, X9), (a4, b20, X10), (a4, b20, X11), (a4, b20, X12), (a4, b20, X13), (a4, b20, X14), (a4, b20, X15), (a4, b20, X16), (a4, b20, X17), (a4, b20, X18), (a4, b21, X1), (a4, b21, X2), (a4, b21, X3), (a4, b21, X4), (a4, b21, X5), (a4, b21, X6), (a4, b21, X7), (a4, b21, X8), (a4, b21, X9), (a4, b21, X10), (a4, b21, X11), (a4, b21, X12), (a4, b21, X13), (a4, b21, X14), (a4, b21, X15), (a4, b21, X16), (a4, b21, X17), (a4, b21, X18), (a4, b22, X1), (a4, b22, X2), (a4, b22, X3), (a4, b22, X4), (a4, b22, X5), (a4, b22, X6), (a4, b22, X7), (a4, b22, X8), (a4, b22, X9), (a4, b22, X10), (a4, b22, X11), (a4, b22, X12), (a4, b22, X13), (a4, b22, X14), (a4, b22, X15), (a4, b22, X16), (a4, b22, X17), (a4, b22, X18), (a4, b23, X1), (a4, b23, X2), (a4, b23, X3), (a4, b23, X4), (a4, b23, X5), (a4, b23, X6), (a4, b23, X7), (a4, b23, X8), (a4, b23, X9), (a4, b23, X10), (a4, b23, X11), (a4, b23, X12), (a4, b23, X13), (a4, b23, X14), (a4, b23, X15), (a4, b23, X16), (a4, b23, X17), (a4, b23, X18), (a4, b24, X1), (a4, b24, X2), (a4, b24, X3), (a4, b24, X4), (a4, b24, X5), (a4, b24, X6), (a4, b24, X7), (a4, b24, X8), (a4, b24, X9), (a4, b24, X10), (a4, b24, X11), (a4, b24, X12), (a4, b24, X13), (a4, b24, X14), (a4, b24, X15), (a4, b24, X16), (a4, b24, X17), (a4, b24, X18), (a4, b25, X1), (a4, b25, X2), (a4, b25, X3), (a4, b25, X4), (a4, b25, X5), (a4, b25, X6), (a4, b25, X7), (a4, b25, X8), (a4, b25, X9), (a4, b25, X10), (a4, b25, X11), (a4, b25, X12), (a4, b25, X13), (a4, b25, X14), (a4, b25, X15), (a4, b25, X16), (a4, b25, X17), (a4, b25, X18), (a4, b26, X1), (a4, b26, X2), (a4, b26, X3), (a4, b26, X4), (a4, b26, X5), (a4, b26, X6), (a4, b26, X7), (a4, b26, X8), (a4, b26, X9), (a4, b26, X10), (a4, b26, X11), (a4, b26, X12), (a4, b26, X13), (a4, b26, X14), (a4, b26, X15), (a4, b26, X16), (a4, b26, X17), (a4, b26, X18), (a4, b27, X1), (a4, b27, X2), (a4, b27, X3), (a4, b27, X4), (a4, b27, X5), (a4, b27, X6), (a4, b27, X7), (a4, b27, X8), (a4, b27, X9), (a4, b27, X10), (a4, b27, X11), (a4, b27, X12), (a4, b27, X13), (a4, b27, X14), (a4, b27, X15), (a4, b27, X16), (a4, b27, X17), (a4, b27, X18),
  • (a5, b1, X1), (a5, b1, X2), (a5, b1, X3), (a5, b1, X4), (a5, b1, X5), (a5, b1, X6), (a5, b1, X7), (a5, b1, X8), (a5, b1, X9), (a5, b1, X10), (a5, b1, X11), (a5, b1, X12), (a5, b1, X13), (a5, b1, X14), (a5, b1, X15), (a5, b1, X16), (a5, b1, X17), (a5, b1, X18), (a5, b2, X1), (a5, b2, X2), (a5, b2, X3), (a5, b2, X4), (a5, b2, X5), (a5, b2, X6), (a5, b2, X7), (a5, b2, X8), (a5, b2, X9), (a5, b2, X10), (a5, b2, X11), (a5, b2, X12), (a5, b2, X13), (a5, b2, X14), (a5, b2, X15), (a5, b2, X16), (a5, b2, X17), (a5, b2, X18), (a5, b3, X1), (a5, b3, X2), (a5, b3, X3), (a5, b3, X4), (a5, b3, X5), (a5, b3, X6), (a5, b3, X7), (a5, b3, X8), (a5, b3, X9), (a5, b3, X10), (a5, b3, X11), (a5, b3, X12), (a5, b3, X13), (a5, b3, X14), (a5, b3, X15), (a5, b3, X16), (a5, b3, X17), (a5, b3, X18), (a5, b4, X1), (a5, b4, X2), (a5, b4, X3), (a5, b4, X4), (a5, b4, X5), (a5, b4, X6), (a5, b4, X7), (a5, b4, X8), (a5, b4, X9), (a5, b4, X10), (a5, b4, X11), (a5, b4, X12), (a5, b4, X13), (a5, b4, X14), (a5, b4, X15), (a5, b4, X16), (a5, b4, X17), (a5, b4, X18), (a5, b5, X1), (a5, b5, X2), (a5, b5, X3), (a5, b5, X4), (a5, b5, X5), (a5, b5, X6), (a5, b5, X7), (a5, b5, X8), (a5, b5, X9), (a5, b5, X10), (a5, b5, X11), (a5, b5, X12), (a5, b5, X13), (a5, b5, X14), (a5, b5, X15), (a5, b5, X16), (a5, b5, X17), (a5, b5, X18), (a5, b6, X1), (a5, b6, X2), (a5, b6, X3), (a5, b6, X4), (a5, b6, X5), (a5, b6, X6), (a5, b6, X7), (a5, b6, X8), (a5, b6, X9), (a5, b6, X10), (a5, b6, X11), (a5, b6, X12), (a5, b6, X13), (a5, b6, X14), (a5, b6, X15), (a5, b6, X16), (a5, b6, X17), (a5, b6, X18), (a5, b7, X1), (a5, b7, X2), (a5, b7, X3), (a5, b7, X4), (a5, b7, X5), (a5, b7, X6), (a5, b7, X7), (a5, b7, X8), (a5, b7, X9), (a5, b7, X10), (a5, b7, X11), (a5, b7, X12), (a5, b7, X13), (a5, b7, X14), (a5, b7, X15), (a5, b7, X16), (a5, b7, X17), (a5, b7, X18), (a5, b8, X1), (a5, b8, X2), (a5, b8, X3), (a5, b8, X4), (a5, b8, X5), (a5, b8, X6), (a5, b8, X7), (a5, b8, X8), (a5, b8, X9), (a5, b8, X10), (a5, b8, X11), (a5, b8, X12), (a5, b8, X13), (a5, b8, X14), (a5, b8, X15), (a5, b8, X16), (a5, b8, X17), (a5, b8, X18), (a5, b9, X1), (a5, b9, X2), (a5, b9, X3), (a5, b9, X4), (a5, b9, X5), (a5, b9, X6), (a5, b9, X7), (a5, b9, X8), (a5, b9, X9), (a5, b9, X10), (a5, b9, X11), (a5, b9, X12), (a5, b9, X13), (a5, b9, X14), (a5, b9, X15), (a5, b9, X16), (a5, b9, X17), (a5, b9, X18), (a5, b10, X1), (a5, b10, X2), (a5, b10, X3), (a5, b10, X4), (a5, b10, X5), (a5, b10, X6), (a5, b10, X7), (a5, b10, X8), (a5, b10, X9), (a5, b10, X10), (a5, b10, X11), (a5, b10, X12), (a5, b10, X13), (a5, b10, X14), (a5, b10, X15), (a5, b10, X16), (a5, b10, X17), (a5, b10, X18), (a5, b11, X1), (a5, b11, X2), (a5, b11, X3), (a5, b11, X4), (a5, b11, X5), (a5, b11, X6), (a5, b11, X7), (a5, b11, X8), (a5, b11, X9), (a5, b11, X10), (a5, b11, X11), (a5, b11, X12), (a5, b11, X13), (a5, b11, X14), (a5, b11, X15), (a5, b11, X16), (a5, b11, X17), (a5, b11, X18), (a5, b12, X1), (a5, b12, X2), (a5, b12, X3), (a5, b12, X4), (a5, b12, X5), (a5, b12, X6), (AZ, b12, X7), (a5, b12, X8), (a5, b12, X9), (a5, b12, X10), (a5, b12, X11), (a5, b12, X12), (a5, b12, X13), (a5, b12, X14), (a5, b12, X15), (a5, b12, X16), (a5, b12, X17), (a5, b12, X18), (a5, b13, X1), (a5, b13, X2), (a5, b13, X3), (a5, b13, X4), (a5, b13, X5), (a5, b13, X6), (a5, b13, X7), (a5, b13, X8), (a5, b13, X9), (a5, b13, X10), (a5, b13, X11), (a5, b13, X12), (a5, b13, X13), (a5, b13, X14), (a5, b13, X15), (a5, b13, X16), (a5, b13, X17), (a5, b13, X18), (a5, b14, X1), (a5, b14, X2), (a5, b14, X3), (a5, b14, X4), (a5, b14, X5), (a5, b14, X6), (a5, b14, X7), (a5, b14, X8), (a5, b14, X9), (a5, b14, X10), (a5, b14, X11), (a5, b14, X12), (a5, b14, X13), (a5, b14, X14), (a5, b14, X15), (a5, b14, X16), (a5, b14, X17), (a5, b14, X18), (a5, b15, X1), (a5, b15, X2), (a5, b15, X3), (a5, b15, X4), (a5, b15, X5), (a5, b15, X6), (a5, b15, X7), (a5, b15, X8), (a5, b15, X9), (a5, b15, X10), (a5, b15, X11), (a5, b15, X12), (a5, b15, X13), (a5, b15, X14), (a5, b15, X15), (a5, b15, X16), (a5, b15, X17), (a5, b15, X18), (a5, b16, X1), (a5, b16, X2), (a5, b16, X3), (a5, b16, X4), (a5, b16, X5), (a5, b16, X6), (a5, b16, X7), (a5, b16, X8), (a5, b16, X9), (a5, b16, X10), (a5, b16, X11), (a5, b16, X12), (a5, b16, X13), (a5, b16, X14), (a5, b16, X15), (a5, b16, X16), (a5, b16, X17), (a5, b16, X18), (a5, b17, X1), (a5, b17, X2), (a5, b17, X3), (a5, b17, X4), (a5, b17, X5), (a5, b17, X6), (a5, b17, X7), (a5, b17, X8), (a5, b17, X9), (a5, b17, X10), (a5, b17, X11), (a5, b17, X12), (a5, b17, X13), (a5, b17, X14), (a5, b17, X15), (a5, b17, X16), (a5, b17, X17), (a5, b17, X18), (a5, b18, X1), (a5, b18, X2), (a5, b18, X3), (a5, b18, X4), (a5, b18, X5), (a5, b18, X6), (a5, b18, X7), (a5, b18, X8), (a5, b18, X9), (a5, b18, X10), (a5, b18, X11), (a5, b18, X12), (a5, b18, X13), (a5, b18, X14), (a5, b18, X15), (a5, b18, X16), (a5, b18, X17), (a5, b18, X18), (a5, b19, X1), (a5, b19, X2), (a5, b19, X3), (a5, b19, X4), (a5, b19, X5), (a5, b19, X6), (a5, b19, X7), (a5, b19, X8), (a5, b19, X9), (a5, b19, X10), (a5, b19, X11), (a5, b19, X12), (a5, b19, X13), (a5, b19, X14), (a5, b19, X15), (a5, b19, X16), (a5, b19, X17), (a5, b19, X18), (a5, b20, X1), (a5, b20, X2), (a5, b20, X3), (a5, b20, X4), (a5, b20, X5), (a5, b20, X6), (a5, b20, X7), (a5, b20, X8), (a5, b20, X9), (a5, b20, X10), (a5, b20, X11), (a5, b20, X12), (a5, b20, X13), (a5, b20, X14), (a5, b20, X15), (a5, b20, X16), (a5, b20, X17), (a5, b20, X18), (a5, b21, X1), (a5, b21, X2), (a5, b21, X3), (a5, b21, X4), (a5, b21, X5), (a5, b21, X6), (a5, b21, X7), (a5, b21, X8), (a5, b21, X9), (a5, b21, X10), (a5, b21, X11), (a5, b21, X12), (a5, b21, X13), (a5, b21, X14), (a5, b21, X15), (a5, b21, X16), (a5, b21, X17), (a5, b21, X18), (a5, b22, X1), (a5, b22, X2), (a5, b22, X3), (a5, b22, X4), (a5, b22, X5), (a5, b22, X6), (a5, b22, X7), (a5, b22, X8), (a5, b22, X9), (a5, b22, X10), (a5, b22, X11), (a5, b22, X12), (a5, b22, X13), (a5, b22, X14), (a5, b22, X15), (a5, b22, X16), (a5, b22, X17), (a5, b22, X18), (a5, b23, X1), (a5, b23, X2), (a5, b23, X3), (a5, b23, X4), (a5, b23, X5), (a5, b23, X6), (a5, b23, X7), (a5, b23, X8), (a5, b23, X9), (a5, b23, X10), (a5, b23, X11), (a5, b23, X12), (a5, b23, X13), (a5, b23, X14), (a5, b23, X15), (a5, b23, X16), (a5, b23, X17), (a5, b23, X18), (a5, b24, X1), (a5, b24, X2), (a5, b24, X3), (a5, b24, X4), (a5, b24, X5), (a5, b24, X6), (a5, b24, X7), (a5, b24, X8), (a5, b24, X9), (a5, b24, X10), (a5, b24, X11), (a5, b24, X12), (a5, b24, X13), (a5, b24, X14), (a5, b24, X15), (a5, b24, X16), (a5, b24, X17), (a5, b24, X18), (a5, b25, X1), (a5, b25, X2), (a5, b25, X3), (a5, b25, X4), (a5, b25, X5), (a5, b25, X6), (a5, b25, X7), (a5, b25, X8), (a5, b25, X9), (a5, b25, X10), (a5, b25, X11), (a5, b25, X12), (a5, b25, X13), (a5, b25, X14), (a5, b25, X15), (a5, b25, X16), (a5, b25, X17), (a5, b25, X18), (a5, b26, X1), (a5, b26, X2), (a5, b26, X3), (a5, b26, X4), (a5, b26, X5), (a5, b26, X6), (a5, b26, X7), (a5, b26, X8), (a5, b26, X9), (a5, b26, X10), (a5, b26, X11), (a5, b26, X12), (a5, b26, X13), (a5, b26, X14), (a5, b26, X15), (a5, b26, X16), (a5, b26, X17), (a5, b26, X18), (a5, b27, X1), (a5, b27, X2), (a5, b27, X3), (a5, b27, X4), (a5, b27, X5), (a5, b27, X6), (a5, b27, X7), (a5, b27, X8), (a5, b27, X9), (a5, b27, X10), (a5, b27, X11), (a5, b27, X12), (a5, b27, X13), (a5, b27, X14), (a5, b27, X15), (a5, b27, X16), (a5, b27, X17), (a5, b27, X18),
  • (a6, b1, X1), (a6, b1, X2), (a6, b1, X3), (a6, b1, X4), (a6, b1, X5), (a6, b1, X6), (a6, b1, X7), (a6, b1, X8), (a6, b1, X9), (a6, b1, X10), (a6, b1, X11), (a6, b1, X12), (a6, b1, X13), (a6, b1, X14), (a6, b1, X15), (a6, b1, X16), (a6, b1, X17), (a6, b1, X18), (a6, b2, X1), (a6, b2, X2), (a6, b2, X3), (a6, b2, X4), (a6, b2, X5), (a6, b2, X6), (a6, b2, X7), (a6, b2, X8), (a6, b2, X9), (a6, b2, X10), (a6, b2, X11), (a6, b2, X12), (a6, b2, X13), (a6, b2, X14), (a6, b2, X15), (a6, b2, X16), (a6, b2, X17), (a6, b2, X18), (a6, b3, X1), (a6, b3, X2), (a6, b3, X3), (a6, b3, X4), (a6, b3, X5), (a6, b3, X6), (a6, b3, X7), (a6, b3, X8), (a6, b3, X9), (a6, b3, X10), (a6, b3, X11), (a6, b3, X12), (a6, b3, X13), (a6, b3, X14), (a6, b3, X15), (a6, b3, X16), (a6, b3, X17), (a6, b3, X18), (a6, b4, X1), (a6, b4, X2), (a6, b4, X3), (a6, b4, X4), (a6, b4, X5), (a6, b4, X6), (a6, b4, X7), (a6, b4, X8), (a6, b4, X9), (a6, b4, X10), (a6, b4, X11), (a6, b4, X12), (a6, b4, X13), (a6, b4, X14), (a6, b4, X15), (a6, b4, X16), (a6, b4, X17), (a6, b4, X18), (a6, b5, X1), (a6, b5, X2), (a6, b5, X3), (a6, b5, X4), (a6, b5, X5), (a6, b5, X6), (a6, b5, X7), (a6, b5, X8), (a6, b5, X9), (a6, b5, X10), (a6, b5, X11), (a6, b5, X12), (a6, b5, X13), (a6, b5, X14), (a6, b5, X15), (a6, b5, X16), (a6, b5, X17), (a6, b5, X18), (a6, b6, X1), (a6, b6, X2), (a6, b6, X3), (a6, b6, X4), (a6, b6, X5), (a6, b6, X6), (a6, b6, X7), (a6, b6, X8), (a6, b6, X9), (a6, b6, X10), (a6, b6, X11), (a6, b6, X12), (a6, b6, X13), (a6, b6, X14), (a6, b6, X15), (a6, b6, X16), (a6, b6, X17), (a6, b6, X18), (a6, b7, Xi), (a6, b7, X2), (a6, b7, X3), (a6, b7, X4), (a6, b7, X5), (a6, b7, X6), (a6, b7, X7), (a6, b7, X8), (a6, b7, X9), (a6, b7, X10), (a6, b7, X11), (a6, b7, X12), (a6, b7, X13), (a6, b7, X14), (a6, b7, X15), (a6, b7, X16), (a6, b7, X17), (a6, b7, X18), (a6, b8, X1), (a6, b8, X2), (a6, b8, X3), (a6, b8, X4), (a6, b8, X5), (a6, b8, X6), (a6, b8, X7), (a6, b8, X8), (a6, b8, X9), (a6, b8, X10), (a6, b8, X11), (a6, b8, X12), (a6, b8, X13), (a6, b8, X14), (a6, b8, X15), (a6, b8, X16), (a6, b8, X17), (a6, b8, X18), (a6, b9, X1), (a6, b9, X2), (a6, b9, X3), (a6, b9, X4), (a6, b9, X5), (a6, b9, X6), (a6, b9, X7), (a6, b9, X8), (a6, b9, X9), (a6, b9, X10), (a6, b9, X11), (a6, b9, X12), (a6, b9, X13), (a6, b9, X14), (a6, b9, X15), (a6, b9, X16), (a6, b9, X17), (a6, b9, X18), (a6, b10, X1), (a6, b10, X2), (a6, b10, X3), (a6, b10, X4), (a6, b10, X5), (a6, b10, X6), (a6, b10, X7), (a6, b10, X8), (a6, b10, X9), (a6, b10, X10), (a6, b10, X11), (a6, b10, X12), (a6, b10, X13), (a6, b10, X14), (a6, b10, X15), (a6, b10, X16), (a6, b10, X17), (a6, b10, X18), (a6, b11, X1), (a6, b11, X2), (a6, b11, X3), (a6, b11, X4), (a6, b11, X5), (a6, b11, X6), (a6, b11, X7), (a6, b11, X8), (a6, b11, X9), (a6, b11, X10), (a6, b11, X11), (a6, b11, X12), (a6, b11, X13), (a6, b11, X14), (a6, b11, X15), (a6, b11, X16), (a6, b11, X17), (a6, b11, X18), (a6, b12, X1), (a6, b12, X2), (a6, b12, X3), (a6, b12, X4), (a6, b12, X5), (a6, b12, X6), (a6, b12, X7), (a6, b12, X8), (a6, b12, X9), (a6, b12, X10), (a6, b12, X11), (a6, b12, X12), (a6, b12, X13), (a6, b12, X14), (a6, b12, X15), (a6, b12, X16), (a6, b12, X17), (a6, b12, X18), (a6, b13, X1), (a6, b13, X2), (a6, b13, X3), (a6, b13, X4), (a6, b13, X5), (a6, b13, X6), (a6, b13, X7), (a6, b13, X8), (a6, b13, X9), (a6, b13, X10), (a6, b13, X11), (a6, b13, X12), (a6, b13, X13), (a6, b13, X14), (a6, b13, X15), (a6, b13, X16), (a6, b13, X17), (a6, b13, X18), (a6, b14, X1), (a6, b14, X2), (a6, b14, X3), (a6, b14, X4), (a6, b14, X5), (a6, b14, X6), (a6, b14, X7), (a6, b14, X8), (a6, b14, X9), (a6, b14, X10), (a6, b14, X11), (a6, b14, X12), (a6, b14, X13), (a6, b14, X14), (a6, b14, X15), (a6, b14, X16), (a6, b14, X17), (a6, b14, X18), (a6, b15, X1), (a6, b15, X2), (a6, b15, X3), (a6, b15, X4), (a6, b15, X5), (a6, b15, X6), (a6, b15, X7), (a6, b15, X8), (a6, b15, X9), (a6, b15, X10), (a6, b15, X11), (a6, b15, X12), (a6, b15, X13), (a6, b15, X14), (a6, b15, X15), (a6, b15, X16), (a6, b15, X17), (a6, b15, X18), (a6, b16, X1), (a6, b16, X2), (a6, b16, X3), (a6, b16, X4), (a6, b16, X5), (a6, b16, X6), (a6, b16, X7), (a6, b16, X8), (a6, b16, X9), (a6, b16, X10), (a6, b16, X11), (a6, b16, X12), (a6, b16, X13), (a6, b16, X14), (a6, b16, X15), (a6, b16, X16), (a6, b16, X17), (a6, b16, X18), (a6, b17, X1), (a6, b17, X2), (a6, b17, X3), (a6, b17, X4), (a6, b17, X5), (a6, b17, X6), (a6, b17, X7), (a6, b17, X8), (a6, b17, X9), (a6, b17, X10), (a6, b17, X11), (a6, b17, X12), (a6, b17, X13), (a6, b17, X14), (a6, b17, X15), (a6, b17, X16), (a6, b17, X17), (a6, b17, X18), (a6, b18, X1), (a6, b18, X2), (a6, b18, X3), (a6, b18, X4), (a6, b18, X5), (a6, b18, X6), (a6, b18, X7), (a6, b18, X8), (a6, b18, X9), (a6, b18, X10), (a6, b18, X11), (a6, b18, X12), (a6, b18, X13), (a6, b18, X14), (a6, b18, X15), (a6, b18, X16), (a6, b18, X17), (a6, b18, X18), (a6, b19, X1), (a6, b19, X2), (a6, b19, X3), (a6, b19, X4), (a6, b19, X5), (a6, b19, X6), (a6, b19, X7), (a6, b19, X8), (a6, b19, X9), (a6, b19, X10), (a6, b19, X11), (a6, b19, X12), (a6, b19, X13), (a6, b19, X14), (a6, b19, X15), (a6, b19, X16), (a6, b19, X17), (a6, b19, X18), (a6, b20, X1), (a6, b20, X2), (a6, b20, X3), (a6, b20, X4), (a6, b20, X5), (a6, b20, X6), (a6, b20, X7), (a6, b20, X8), (a6, b20, X9), (a6, b20, X10), (a6, b20, X11), (a6, b20, X12), (a6, b20, X13), (a6, b20, X14), (a6, b20, X15), (a6, b20, X16), (a6, b20, X17), (a6, b20, X18), (a6, b21, X1), (a6, b21, X2), (a6, b21, X3), (a6, b21, X4), (a6, b21, X5), (a6, b21, X6), (a6, b21, X7), (a6, b21, X8), (a6, b21, X9), (a6, b21, X10), (a6, b21, X11), (a6, b21, X12), (a6, b21, X13), (a6, b21, X14), (a6, b21, X15), (a6, b21, X16), (a6, b21, X17), (a6, b21, X18), (a6, b22, X1), (a6, b22, X2), (a6, b22, X3), (a6, b22, X4), (a6, b22, X5), (a6, b22, X6), (a6, b22, X7), (a6, b22, X8), (a6, b22, X9), (a6, b22, X10), (a6, b22, X11), (a6, b22, X12), (a6, b22, X13), (a6, b22, X14), (a6, b22, X15), (a6, b22, X16), (a6, b22, X17), (a6, b22, X18), (a6, b23, X1), (a6, b23, X2), (a6, b23, X3), (a6, b23, X4), (a6, b23, X5), (a6, b23, X6), (a6, b23, X7), (a6, b23, X8), (a6, b23, X9), (a6, b23, X10), (a6, b23, X11), (a6, b23, X12), (a6, b23, X13), (a6, b23, X14), (a6, b23, X15), (a6, b23, X16), (a6, b23, X17), (a6, b23, X18), (a6, b24, X1), (a6, b24, X2), (a6, b24, X3), (a6, b24, X4), (a6, b24, X5), (a6, b24, X6), (a6, b24, X7), (a6, b24, X8), (a6, b24, X9), (a6, b24, X10), (a6, b24, X11), (a6, b24, X12), (a6, b24, X13), (a6, b24, X14), (a6, b24, X15), (a6, b24, X16), (a6, b24, X17), (a6, b24, X18), (a6, b25, X1), (a6, b25, X2), (a6, b25, X3), (a6, b25, X4), (a6, b25, X5), (a6, b25, X6), (a6, b25, X7), (a6, b25, X8), (a6, b25, X9), (a6, b25, X10), (a6, b25, X11), (a6, b25, X12), (a6, b25, X13), (a6, b25, X14), (a6, b25, X15), (a6, b25, X16), (a6, b25, X17), (a6, b25, X18), (a6, b26, X1), (a6, b26, X2), (a6, b26, X3), (a6, b26, X4), (a6, b26, X5), (a6, b26, X6), (a6, b26, X7), (a6, b26, X8), (a6, b26, X9), (a6, b26, X10), (a6, b26, X11), (a6, b26, X12), (a6, b26, X13), (a6, b26, X14), (a6, b26, X15), (a6, b26, X16), (a6, b26, X17), (a6, b26, X18), (a6, b27, X1), (a6, b27, X2), (a6, b27, X3), (a6, b27, X4), (a6, b27, X5), (a6, b27, X6), (a6, b27, X7), (a6, b27, X8), (a6, b27, X9), (a6, b27, X10), (a6, b27, X11), (a6, b27, X12), (a6, b27, X13), (a6, b27, X14), (a6, b27, X15), (a6, b27, X16), (a6, b27, X17), (a6, b27, X18),
  • (a7, b1, X1), (a7, b1, X2), (a7, b1, X3), (a7, b1, X4), (a7, b1, X5), (a7, b1, X6), (a7, b1, X7), (a7, b1, X8), (a7, b1, X9), (a7, b1, X10), (a7, b1, X11), (a7, b1, X12), (a7, b1, X13), (a7, b1, X14), (a7, b1, X15), (a7, b1, X16), (a7, b1, X17), (a7, b1, X18), (a7, b2, X1), (a7, b2, X2), (a7, b2, X3), (a7, b2, X4), (a7, b2, X5), (a7, b2, X6), (a7, b2, X7), (a7, b2, X8), (a7, b2, X9), (a7, b2, X10), (a7, b2, X11), (a7, b2, X12), (a7, b2, X13), (a7, b2, X14), (a7, b2, X15), (a7, b2, X16), (a7, b2, X17), (a7, b2, X18), (a7, b3, X1), (a7, b3, X2), (a7, b3, X3), (a7, b3, X4), (a7, b3, X5), (a7, b3, X6), (a7, b3, X7), (a7, b3, X8), (a7, b3, X9), (a7, b3, X10), (a7, b3, X11), (a7, b3, X12), (a7, b3, X13), (a7, b3, X14), (a7, b3, X15), (a7, b3, X16), (a7, b3, X17), (a7, b3, X18), (a7, b4, X1), (a7, b4, X2), (a7, b4, X3), (a7, b4, X4), (a7, b4, X5), (a7, b4, X6), (a7, b4, X7), (a7, b4, X8), (a7, b4, X9), (a7, b4, X10), (a7, b4, X11), (a7, b4, X12), (a7, b4, X13), (a7, b4, X14), (a7, b4, X15), (a7, b4, X16), (a7, b4, X17), (a7, b4, X18), (a7, b5, X1), (a7, b5, X2), (a7, b5, X3), (a7, b5, X4), (a7, b5, X5), (a7, b5, X6), (a7, b5, X7), (a7, b5, X8), (a7, b5, X9), (a7, b5, X10), (a7, b5, X11), (a7, b5, X12), (a7, b5, X13), (a7, b5, X14), (a7, b5, X15), (a7, b5, X16), (a7, b5, X17), (a7, b5, X18), (a7, b6, X1), (a7, b6, X2), (a7, b6, X3), (a7, b6, X4), (a7, b6, X5), (a7, b6, X6), (a7, b6, X7), (a7, b6, X8), (a7, b6, X9), (a7, b6, X10), (a7, b6, X11), (a7, b6, X12), (a7, b6, X13), (a7, b6, X14), (a7, b6, X15), (a7, b6, X16), (a7, b6, X17), (a7, b6, X18), (a7, b7, X1), (a7, b7, X2), (a7, b7, X3), (a7, b7, X4), (a7, b7, X5), (a7, b7, X6), (a7, b7, X7), (a7, b7, X8), (a7, b7, X9), (a7, b7, X10), (a7, b7, X11), (a7, b7, X12), (a7, b7, X13), (a7, b7, X14), (a7, b7, X15), (a7, b7, X16), (a7, b7, X17), (a7, b7, X18), (a7, b8, X1), (a7, b8, X2), (a7, b8, X3), (a7, b8, X4), (a7, b8, X5), (a7, b8, X6), (a7, b8, X7), (a7, b8, X8), (a7, b8, X9), (a7, b8, X10), (a7, b8, X11), (a7, b8, X12), (a7, b8, X13), (a7, b8, X14), (a7, b8, X15), (a7, b8, X16), (a7, b8, X17), (a7, b8, X18), (a7, b9, X1), (a7, b9, X2), (a7, b9, X3), (a7, b9, X4), (a7, b9, X5), (a7, b9, X6), (a7, b9, X7), (a7, b9, X8), (a7, b9, X9), (a7, b9, X10), (a7, b9, X11), (a7, b9, X12), (a7, b9, X13), (a7, b9, X14), (a7, b9, X15), (a7, b9, X16), (a7, b9, X17), (a7, b9, X18), (a7, b10, X1), (a7, b10, X2), (a7, b10, X3), (a7, b10, X4), (a7, b10, X5), (a7, b10, X6), (a7, b10, X7), (a7, b10, X8), (a7, b10, X9), (a7, b10, X10), (a7, b10, X11), (a7, b10, X12), (a7, b10, X13), (a7, b10, X14), (a7, b10, X15), (a7, b10, X16), (a7, b10, X17), (a7, b10, X18), (a7, b11, X1), (a7, b11, X2), (a7, b11, X3), (a7, b11, X4), (a7, b11, X5), (a7, b11, X6), (a7, b11, X7), (a7, b11, X8), (a7, b11, X9), (a7, b11, X10), (a7, b11, X11), (a7, b11, X12), (a7, b11, X13), (a7, b11, X14), (a7, b11, X15), (a7, b11, X16), (a7, b11, X17), (a7, b11, X18), (a7, b12, X1), (a7, b12, X2), (a7, b12, X3), (a7, b12, X4), (a7, b12, X5), (a7, b12, X6), (a7, b12, X7), (a7, b12, X8), (a7, b12, X9), (a7, b12, X10), (a7, b12, X11), (a7, b12, X12), (a7, b12, X13), (a7, b12, X14), (a7, b12, X15), (a7, b12, X16), (a7, b12, X17), (a7, b12, X18), (a7, b13, X1), (a7, b13, X2), (a7, b13, X3), (a7, b13, X4), (a7, b13, X5), (a7, b13, X6), (a7, b13, X7), (a7, b13, X8), (a7, b13, X9), (a7, b13, X10), (a7, b13, X11), (a7, b13, X12), (a7, b13, X13), (a7, b13, X14), (a7, b13, X15), (a7, b13, X16), (a7, b13, X17), (a7, b13, X18), (a7, b14, X1), (a7, b14, X2), (a7, b14, X3), (a7, b14, X4), (a7, b14, X5), (a7, b14, X6), (a7, b14, X7), (a7, b14, X8), (a7, b14, X9), (a7, b14, X10), (a7, b14, X11), (a7, b14, X12), (a7, b14, X13), (a7, b14, X14), (a7, b14, X15), (a7, b14, X16), (a7, b14, X17), (a7, b14, X18), (a7, b15, X1), (a7, b15, X2), (a7, b15, X3), (a7, b15, X4), (a7, b15, X5), (a7, b15, X6), (a7, b15, X7), (a7, b15, X8), (a7, b15, X9), (a7, b15, X10), (a7, b15, X11), (a7, b15, X12), (a7, b15, X13), (a7, b15, X14), (a7, b15, X15), (a7, b15, X16), (a7, b15, X17), (a7, b15, X18), (a7, b16, X1), (a7, b16, X2), (a7, b16, X3), (a7, b16, X4), (a7, b16, X5), (a7, b16, X6), (a7, b16, X7), (a7, b16, X8), (a7, b16, X9), (a7, b16, X10), (a7, b16, X11), (a7, b16, X12), (a7, b16, X13), (a7, b16, X14), (a7, b16, X15), (a7, b16, X16), (a7, b16, X17), (a7, b16, X18), (a7, b17, X1), (a7, b17, X2), (a7, b17, X3), (a7, b17, X4), (a7, b17, X5), (a7, b17, X6), (a7, b17, X7), (a7, b17, X8), (a7, b17, X9), (a7, b17, X10), (a7, b17, X11), (a7, b17, X12), (a7, b17, X13), (a7, b17, X14), (a7, b17, X15), (a7, b17, X16), (a7, b17, X17), (a7, b17, X18), (a7, b18, X1), (a7, b18, X2), (a7, b18, X3), (a7, b18, X4), (a7, b18, X5), (a7, b18, X6), (a7, b18, X7), (a7, b18, X8), (a7, b18, X9), (a7, b18, X10), (a7, b18, X11), (a7, b18, X12), (a7, b18, X13), (a7, b18, X14), (a7, b18, X15), (a7, b18, X16), (a7, b18, X17), (a7, b18, X18), (a7, b19, X1), (a7, b19, X2), (a7, b19, X3), (a7, b19, X4), (a7, b19, X5), (a7, b19, X6), (a7, b19, X7), (a7, b19, X8), (a7, b19, X9), (a7, b19, X10), (a7, b19, X11), (a7, b19, X12), (a7, b19, X13), (a7, b19, X14), (a7, b19, X15), (a7, b19, X16), (a7, b19, X17), (a7, b19, X18), (a7, b20, X1), (a7, b20, X2), (a7, b20, X3), (a7, b20, X4), (a7, b20, X5), (a7, b20, X6), (a7, b20, X7), (a7, b20, X8), (a7, b20, X9), (a7, b20, X10), (a7, b20, X11), (a7, b20, X12), (a7, b20, X13), (a7, b20, X14), (a7, b20, X15), (a7, b20, X16), (a7, b20, X17), (a7, b20, X18), (a7, b21, X1), (a7, b21, X2), (a7, b21, X3), (a7, b21, X4), (a7, b21, X5), (a7, b21, X6), (a7, b21, X7), (a7, b21, X8), (a7, b21, X9), (a7, b21, X10), (a7, b21, X11), (a7, b21, X12), (a7, b21, X13), (a7, b21, X14), (a7, b21, X15), (a7, b21, X16), (a7, b21, X17), (a7, b21, X18), (a7, b22, X1), (a7, b22, X2), (a7, b22, X3), (a7, b22, X4), (a7, b22, X5), (a7, b22, X6), (a7, b22, X7), (a7, b22, X8), (a7, b22, X9), (a7, b22, X10), (a7, b22, X11), (a7, b22, X12), (a7, b22, X13), (a7, b22, X14), (a7, b22, X15), (a7, b22, X16), (a7, b22, X17), (a7, b22, X18), (a7, b23, X1), (a7, b23, X2), (a7, b23, X3), (a7, b23, X4), (a7, b23, X5), (a7, b23, X6), (a7, b23, X7), (a7, b23, X8), (a7, b23, X9), (a7, b23, X10), (a7, b23, X11), (a7, b23, X12), (a7, b23, X13), (a7, b23, X14), (a7, b23, X15), (a7, b23, X16), (a7, b23, X17), (a7, b23, X18), (a7, b24, X1), (a7, b24, X2), (a7, b24, X3), (a7, b24, X4), (a7, b24, X5), (a7, b24, X6), (a7, b24, X7), (a7, b24, X8), (a7, b24, X9), (a7, b24, X10), (a7, b24, X11), (a7, b24, X12), (a7, b24, X13), (a7, b24, X14), (a7, b24, X15), (a7, b24, X16), (a7, b24, X17), (a7, b24, X18), (a7, b25, X1), (a7, b25, X2), (a7, b25, X3), (a7, b25, X4), (a7, b25, X5), (a7, b25, X6), (a7, b25, X7), (a7, b25, X8), (a7, b25, X9), (a7, b25, X10), (a7, b25, X11), (a7, b25, X12), (a7, b25, X13), (a7, b25, X14), (a7, b25, X15), (a7, b25, X16), (a7, b25, X17), (a7, b25, X18), (a7, b26, X1), (a7, b26, X2), (a7, b26, X3), (a7, b26, X4), (a7, b26, X5), (a7, b26, X6), (a7, b26, X7), (a7, b26, X8), (a7, b26, X9), (a7, b26, X10), (a7, b26, X11), (a7, b26, X12), (a7, b26, X13), (a7, b26, X14), (a7, b26, X15), (a7, b26, X16), (a7, b26, X17), (a7, b26, X18), (a7, b27, X1), (a7, b27, X2), (a7, b27, X3), (a7, b27, X4), (a7, b27, X5), (a7, b27, X6), (a7, b27, X7), (a7, b27, X8), (a7, b27, X9), (a7, b27, X10), (a7, b27, X11), (a7, b27, X12), (a7, b27, X13), (a7, b27, X14), (a7, b27, X15), (a7, b27, X16), (a7, b27, X17), (a7, b27, X18),
  • (a8, b1, X1), (a8, b1, X2), (a8, 131, X3), (a8, b1, X4), (a8, b1, X5), (a8, b1, X6), (a8, b1, X7), (a8, b1, X8), (a8, b1, X9), (a8, b1, X10), (a8, b1, X11), (a8, b1, X12), (a8, b1, X13), (a8, b1, X14), (a8, b1, X15), (a8, b1, X16), (a8, b1, X17), (a8, b1, X18), (a8, b2, X1), (a8, b2, X2), (a8, b2, X3), (a8, b2, X4), (a8, b2, X5), (a8, b2, X6), (a8, b2, X7), (a8, b2, X8), (a8, b2, X9), (a8, b2, X10), (a8, b2, X11), (a8, b2, X12), (a8, b2, X13), (a8, b2, X14), (a8, b2, X15), (a8, b2, X16), (a8, b2, X17), (a8, b2, X18), (a8, b3, X1), (a8, b3, X2), (a8, b3, X3), (a8, b3, X4), (a8, b3, X5), (a8, b3, X6), (a8, b3, X7), (a8, b3, X8), (a8, b3, X9), (a8, b3, X10), (a8, X11), (a8, b3, X12), (a8, b3, X13), (a8, b3, X14), (a8, b3, X15), (a8, b3, X16), (a8, b3, X17), (a8, b3, X18), (a8, b4, X1), (a8, b4, X2), (a8, b4, X3), (a8, b4, X4), (a8, b4, X5), (a8, b4, X6), (a8, b4, X7), (a8, b4, X8), (a8, b4, X9), (a8, b4, X10), (a8, b4, X11), (a8, b4, X12), (a8, b4, X13), (a8, b4, X14), (a8, b4, X15), (a8, b4, X16), (a8, b4, X17), (a8, b4, X18), (a8, b5, X1), (a8, b5, X2), (a8, b5, X3), (a8, b5, X4), (a8, b5, X5), (a8, b5, X6), (a8, b5, X7), (a8, b5, X8), (a8, b5, X9), (a8, b5, X10), (a8, b5, X11), (a8, b5, X12), (a8, b5, X13), (a8, b5, X14), (a8, b5, X15), (a8, b5, X16), (a8, b5, X17), (a8, b5, X18), (a8, b6, X1), (a8, b6, X2), (a8, b6, X3), (a8, b6, X4), (a8, b6, X5), (a8, b6, X6), (a8, b6, X7), (a8, b6, X8), (a8, b6, X9), (a8, b6, X10), (a8, b6, X11), (a8, b6, X12), (a8, b6, X13), (a8, b6, X14), (a8, b6, X15), (a8, b6, X16), (a8, b6, X17), (a8, b6, X18), (a8, b7, X1), (a8, b7, X2), (a8, b7, X3), (a8, b7, X4), (a8, b7, X5), (a8, b7, X6), (a8, b7, X7), (a8, b7, X8), (a8, b7, X9), (a8, b7, X10), (a8, b7, X11), (a8, b7, X12), (a8, b7, X13), (a8, b7, X14), (a8, b7, X15), (a8, b7, X16), (a8, b7, X17), (a8, b7, X18), (a8, b8, X1), (a8, b8, X2), (a8, b8, X3), (a8, b8, X4), (a8, b8, X5), (a8, b8, X6), (a8, b8, X7), (a8, b8, X8), (a8, b8, X9), (a8, b8, X10), (a8, b8, X11), (a8, b8, X12), (a8, b8, X13), (a8, b8, X14), (a8, b8, X15), (a8, b8, X16), (a8, b8, X17), (a8, b8, X18), (a8, b9, X1), (a8, b9, X2), (a8, b9, X3), (a8, b9, X4), (a8, b9, X5), (a8, b9, X6), (a8, b9, X7), (a8, b9, X8), (a8, b9, X9), (a8, b9, X10), (a8, b9, X11), (a8, b9, X12), (a8, b9, X13), (a8, b9, X14), (a8, b9, X15), (a8, b9, X16), (a8, b9, X17), (a8, b9, X18), (a8, b10, X1), (a8, b10, X2), (a8, b10, X3), (a8, b10, X4), (a8, b10, X5), (a8, b10, X6), (a8, b10, X7), (a8, b10, X8), (a8, b10, X9), (a8, b10, X10), (a8, b10, X11), (a8, b10, X12), (a8, b10, X13), (a8, b10, X14), (a8, b10, X15), (a8, b10, X16), (a8, b10, X17), (a8, b10, X18), (a8, b11, X1), (a8, b11, X2), (a8, b11, X3), (a8, b11, X4), (a8, b11, X5), (a8, b11, X6), (a8, b11, X7), (a8, b11, X8), (a8, b11, X9), (a8, b11, X10), (a8, b11, X11), (a8, b11, X12), (a8, b11, X13), (a8, b11, X14), (a8, b11, X15), (a8, b11, X16), (a8, b11, X17), (a8, b11, X18), (a8, b12, X1), (a8, b12, X2), (a8, b12, X3), (a8, b12, X4), (a8, b12, X5), (a8, b12, X6), (a8, b12, X7), (a8, b12, X8), (a8, b12, X9), (a8, b12, X10), (a8, b12, X11), (a8, b12, X12), (a8, b12, X13), (a8, b12, X14), (a8, b12, X15), (a8, b12, X16), (a8, b12, X17), (a8, b12, X18), (a8, b13, X1), (a8, b13, X2), (a8, b13, X3), (a8, b13, X4), (a8, b13, X5), (a8, b13, X6), (a8, b13, X7), (a8, b13, X8), (a8, b13, X9), (a8, b13, X10), (a8, b13, X11), (a8, b13, X12), (a8, b13, X13), (a8, b13, X14), (a8, b13, X15), (a8, b13, X16), (a8, b13, X17), (a8, b13, X18), (a8, b14, X1), (a8, b14, X2), (a8, b14, X3), (a8, b14, X4), (a8, b14, X5), (a8, b14, X6), (a8, b14, X7), (a8, b14, X8), (a8, b14, X9), (a8, b14, X10), (a8, b14, X11), (a8, b14, X12), (a8, b14, X13), (a8, b14, X14), (a8, b14, X15), (a8, b14, X16), (a8, b14, X17), (a8, b14, X18), (a8, b15, X1), (a8, b15, X2), (a8, b15, X3), (a8, b15, X4), (a8, b15, X5), (a8, b15, X6), (a8, b15, X7), (a8, b15, X8), (a8, b15, X9), (a8, b15, X10), (a8, b15, X11), (a8, b15, X12), (a8, b15, X13), (a8, b15, X14), (a8, b15, X15), (a8, b15, X16), (a8, b15, X17), (a8, b15, X18), (a8, b16, X1), (a8, b16, X2), (a8, b16, X3), (a8, b16, X4), (a8, b16, X5), (a8, b16, X6), (a8, b16, X7), (a8, b16, X8), (a8, b16, X9), (a8, b16, X10), (a8, b16, X11), (a8, b16, X12), (a8, b16, X13), (a8, b16, X14), (a8, b16, X15), (a8, b16, X16), (a8, b16, X17), (a8, b16, X18), (a8, b17, X1), (a8, b17, X2), (a8, b17, X3), (a8, b17, X4), (a8, b17, X5), (a8, b17, X6), (a8, b17, X7), (a8, b17, X8), (a8, b17, X9), (a8, b17, X10), (a8, b17, X11), (a8, b17, X12), (a8, b17, X13), (a8, b17, X14), (a8, b17, X15), (a8, b17, X16), (a8, b17, X17), (a8, b17, X18), (a8, b18, X1), (a8, b18, X2), (a8, b18, X3), (a8, b18, X4), (a8, b18, X5), (a8, b18, X6), (a8, b18, X7), (a8, b18, X8), (a8, b18, X9), (a8, b18, X10), (a8, b18, X11), (a8, b18, X12), (a8, b18, X13), (a8, b18, X14), (a8, b18, X15), (a8, b18, X16), (a8, b18, X17), (a8, b18, X18), (a8, b19, X1), (a8, b19, X2), (a8, b19, X3), (a8, b19, X4), (a8, b19, X5), (a8, b19, X6), (a8, b19, X7), (a8, b19, X8), (a8, b19, X9), (a8, b19, X10), (a8, b19, X11), (a8, b19, X12), (a8, b19, X13), (a8, b19, X14), (a8, b19, X15), (a8, b19, X16), (a8, b19, X17), (a8, b19, X18), (a8, b20, X1), (a8, b20, X2), (a8, b20, X3), (a8, b20, X4), (a8, b20, X5), (a8, b20, X6), (a8, b20, X7), (a8, b20, X8), (a8, b20, X9), (a8, b20, X10), (a8, b20, X11), (a8, b20, X12), (a8, b20, X13), (a8, b20, X14), (a8, b20, X15), (a8, b20, X16), (a8, b20, X17), (a8, b20, X18), (a8, b21, X1), (a8, b21, X2), (a8, b21, X3), (a8, b21, X4), (a8, b21, X5), (a8, b21, X6), (a8, b21, X7), (a8, b21, X8), (a8, b21, X9), (a8, b21, X10), (a8, b21, X11), (a8, b21, X12), (a8, b21, X13), (a8, b21, X14), (a8, b21, X15), (a8, b21, X16), (a8, b21, X17), (a8, b21, X18), (a8, b22, X1), (a8, b22, X2), (a8, b22, X3), (a8, b22, X4), (a8, b22, X5), (a8, b22, X6), (a8, b22, X7), (a8, b22, X8), (a8, b22, X9), (a8, b22, X10), (a8, b22, X11), (a8, b22, X12), (a8, b22, X13), (a8, b22, X14), (a8, b22, X15), (a8, b22, X16), (a8, b22, X17), (a8, b22, X18), (a8, b23, X1), (a8, b23, X2), (a8, b23, X3), (a8, b23, X4), (a8, b23, X5), (a8, b23, X6), (a8, b23, X7), (a8, b23, X8), (a8, b23, X9), (a8, b23, X10), (a8, b23, X11), (a8, b23, X12), (a8, b23, X13), (a8, b23, X14), (a8, b23, X15), (a8, b23, X16), (a8, b23, X17), (a8, b23, X18), (a8, b24, X1), (a8, b24, X2), (a8, b24, X3), (a8, b24, X4), (a8, b24, X5), (a8, b24, X6), (a8, b24, X7), (a8, b24, X8), (a8, b24, X9), (a8, b24, X10), (a8, b24, X11), (a8, b24, X12), (a8, b24, X13), (a8, b24, X14), (a8, b24, X15), (a8, b24, X16), (a8, b24, X17), (a8, b24, X18), (a8, b25, X1), (a8, b25, X2), (a8, b25, X3), (a8, b25, X4), (a8, b25, X5), (a8, b25, X6), (a8, b25, X7), (a8, b25, X8), (a8, b25, X9), (a8, b25, X10), (a8, b25, X11), (a8, b25, X12), (a8, b25, X13), (a8, b25, X14), (a8, b25, X15), (a8, b25, X16), (a8, b25, X17), (a8, b25, X18), (a8, b26, X1), (a8, b26, X2), (a8, b26, X3), (a8, b26, X4), (a8, b26, X5), (a8, b26, X6), (a8, b26, X7), (a8, b26, X8), (a8, b26, X9), (a8, b26, X10), (a8, b26, X11), (a8, b26, X12), (a8, b26, X13), (a8, b26, X14), (a8, b26, X15), (a8, b26, X16), (a8, b26, X17), (a8, b26, X18), (a8, b27, X1), (a8, b27, X2), (a8, b27, X3), (a8, b27, X4), (a8, b27, X5), (a8, b27, X6), (a8, b27, X7), (a8, b27, X8), (a8, b27, X9), (a8, b27, X10), (a8, b27, X11), (a8, b27, X12), (a8, b27, X13), (a8, b27, X14), (a8, b27, X15), (a8, b27, X16), (a8, b27, X17), (a8, b27, X18),
  • (a9, b1, X1), (a9, b1, X2), (a9, b1, X3), (a9, b1, X4), (a9, b1, X5), (a9, b1, X6), (a9, b1, X7), (a9, b1, X8), (a9, b1, X9), (a9, b1, X10), (a9, b1, X11), (a9, b1, X12), (a9, b1, X13), (a9, b1, X14), (a9, b1, X15), (a9, b1, X16), (a9, b1, X17), (a9, b1, X18), (a9, b2, X1), (a9, b2, X2), (a9, b2, X3), (a9, b2, X4), (a9, b2, X5), (a9, b2, X6), (a9, b2, X7), (a9, b2, X8), (a9, b2, X9), (a9, b2, X10), (a9, b2, X11), (a9, b2, X12), (a9, b2, X13), (a9, b2, X14), (a9, b2, X15), (a9, b2, X16), (a9, b2, X17), (a9, b2, X18), (a9, b3, X1), (a9, b3, X2), (a9, b3, X3), (a9, b3, X4), (a9, b3, X5), (a9, b3, X6), (a9, b3, X7), (a9, b3, X8), (a9, b3, X9), (a9, b3, X10), (a9, b3, X11), (a9, b3, X12), (a9, b3, X13), (a9, b3, X14), (a9, b3, X15), (a9, b3, X16), (a9, b3, X17), (a9, b3, X18), (a9, b4, X1), (a9, b4, X2), (a9, b4, X3), (a9, b4, X4), (a9, b4, X5), (a9, b4, X6), (a9, b4, X7), (a9, b4, X8), (a9, b4, X9), (a9, b4, X10), (a9, b4, X11), (a9, b4, X12), (a9, b4, X13), (a9, b4, X14), (a9, b4, X15), (a9, b4, X16), (a9, b4, X17), (a9, b4, X18), (a9, b5, X1), (a9, b5, X2), (a9, b5, X3), (a9, b5, X4), (a9, b5, X5), (a9, b5, X6), (a9, b5, X7), (a9, b5, X8), (a9, b5, X9), (a9, b5, X10), (a9, b5, X11), (a9, b5, X12), (a9, b5, X13), (a9, b5, X14), (a9, b5, X15), (a9, b5, X16), (a9, b5, X17), (a9, b5, X18), (a9, b6, X1), (a9, b6, X2), (a9, b6, X3), (a9, b6, X4), (a9, b6, X5), (a9, b6, X6), (a9, b6, X7), (a9, b6, X8), (a9, b6, X9), (a9, b6, X10), (a9, b6, X11), (a9, b6, X12), (a9, b6, X13), (a9, b6, X14), (a9, b6, X15), (a9, b6, X16), (a9, b6, X17), (a9, b6, X18), (a9, b7, X1), (a9, b7, X2), (a9, b7, X3), (a9, b7, X4), (a9, b7, X5), (a9, b7, X6), (a9, b7, X7), (a9, b7, X8), (a9, b7, X9), (a9, b7, X10), (a9, b7, X11), (a9, b7, X12), (a9, b7, X13), (a9, b7, X14), (a9, b7, X15), (a9, b7, X16), (a9, b7, X17), (a9, b7, X18), (a9, b8, X1), (a9, b8, X2), (a9, b8, X3), (a9, b8, X4), (a9, b8, X5), (a9, b8, X6), (a9, b8, X7), (a9, b8, X8), (a9, b8, X9), (a9, b8, X10), (a9, b8, X11), (a9, b8, X12), (a9, b8, X13), (a9, b8, X14), (a9, b8, X15), (a9, b8, X16), (a9, b8, X17), (a9, b8, X18), (a9, b9, X1), (a9, b9, X2), (a9, b9, X3), (a9, b9, X4), (a9, b9, X5), (a9, b9, X6), (a9, b9, X7), (a9, b9, X8), (a9, b9, X9), (a9, b9, X10), (a9, b9, X11), (a9, b9, X12), (a9, b9, X13), (a9, b9, X14), (a9, b9, X15), (a9, b9, X16), (a9, b9, X17), (a9, b9, X18), (a9, b10, X1), (a9, b10, X2), (a9, b10, X3), (a9, b10, X4), (a9, b10, X5), (a9, b10, X6), (a9, b10, X7), (a9, b10, X8), (a9, MO, X9), (a9, b10, X10), (a9, b10, X11), (a9, b10, X12), (a9, b10, X13), (a9, b10, X14), (a9, b10, X15), (a9, b10, X16), (a9, b10, X17), (a9, b10, X18), (a9, b11, X1), (a9, b11, X2), (a9, b11, X3), (a9, b11, X4), (a9, b11, X5), (a9, b11, X6), (a9, b11, X7), (a9, b11, X8), (a9, b11, X9), (a9, b11, X10), (a9, b11, X11), (a9, b11, X12), (a9, b11, X13), (a9, b11, X14), (a9, b11, X15), (a9, b11, X16), (a9, b11, X17), (a9, b11, X18), (a9, b12, X1), (a9, b12, X2), (a9, b12, X3), (a9, b12, X4), (a9, b12, X5), (a9, b12, X6), (a9, b12, X7), (a9, b12, X8), (a9, b12, X9), (a9, b12, X10), (a9, b12, X11), (a9, b12, X12), (a9, b12, X13), (a9, b12, X14), (a9, b12, X15), (a9, b12, X16), (a9, b12, X17), (a9, b12, X18), (a9, b13, X1), (a9, b13, X2), (a9, b13, X3), (a9, b13, X4), (a9, b13, X5), (a9, b13, X6), (a9, b13, X7), (a9, b13, X8), (a9, b13, X9), (a9, b13, X10), (a9, b13, X11), (a9, b13, X12), (a9, b13, X13), (a9, b13, X14), (a9, b13, X15), (a9, b13, X16), (a9, b13, X17), (a9, b13, X18), (a9, b14, X1), (a9, b14, X2), (a9, b14, X3), (a9, b14, X4), (a9, b14, X5), (a9, b14, X6), (a9, b14, X7), (a9, b14, X8), (a9, b14, X9), (a9, b14, X10), (a9, b14, X11), (a9, b14, X12), (a9, b14, X13), (a9, b14, X14), (a9, b14, X15), (a9, b14, X16), (a9, b14, X17), (a9, b14, X18), (a9, b15, X1), (a9, b15, X2), (a9, b15, X3), (a9, b15, X4), (a9, b15, X5), (a9, b15, X6), (a9, b15, X7), (a9, b15, X8), (a9, b15, X9), (a9, b15, X10), (a9, b15, X11), (a9, b15, X12), (a9, b15, X13), (a9, b15, X14), (a9, b15, X15), (a9, b15, X16), (a9, b15, X17), (a9, b15, X18), (a9, b16, X1), (a9, b16, X2), (a9, b16, X3), (a9, b16, X4), (a9, b16, X5), (a9, b16, X6), (a9, b16, X7), (a9, b16, X8), (a9, b16, X9), (a9, b16, X10), (a9, b16, X11), (a9, b16, X12), (a9, b16, X13), (a9, b16, X14), (a9, b16, X15), (a9, b16, X16), (a9, b16, X17), (a9, b16, X18), (a9, b17, X1), (a9, b17, X2), (a9, b17, X3), (a9, b17, X4), (a9, b17, X5), (a9, b17, X6), (a9, b17, X7), (a9, b17, X8), (a9, b17, X9), (a9, b17, X10), (a9, b17, X11), (a9, b17, X12), (a9, b17, X13), (a9, b17, X14), (a9, b17, X15), (a9, b17, X16), (a9, b17, X17), (a9, b17, X18), (a9, b18, X1), (a9, b18, X2), (a9, b18, X3), (a9, b18, X4), (a9, b18, X5), (a9, b18, X6), (a9, b18, X7), (a9, b18, X8), (a9, b18, X9), (a9, b18, X10), (a9, b18, X11), (a9, b18, X12), (a9, b18, X13), (a9, b18, X14), (a9, b18, X15), (a9, b18, X16), (a9, b18, X17), (a9, b18, X18), (a9, b19, X1), (a9, b19, X2), (a9, b19, X3), (a9, b19, X4), (a9, b19, X5), (a9, b19, X6), (a9, b19, X7), (a9, b19, X8), (a9, b19, X9), (a9, b19, X10), (a9, b19, X11), (a9, b19, X12), (a9, b19, X13), (a9, b19, X14), (a9, b19, X15), (a9, b19, X16), (a9, b19, X17), (a9, b19, X18), (a9, b20, X1), (a9, b20, X2), (a9, b20, X3), (a9, b20, X4), (a9, b20, X5), (a9, b20, X6), (a9, b20, X7), (a9, b20, X8), (a9, b20, X9), (a9, b20, X10), (a9, b20, X11), (a9, b20, X12), (a9, b20, X13), (a9, b20, X14), (a9, b20, X15), (a9, b20, X16), (a9, b20, X17), (a9, b20, X18), (a9, b21, X1), (a9, b21, X2), (a9, b21, X3), (a9, b21, X4), (a9, b21, X5), (a9, b21, X6), (a9, b21, X7), (a9, b21, X8), (a9, b21, X9), (a9, b21, X10), (a9, b21, X11), (a9, b21, X12), (a9, b21, X13), (a9, b21, X14), (a9, b21, X15), (a9, b21, X16), (a9, b21, X17), (a9, b21, X18), (a9, b22, X1), (a9, b22, X2), (a9, b22, X3), (a9, b22, X4), (a9, b22, X5), (a9, b22, X6), (a9, b22, X7), (a9, b22, X8), (a9, b22, X9), (a9, b22, X10), (a9, b22, X11), (a9, b22, X12), (a9, b22, X13), (a9, b22, X14), (a9, b22, X15), (a9, b22, X16), (a9, b22, X17), (a9, b22, X18), (a9, b23, X1), (a9, b23, X2), (a9, b23, X3), (a9, b23, X4), (a9, b23, X5), (a9, b23, X6), (a9, b23, X7), (a9, b23, X8), (a9, b23, X9), (a9, b23, X10), (a9, b23, X11), (a9, b23, X12), (a9, b23, X13), (a9, b23, X14), (a9, b23, X15), (a9, b23, X16), (a9, b23, X17), (a9, b23, X18), (a9, b24, X1), (a9, b24, X2), (a9, b24, X3), (a9, b24, X4), (a9, b24, X5), (a9, b24, X6), (a9, b24, X7), (a9, b24, X8), (a9, b24, X9), (a9, b24, X10), (a9, b24, X11), (a9, b24, X12), (a9, b24, X13), (a9, b24, X14), (a9, b24, X15), (a9, b24, X16), (a9, b24, X17), (a9, b24, X18), (a9, b25, X1), (a9, b25, X2), (a9, b25, X3), (a9, b25, X4), (a9, b25, X5), (a9, b25, X6), (a9, b25, X7), (a9, b25, X8), (a9, b25, X9), (a9, b25, X10), (a9, b25, X11), (a9, b25, X12), (a9, b25, X13), (a9, b25, X14), (a9, b25, X15), (a9, b25, X16), (a9, b25, X17), (a9, b25, X18), (a9, b26, X1), (a9, b26, X2), (a9, b26, X3), (a9, b26, X4), (a9, b26, X5), (a9, b26, X6), (a9, b26, X7), (a9, b26, X8), (a9, b26, X9), (a9, b26, X10), (a9, b26, X11), (a9, b26, X12), (a9, b26, X13), (a9, b26, X14), (a9, b26, X15), (a9, b26, X16), (a9, b26, X17), (a9, b26, X18), (a9, b27, X1), (a9, b27, X2), (a9, b27, X3), (a9, b27, X4), (a9, b27, X5), (a9, b27, X6), (a9, b27, X7), (a9, b27, X8), (a9, b27, X9), (a9, b27, X10), (a9, b27, X11), (a9, b27, X12), (a9, b27, X13), (a9, b27, X14), (a9, b27, X15), (a9, b27, X16), (a9, b27, X17), (a9, b27, X18),
  • (a10, b1, X1), (a10, b1, X2), (a10, b1, X3), (a10, b1, X4), (a10, b1, X5), (a10, b1, X6), (a10, b1, X7), (a10, b1, X8), (a10, b1, X9), (a10, b1, X10), (a10, b1, X11), (a10, b1, X12), (a10, b1, X13), (a10, b1, X14), (a10, b1, X15), (a10, b1, X16), (a10, b1, X17), (a10, b1, X18), (a10, b2, X1), (a10, b2, X2), (a10, b2, X3), (a10, b2, X4), (a10, b2, X5), (a10, b2, X6), (a10, b2, X7), (a10, b2, X8), (a10, b2, X9), (a10, b2, X10), (a10, b2, X11), (a10, b2, X12), (a10, b2, X13), (a10, b2, X14), (a10, b2, X15), (a10, b2, X16), (a10, b2, X17), (a10, b2, X18), (a10, b3, X1), (a10, b3, X2), (a10, b3, X3), (a10, b3, X4), (a10, b3, X5), (a10, b3, X6), (a10, b3, X7), (a10, b3, X8), (a10, b3, X9), (a10, b3, X10), (a10, b3, X11), (a10, b3, X12), (a10, b3, X13), (a10, b3, X14), (a10, b3, X15), (a10, b3, X16), (a10, b3, X17), (a10, b3, X18), (a10, b4, X1), (a10, b4, X2), (a10, b4, X3), (a10, b4, X4), (a10, b4, X5), (a10, b4, X6), (a10, b4, X7), (a10, b4, X8), (a10, b4, X9), (a10, b4, X10), (a10, b4, X11), (a10, b4, X12), (a10, b4, X13), (a10, b4, X14), (a10, b4, X15), (a10, b4, X16), (a10, b4, X17), (a10, b4, X18), (a10, b5, X1), (a10, b5, X2), (a10, b5, X3), (a10, b5, X4), (a10, b5, X5), (a10, b5, X6), (a10, b5, X7), (a10, b5, X8), (a10, b5, X9), (a10, b5, X10), (a10, b5, X11), (a10, b5, X12), (a10, b5, X13), (a10, b5, X14), (a10, b5, X15), (a10, b5, X16), (a10, b5, X17), (a10, b5, X18), (a10, b6, X1), (a10, b6, X2), (a10, b6, X3), (a10, b6, X4), (a10, b6, X5), (a10, b6, X6), (a10, b6, X7), (a10, b6, X8), (a10, b6, X9), (a10, b6, X10), (a10, b6, X11), (a10, b6, X12), (a10, b6, X13), (a10, b6, X14), (a10, b6, X15), (a10, b6, X16), (a10, b6, X17), (a10, b6, X18), (a10, b7, X1), (a10, b7, X2), (a10, b7, X3), (a10, b7, X4), (a10, b7, X5), (a10, b7, X6), (a10, b7, X7), (a10, b7, X8), (a10, b7, X9), (a10, b7, X10), (a10, b7, X11), (a10, b7, X12), (a10, b7, X13), (a10, b7, X14), (a10, b7, X15), (a10, b7, X16), (a10, b7, X17), (a10, b7, X18), (a10, b8, X1), (a10, b8, X2), (a10, b8, X3), (a10, b8, X4), (a10, b8, X5), (a10, b8, X6), (a10, b8, X7), (a10, b8, X8), (a10, b8, X9), (a10, b8, X10), (a10, b8, X11), (a10, b8, X12), (a10, b8, X13), (a10, b8, X14), (a10, b8, X15), (a10, b8, X16), (a10, b8, X17), (a10, b8, X18), (a10, b9, X1), (a10, b9, X2), (a10, b9, X3), (a10, b9, X4), (a10, b9, X5), (a10, b9, X6), (a10, b9, X7), (a10, b9, X8), (a10, b9, X9), (a10, b9, X10), (a10, b9, X11), (a10, b9, X12), (a10, b9, X13), (a10, b9, X14), (a10, b9, X15), (a10, b9, X16), (a10, b9, X17), (a10, b9, X18), (a10, b10, X1), (a10, b10, X2), (a10, b10, X3), (a10, b10, X4), (a10, b10, X5), (a10, b10, X6), (a10, b10, X7), (a10, b10, X8), (a10, b10, X9), (a10, b10, X10), (a10, b10, X11), (a10, b10, X12), (a10, b10, X13), (a10, b10, X14), (a10, b10, X15), (a10, b10, X16), (a10, b10, X17), (a10, b10, X18), (a10, b11, X1), (a10, b11, X2), (a10, b11, X3), (a10, b11, X4), (a10, b11, X5), (a10, b11, X6), (a10, b11, X7), (a10, b11, X8), (a10, b11, X9), (a10, b11, X10), (a10, b11, X11), (a10, b11, X12), (a10, b11, X13), (a10, b11, X14), (a10, b11, X15), (a10, b11, X16), (a10, b11, X17), (a10, b11, X18), (a10, b12, X1), (a10, b12, X2), (a10, b12, X3), (a10, b12, X4), (a10, b12, X5), (a10, b12, X6), (a10, b12, X7), (a10, b12, X8), (a10, b12, X9), (a10, b12, X10), (a10, b12, X11), (a10, b12, X12), (a10, b12, X13), (a10, b12, X14), (a10, b12, X15), (a10, b12, X16), (a10, b12, X17), (a10, b12, X18), (a10, b13, X1), (a10, b13, X2), (a10, b13, X3), (a10, b13, X4), (a10, b13, X5), (a10, b13, X6), (a10, b13, X7), (a10, b13, X8), (a10, b13, X9), (a10, b13, X10), (a10, b13, X11), (a10, b13, X12), (a10, b13, X13), (a10, b13, X14), (a10, b13, X15), (a10, b13, X16), (a10, b13, X17), (a10, b13, X18), (a10, b14, X1), (a10, b14, X2), (a10, b14, X3), (a10, b14, X4), (a10, b14, X5), (a10, b14, X6), (a10, b14, X7), (a10, b14, X8), (a10, b14, X9), (a10, b14, X10), (a10, b14, X11), (a10, b14, X12), (a10, b14, X13), (a10, b14, X14), (a10, b14, X15), (a10, b14, X16), (a10, b14, X17), (a10, b14, X18), (a10, b15, X1), (a10, b15, X2), (a10, b15, X3), (a10, b15, X4), (a10, b15, X5), (a10, b15, X6), (a10, b15, X7), (a10, b15, X8), (a10, b15, X9), (a10, b15, X10), (a10, b15, X11), (a10, b15, X12), (a10, b15, X13), (a10, b15, X14), (a10, b15, X15), (a10, b15, X16), (a10, b15, X17), (a10, b15, X18), (a10, b16, X1), (a10, b16, X2), (a10, b16, X3), (a10, b16, X4), (a10, b16, X5), (a10, b16, X6), (a10, b16, X7), (a10, b16, X8), (a10, b16, X9), (a10, b16, X10), (a10, b16, X11), (a10, b16, X12), (a10, b16, X13), (a10, b16, X14), (a10, b16, X15), (a10, b16, X16), (a10, b16, X17), (a10, b16, X18), (a10, b17, X1), (a10, b17, X2), (a10, b17, X3), (a10, b17, X4), (a10, b17, X5), (a10, b17, X6), (a10, b17, X7), (a10, b17, X8), (a10, b17, X9), (a10, b17, X10), (a10, b17, X11), (a10, b17, X12), (a10, b17, X13), (a10, b17, X14), (a10, b17, X15), (a10, b17, X16), (a10, b17, X17), (a10, b17, X18), (a10, b18, X1), (a10, b18, X2), (a10, b18, X3), (a10, b18, X4), (a10, b18, X5), (a10, b18, X6), (a10, b18, X7), (a10, b18, X8), (a10, b18, X9), (a10, b18, X10), (a10, b18, X11), (a10, b18, X12), (a10, b18, X13), (a10, b18, X14), (a10, b18, X15), (a10, b18, X16), (a10, b18, X17), (a10, b18, X18), (a10, b19, X1), (a10, b19, X2), (a10, b19, X3), (a10, b19, X4), (a10, b19, X5), (a10, b19, X6), (a10, b19, X7), (a10, b19, X8), (a10, b19, X9), (a10, b19, X10), (a10, b19, X11), (a10, b19, X12), (a10, b19, X13), (a10, b19, X14), (a10, b19, X15), (a10, b19, X16), (a10, b19, X17), (a10, b19, X18), (a10, b20, X1), (a10, b20, X2), (a10, b20, X3), (a10, b20, X4), (a10, b20, X5), (a10, b20, X6), (a10, b20, X7), (a10, b20, X8), (a10, b20, X9), (a10, b20, X10), (a10, b20, X11), (a10, b20, X12), (a10, b20, X13), (a10, b20, X14), (a10, b20, X15), (a10, b20, X16), (a10, b20, X17), (a10, b20, X18), (a10, b21, X1), (a10, b21, X2), (a10, b21, X3), (a10, b21, X4), (a10, b21, X5), (a10, b21, X6), (a10, b21, X7), (a10, b21, X8), (a10, b21, X9), (a10, b21, X10), (a10, b21, X11), (a10, b21, X12), (a10, b21, X13), (a10, b21, X14), (a10, b21, X15), (a10, b21, X16), (a10, b21, X17), (a10, b21, X18), (a10, b22, X1), (a10, b22, X2), (a10, b22, X3), (a10, b22, X4), (a10, b22, X5), (a10, b22, X6), (a10, b22, X7), (a10, b22, X8), (a10, b22, X9), (a10, b22, X10), (a10, b22, X11), (a10, b22, X12), (a10, b22, X13), (a10, b22, X14), (a10, b22, X15), (a10, b22, X16), (a10, b22, X17), (a10, b22, X18), (a10, b23, X1), (a10, b23, X2), (a10, b23, X3), (a10, b23, X4), (a10, b23, X5), (a10, b23, X6), (a10, b23, X7), (a10, b23, X8), (a10, b23, X9), (a10, b23, X10), (a10, b23, X11), (a10, b23, X12), (a10, b23, X13), (a10, b23, X14), (a10, b23, X15), (a10, b23, X16), (a10, b23, X17), (a10, b23, X18), (a10, b24, X1), (a10, b24, X2), (a10, b24, X3), (a10, b24, X4), (a10, b24, X5), (a10, b24, X6), (a10, b24, X7), (a10, b24, X8), (a10, b24, X9), (a10, b24, X10), (a10, b24, X11), (a10, b24, X12), (a10, b24, X13), (a10, b24, X14), (a10, b24, X15), (a10, b24, X16), (a10, b24, X17), (a10, b24, X18), (a10, b25, X1), (a10, b25, X2), (a10, b25, X3), (a10, b25, X4), (a10, b25, X5), (a10, b25, X6), (a10, b25, X7), (a10, b25, X8), (a10, b25, X9), (a10, b25, X10), (a10, b25, X11), (a10, b25, X12), (a10, b25, X13), (a10, b25, X14), (a10, b25, X15), (a10, b25, X16), (a10, b25, X17), (a10, b25, X18), (a10, b26, X1), (a10, b26, X2), (a10, b26, X3), (a10, b26, X4), (a10, b26, X5), (a10, b26, X6), (a10, b26, X7), (a10, b26, X8), (a10, b26, X9), (a10, b26, X10), (a10, b26, X11), (a10, b26, X12), (a10, b26, X13), (a10, b26, X14), (a10, b26, X15), (a10, b26, X16), (a10, b26, X17), (a10, b26, X18), (a10, b27, X1), (a10, b27, X2), (a10, b27, X3), (a10, b27, X4), (a10, b27, X5), (a10, b27, X6), (a10, b27, X7), (a10, b27, X8), (a10, b27, X9), (a10, b27, X10), (a10, b27, X11), (a10, b27, X12), (a10, b27, X13), (a10, b27, X14), (a10, b27, X15), (a10, b27, X16), (a10, b27, X17), (a10, b27, X18),
  • (a11, b1, X1), (a11, b1, X2), (a11, b1, X3), (a11, b1, X4), (a11, b1, X5), (a11, b1, X6), (a11, b1, X7), (a11, b1, X8), (a11, b1, X9), (a11, b1, X10), (a11, b1, X11), (a11, b1, X12), (a11, b1, X13), (a11, b1, X14), (a11, b1, X15), (a11, b1, X16), (a11, b1, X17), (a11, b1, X18), (a11, b2, X1), (a11, b2, X2), (a11, b2, X3), (a11, b2, X4), (a11, b2, X5), (a11, b2, X6), (a11, b2, X7), (a11, b2, X8), (a11, b2, X9), (a11, b2, X10), (a11, b2, X11), (a11, b2, X12), (a11, b2, X13), (a11, b2, X14), (a11, b2, X15), (a11, b2, X16), (a11, b2, X17), (a11, b2, X18), (a11, b3, X1), (a11, b3, X2), (a11, b3, X3), (a11, b3, X4), (a11, b3, X5), (a11, b3, X6), (a11, b3, X7), (a11, b3, X8), (a11, b3, X9), (a11, b3, X10), (a11, b3, X11), (a11, b3, X12), (a11, b3, X13), (a11, b3, X14), (a11, b3, X15), (a11, b3, X16), (a11, b3, X17), (a11, b3, X18), (a11, b4, X1), (a11, b4, X2), (a11, b4, X3), (a11, b4, X4), (a11, b4, X5), (a11, b4, X6), (a11, b4, X7), (a11, b4, X8), (a11, b4, X9), (a11, b4, X10), (a11, b4, X11), (a11, b4, X12), (a11, b4, X13), (a11, b4, X14), (a11, b4, X15), (a11, b4, X16), (a11, b4, X17), (a11, b4, X18), (a11, b5, X1), (a11, b5, X2), (a11, b5, X3), (a11, b5, X4), (a11, b5, X5), (a11, b5, X6), (a11, b5, X7), (a11, b5, X8), (a11, b5, X9), (a11, b5, X10), (a11, b5, X11), (a11, b5, X12), (a11, b5, X13), (a11, b5, X14), (a11, b5, X15), (a11, b5, X16), (a11, b5, X17), (a11, b5, X18), (a11, b6, X1), (a11, b6, X2), (a11, b6, X3), (a11, b6, X4), (a11, b6, X5), (a11, b6, X6), (a11, b6, X7), (a11, b6, X8), (a11, b6, X9), (a11, b6, X10), (a11, b6, X11), (a11, b6, X12), (a11, b6, X13), (a11, b6, X14), (a11, b6, X15), (a11, b6, X16), (a11, b6, X17), (a11, b6, X18), (a11, b7, X1), (a11, b7, X2), (a11, b7, X3), (a11, b7, X4), (a11, b7, X5), (a11, b7, X6), (a11, b7, X7), (a11, b7, X8), (a11, b7, X9), (a11, b7, X10), (a11, b7, X11), (a11, b7, X12), (a11, b7, X13), (a11, b7, X14), (a11, b7, X15), (a11, b7, X16), (a11, b7, X17), (a11, b7, X18), (a11, b8, X1), (a11, b8, X2), (a11, b8, X3), (a11, b8, X4), (a11, b8, X5), (a11, b8, X6), (a11, b8, X7), (a11, b8, X8), (a11, b8, X9), (a11, b8, X10), (a11, b8, X11), (a11, b8, X12), (a11, b8, X13), (a11, b8, X14), (a11, b8, X15), (a11, b8, X16), (a11, b8, X17), (a11, b8, X18), (a11, b9, X1), (a11, b9, X2), (a11, b9, X3), (a11, b9, X4), (a11, b9, X5), (a11, b9, X6), (a11, b9, X7), (a11, b9, X8), (a11, b9, X9), (a11, b9, X10), (a11, b9, X11), (a11, b9, X12), (a11, b9, X13), (a11, b9, X14), (a11, b9, X15), (a11, b9, X16), (a11, b9, X17), (a11, b9, X18), (a11, b10, X1), (a11, b10, X2), (a11, b10, X3), (a11, b10, X4), (a11, b10, X5), (a11, b10, X6), (a11, b10, X7), (a11, b10, X8), (a11, b10, X9), (a11, b10, X10), (a11, b10, X11), (a11, b10, X12), (a11, b10, X13), (a11, b10, X14), (a11, b10, X15), (a11, b10, X16), (a11, b10, X17), (a11, b10, X18), (a11, b11, X1), (a11, b11, X2), (a11, b11, X3), (a11, b11, X4), (a11, b11, X5), (a11, b11, X6), (a11, b11, X7), (a11, b11, X8), (a11, b11, X9), (a11, b11, X10), (a11, b11, X11), (a11, b11, X12), (a11, b11, X13), (a11, b11, X14), (a11, b11, X15), (a11, b11, X16), (a11, b11, X17), (a11, b11, X18), (a11, b12, X1), (a11, b12, X2), (a11, b12, X3), (a11, b12, X4), (a11, b12, X5), (a11, b12, X6), (a11, b12, X7), (a11, b12, X8), (a11, b12, X9), (a11, b12, X10), (a11, b12, X11), (a11, b12, X12), (a11, b12, X13), (a11, b12, X14), (a11, b12, X15), (a11, b12, X16), (a11, b12, X17), (a11, b12, X18), (a11, b13, X1), (a11, b13, X2), (a11, b13, X3), (a11, b13, X4), (a11, b13, X5), (a11, b13, X6), (a11, b13, X7), (a11, b13, X8), (a11, b13, X9), (a11, b13, X10), (a11, b13, X11), (a11, b13, X12), (a11, b13, X13), (a11, b13, X14), (a11, b13, X15), (a11, b13, X16), (a11, b13, X17), (a11, b13, X18), (a11, b14, X1), (a11, b14, X2), (a11, b14, X3), (a11, b14, X4), (a11, b14, X5), (a11, b14, X6), (a11, b14, X7), (a11, b14, X8), (a11, b14, X9), (a11, b14, X10), (a11, b14, X11), (a11, b14, X12), (a11, b14, X13), (a11, b14, X14), (a11, b14, X15), (a11, b14, X16), (a11, b14, X17), (a11, b14, X18), (a11, b15, X1), (a11, b15, X2), (a11, b15, X3), (a11, b15, X4), (a11, b15, X5), (a11, b15, X6), (a11, b15, X7), (a11, b15, X8), (a11, b15, X9), (a11, b15, X10), (a11, b15, X11), (a11, b15, X12), (a11, b15, X13), (a11, b15, X14), (a11, b15, X15), (a11, b15, X16), (a11, b15, X17), (a11, b15, X18), (a11, b16, X1), (a11, b16, X2), (a11, b16, X3), (a11, b16, X4), (a11, b16, X5), (a11, b16, X6), (a11, b16, X7), (a11, b16, X8), (a11, b16, X9), (a11, b16, X10), (a11, b16, X11), (a11, b16, X12), (a11, b16, X13), (a11, b16, X14), (a11, b16, X15), (a11, b16, X16), (a11, b16, X17), (a11, b16, X18), (a11, b17, X1), (a11, b17, X2), (a11, b17, X3), (a11, b17, X4), (a11, b17, X5), (a11, b17, X6), (a11, b17, X7), (a11, b17, X8), (a11, b17, X9), (a11, b17, X10), (a11, b17, X11), (a11, b17, X12), (a11, b17, X13), (a11, b17, X14), (a11, b17, X15), (a11, b17, X16), (a11, b17, X17), (a11, b17, X18), (a11, b18, X1), (a11, b18, X2), (a11, b18, X3), (a11, b18, X4), (a11, b18, X5), (a11, b18, X6), (a11, b18, X7), (a11, b18, X8), (a11, b18, X9), (a11, b18, X10), (a11, b18, X11), (a11, b18, X12), (a11, b18, X13), (a11, b18, X14), (a11, b18, X15), (a11, b18, X16), (a11, b18, X17), (a11, b18, X18), (a11, b19, X1), (a11, b19, X2), (a11, b19, X3), (a11, b19, X4), (a11, b19, X5), (a11, b19, X6), (a11, b19, X7), (a11, b19, X8), (a11, b19, X9), (a11, b19, X10), (a11, b19, X11), (a11, b19, X12), (a11, b19, X13), (a11, b19, X14), (a11, b19, X15), (a11, b19, X16), (a11, b19, X17), (a11, b19, X18), (a11, b20, X1), (a11, b20, X2), (a11, b20, X3), (a11, b20, X4), (a11, b20, X5), (a11, b20, X6), (a11, b20, X7), (a11, b20, X8), (a11, b20, X9), (a11, b20, X10), (a11, b20, X11), (a11, b20, X12), (a11, b20, X13), (a11, b20, X14), (a11, b20, X15), (a11, b20, X16), (a11, b20, X17), (a11, b20, X18), (a11, b21, X1), (a11, b21, X2), (a11, b21, X3), (a11, b21, X4), (a11, b21, X5), (a11, b21, X6), (a11, b21, X7), (a11, b21, X8), (a11, b21, X9), (a11, b21, X10), (a11, b21, X11), (a11, b21, X12), (a11, b21, X13), (a11, b21, X14), (a11, b21, X15), (a11, b21, X16), (a11, b21, X17), (a11, b21, X18), (a11, b22, X1), (a11, b22, X2), (a11, b22, X3), (a11, b22, X4), (a11, b22, X5), (a11, b22, X6), (a11, b22, X7), (a11, b22, X8), (a11, b22, X9), (a11, b22, X10), (a11, b22, X11), (a11, b22, X12), (a11, b22, X13), (a11, b22, X14), (a11, b22, X15), (a11, b22, X16), (a11, b22, X17), (a11, b22, X18), (a11, b23, X1), (a11, b23, X2), (a11, b23, X3), (a11, b23, X4), (a11, b23, X5), (a11, b23, X6), (a11, b23, X7), (a11, b23, X8), (a11, b23, X9), (a11, b23, X10), (a11, b23, X11), (a11, b23, X12), (a11, b23, X13), (a11, b23, X14), (a11, b23, X15), (a11, b23, X16), (a11, b23, X17), (a11, b23, X18), (a11, b24, X1), (a11, b24, X2), (a11, b24, X3), (a11, b24, X4), (a11, b24, X5), (a11, b24, X6), (a11, b24, X7), (a11, b24, X8), (a11, b24, X9), (a11, b24, X10), (a11, b24, X11), (a11, b24, X12), (a11, b24, X13), (a11, b24, X14), (a11, b24, X15), (a11, b24, X16), (a11, b24, X17), (a11, b24, X18), (a11, b25, X1), (a11, b25, X2), (a11, b25, X3), (a11, b25, X4), (a11, b25, X5), (a11, b25, X6), (a11, b25, X7), (a11, b25, X8), (a11, b25, X9), (a11, b25, X10), (a11, b25, X11), (a11, b25, X12), (a11, b25, X13), (a11, b25, X14), (a11, b25, X15), (a11, b25, X16), (a11, b25, X17), (a11, b25, X18), (a11, b26, X1), (a11, b26, X2), (a11, b26, X3), (a11, b26, X4), (a11, b26, X5), (a11, b26, X6), (a11, b26, X7), (a11, b26, X8), (a11, b26, X9), (a11, b26, X10), (a11, b26, X11), (a11, b26, X12), (a11, b26, X13), (a11, b26, X14), (a11, b26, X15), (a11, b26, X16), (a11, b26, X17), (a11, b26, X18), (a11, b27, X1), (a11, b27, X2), (a11, b27, X3), (a11, b27, X4), (a11, b27, X5), (a11, b27, X6), (a11, b27, X7), (a11, b27, X8), (a11, b27, X9), (a11, b27, X10), (a11, b27, X11), (a11, b27, X12), (a11, b27, X13), (a11, b27, X14), (a11, b27, X15), (a11, b27, X16), (a11, b27, X17), (a11, b27, X18),
  • (a12, b1, X1), (a12, b1, X2), (a12, b1, X3), (a12, b1, X4), (a12, b1, X5), (a12, b1, X6), (a12, b1, X7), (a12, b1, X8), (a12, b1, X9), (a12, b1, X10), (a12, b1, X11), (a12, b1, X12), (a12, b1, X13), (a12, b1, X14), (a12, b1, X15), (a12, b1, X16), (a12, b1, X17), (a12, b1, X18), (a12, b2, X1), (a12, b2, X2), (a12, b2, X3), (a12, b2, X4), (a12, b2, X5), (a12, b2, X6), (a12, b2, X7), (a12, b2, X8), (a12, b2, X9), (a12, b2, X10), (a12, b2, X11), (a12, b2, X12), (a12, b2, X13), (a12, b2, X14), (a12, b2, X15), (a12, b2, X16), (a12, b2, X17), (a12, b2, X18), (a12, b3, X1), (a12, b3, X2), (a12, b3, X3), (a12, b3, X4), (a12, b3, X5), (a12, b3, X6), (a12, b3, X7), (a12, b3, X8), (a12, b3, X9), (a12, b3, X10), (a12, b3, X11), (a12, b3, X12), (a12, b3, X13), (a12, b3, X14), (a12, b3, X15), (a12, b3, X16), (a12, b3, X17), (a12, b3, X18), (a12, b4, X1), (a12, b4, X2), (a12, b4, X3), (a12, b4, X4), (a12, b4, X5), (a12, b4, X6), (a12, b4, X7), (a12, b4, X8), (a12, b4, X9), (a12, b4, X10), (a12, b4, X11), (a12, b4, X12), (a12, b4, X13), (a12, b4, X14), (a12, b4, X15), (a12, b4, X16), (a12, b4, X17), (a12, b4, X18), (a12, b5, X1), (a12, b5, X2), (a12, b5, X3), (a12, b5, X4), (a12, b5, X5), (a12, b5, X6), (a12, b5, X7), (a12, b5, X8), (a12, b5, X9), (a12, b5, X10), (a12, b5, X11), (a12, b5, X12), (a12, b5, X13), (a12, b5, X14), (a12, b5, X15), (a12, b5, X16), (a12, b5, X17), (a12, b5, X18), (a12, b6, X1), (a12, b6, X2), (a12, b6, X3), (a12, b6, X4), (a12, b6, X5), (a12, b6, X6), (a12, b6, X7), (a12, b6, X8), (a12, b6, X9), (a12, b6, MO), (a12, b6, X11), (a12, b6, X12), (a12, b6, X13), (a12, b6, X14), (a12, b6, X15), (a12, b6, X16), (a12, b6, X17), (a12, b6, X18), (a12, b7, X1), (a12, b7, X2), (a12, b7, X3), (a12, b7, X4), (a12, b7, X5), (a12, b7, X6), (a12, b7, X7), (a12, b7, X8), (a12, b7, X9), (a12, b7, X10), (a12, b7, X11), (a12, b7, X12), (a12, b7, X13), (a12, b7, X14), (a12, b7, X15), (a12, b7, X16), (a12, b7, X17), (a12, b7, X18), (a12, b8, X1), (a12, b8, X2), (a12, b8, X3), (a12, b8, X4), (a12, b8, X5), (a12, b8, X6), (a12, b8, X7), (a12, b8, X8), (a12, b8, X9), (a12, b8, X10), (a12, b8, X11), (a12, b8, X12), (a12, b8, X13), (a12, b8, X14), (a12, b8, X15), (a12, b8, X16), (a12, b8, X17), (a12, b8, X18), (a12, b9, X1), (a12, b9, X2), (a12, b9, X3), (a12, b9, X4), (a12, b9, X5), (a12, b9, X6), (a12, b9, X7), (a12, b9, X8), (a12, b9, X9), (a12, b9, X10), (a12, b9, X11), (a12, b9, X12), (a12, b9, X13), (a12, b9, X14), (a12, b9, X15), (a12, b9, X16), (a12, b9, X17), (a12, b9, X18), (a12, b10, X1), (a12, b10, X2), (a12, b10, X3), (a12, b10, X4), (a12, b10, X5), (a12, b10, X6), (a12, b10, X7), (a12, b10, X8), (a12, b10, X9), (a12, b10, X10), (a12, b10, X11), (a12, b10, X12), (a12, b10, X13), (a12, b10, X14), (a12, b10, X15), (a12, b10, X16), (a12, b10, X17), (a12, b10, X18), (a12, b11, X1), (a12, b11, X2), (a12, b11, X3), (a12, b11, X4), (a12, b11, X5), (a12, b11, X6), (a12, b11, X7), (a12, b11, X8), (a12, b11, X9), (a12, b11, X10), (a12, b11, X11), (a12, b11, X12), (a12, b11, X13), (a12, b11, X14), (a12, b11, X15), (a12, b11, X16), (a12, b11, X17), (a12, b11, X18), (a12, b12, X1), (a12, b12, X2), (a12, b12, X3), (a12, b12, X4), (a12, b12, X5), (a12, b12, X6), (a12, b12, X7), (a12, b12, X8), (a12, b12, X9), (a12, b12, X10), (a12, b12, X11), (a12, b12, X12), (a12, b12, X13), (a12, b12, X14), (a12, b12, X15), (a12, b12, X16), (a12, b12, X17), (a12, b12, X18), (a12, b13, X1), (a12, b13, X2), (a12, b13, X3), (a12, b13, X4), (a12, b13, X5), (a12, b13, X6), (a12, b13, X7), (a12, b13, X8), (a12, b13, X9), (a12, b13, X10), (a12, b13, X11), (a12, b13, X12), (a12, b13, X13), (a12, b13, X14), (a12, b13, X15), (a12, b13, X16), (a12, b13, X17), (a12, b13, X18), (a12, b14, X1), (a12, b14, X2), (a12, b14, X3), (a12, b14, X4), (a12, b14, X5), (a12, b14, X6), (a12, b14, X7), (a12, b14, X8), (a12, b14, X9), (a12, b14, X10), (a12, b14, X11), (a12, b14, X12), (a12, b14, X13), (a12, b14, X14), (a12, b14, X15), (a12, b14, X16), (a12, b14, X17), (a12, b14, X18), (a12, b15, X1), (a12, b15, X2), (a12, b15, X3), (a12, b15, X4), (a12, b15, X5), (a12, b15, X6), (a12, b15, X7), (a12, b15, X8), (a12, b15, X9), (a12, b15, X10), (a12, b15, X11), (a12, b15, X12), (a12, b15, X13), (a12, b15, X14), (a12, b15, X15), (a12, b15, X16), (a12, b15, X17), (a12, b15, X18), (a12, b16, X1), (a12, b16, X2), (a12, b16, X3), (a12, b16, X4), (a12, b16, X5), (a12, b16, X6), (a12, b16, X7), (a12, b16, X8), (a12, b16, X9), (a12, b16, X10), (a12, b16, X11), (a12, b16, X12), (a12, b16, X13), (a12, b16, X14), (a12, b16, X15), (a12, b16, X16), (a12, b16, X17), (a12, b16, X18), (a12, b17, X1), (a12, b17, X2), (a12, b17, X3), (a12, b17, X4), (a12, b17, X5), (a12, b17, X6), (a12, b17, X7), (a12, b17, X8), (a12, b17, X9), (a12, b17, X10), (a12, b17, X11), (a12, b17, X12), (a12, b17, X13), (a12, b17, X14), (a12, b17, X15), (a12, b17, X16), (a12, b17, X17), (a12, b17, X18), (a12, b18, X1), (a12, b18, X2), (a12, b18, X3), (a12, b18, X4), (a12, b18, X5), (a12, b18, X6), (a12, b18, X7), (a12, b18, X8), (a12, b18, X9), (a12, b18, X10), (a12, b18, X11), (a12, b18, X12), (a12, b18, X13), (a12, b18, X14), (a12, b18, X15), (a12, b18, X16), (a12, b18, X17), (a12, b18, X18), (a12, b19, X1), (a12, b19, X2), (a12, b19, X3), (a12, b19, X4), (a12, b19, X5), (a12, b19, X6), (a12, b19, X7), (a12, b19, X8), (a12, b19, X9), (a12, b19, X10), (a12, b19, X11), (a12, b19, X12), (a12, b19, X13), (a12, b19, X14), (a12, b19, X15), (a12, b19, X16), (a12, b19, X17), (a12, b19, X18), (a12, b20, X1), (a12, b20, X2), (a12, b20, X3), (a12, b20, X4), (a12, b20, X5), (a12, b20, X6), (a12, b20, X7), (a12, b20, X8), (a12, b20, X9), (a12, b20, X10), (a12, b20, X11), (a12, b20, X12), (a12, b20, X13), (a12, b20, X14), (a12, b20, X15), (a12, b20, X16), (a12, b20, X17), (a12, b20, X18), (a12, b21, X1), (a12, b21, X2), (a12, b21, X3), (a12, b21, X4), (a12, b21, X5), (a12, b21, X6), (a12, b21, X7), (a12, b21, X8), (a12, b21, X9), (a12, b21, X10), (a12, b21, X11), (a12, b21, X12), (a12, b21, X13), (a12, b21, X14), (a12, b21, X15), (a12, b21, X16), (a12, b21, X17), (a12, b21, X18), (a12, b22, X1), (a12, b22, X2), (a12, b22, X3), (a12, b22, X4), (a12, b22, X5), (a12, b22, X6), (a12, b22, X7), (a12, b22, X8), (a12, b22, X9), (a12, b22, X10), (a12, b22, X11), (a12, b22, X12), (a12, b22, X13), (a12, b22, X14), (a12, b22, X15), (a12, b22, X16), (a12, b22, X17), (a12, b22, X18), (a12, b23, X1), (a12, b23, X2), (a12, b23, X3), (a12, b23, X4), (a12, b23, X5), (a12, b23, X6), (a12, b23, X7), (a12, b23, X8), (a12, b23, X9), (a12, b23, X10), (a12, b23, X11), (a12, b23, X12), (a12, b23, X13), (a12, b23, X14), (a12, b23, X15), (a12, b23, X16), (a12, b23, X17), (a12, b23, X18), (a12, b24, X1), (a12, b24, X2), (a12, b24, X3), (a12, b24, X4), (a12, b24, X5), (a12, b24, X6), (a12, b24, X7), (a12, b24, X8), (a12, b24, X9), (a12, b24, X10), (a12, b24, X11), (a12, b24, X12), (a12, b24, X13), (a12, b24, X14), (a12, b24, X15), (a12, b24, X16), (a12, b24, X17), (a12, b24, X18), (a12, b25, X1), (a12, b25, X2), (a12, b25, X3), (a12, b25, X4), (a12, b25, X5), (a12, b25, X6), (a12, b25, X7), (a12, b25, X8), (a12, b25, X9), (a12, b25, X10), (a12, b25, X11), (a12, b25, X12), (a12, b25, X13), (a12, b25, X14), (a12, b25, X15), (a12, b25, X16), (a12, b25, X17), (a12, b25, X18), (a12, b26, X1), (a12, b26, X2), (a12, b26, X3), (a12, b26, X4), (a12, b26, X5), (a12, b26, X6), (a12, b26, X7), (a12, b26, X8), (a12, b26, X9), (a12, b26, X10), (a12, b26, X11), (a12, b26, X12), (a12, b26, X13), (a12, b26, X14), (a12, b26, X15), (a12, b26, X16), (a12, b26, X17), (a12, b26, X18), (a12, b27, X1), (a12, b27, X2), (a12, b27, X3), (a12, b27, X4), (a12, b27, X5), (a12, b27, X6), (a12, b27, X7), (a12, b27, X8), (a12, b27, X9), (a12, b27, X10), (a12, b27, X11), (a12, b27, X12), (a12, b27, X13), (a12, b27, X14), (a12, b27, X15), (a12, b27, X16), (a12, b27, X17), (a12, b27, X18).
  • Since the compound (I) has high affinity for the NMDA receptor, particularly, NR1/NR2B receptor, and has high subtype selectivity, and high selectivity for other receptor, it can be a medicament with the reduced side effect (e.g. influence on motion function). In addition, the compound (I) also has an advantage that stability is high, oral absorbability is high, good bioavailability is exhibited, clearance is low, brain transferability is high, a half life is long, a non-protein binding rate is high, drug efficacy sustainability is high, and/or the liver enzyme inhibiting activity is low.
  • The compound (I) can be orally or parenterally administered to an animal including a human, as a medicament, particularly, as a preventive/remedy for various central diseases resulting from the NMDA receptor, particularly the NR1/NR2B receptor (e.g. cerebral stroke, cerebral infarction, brain trauma, chronic neurodegenerative diseases), or as an analgesic for cancer pain. Examples of a dosage form include granules, tablets, capsules, injectables and the like. Upon formulation into preparations, if desired, various additives, for example, excipients, disintegrating agents, binders, lubricants, stabilizers, coloring agents, and coating agents can be used. A dose is different depending on an age, a weight and condition of a subject, and an administration method, and is not particularly limited, but usually, is about 1 mg to about 5000 mg in the case of oral administration, and about 0.1 mg to about 1000 mg in the case of parenteral administration, per adult one day.
  • The present invention will be explained in more detail below by way of Examples, but the present invention is not limited by these Examples. A melting point described in the text is an uncorrected value. In addition, 1H-NMR was measured in a solvent of deuterium chloroform (CDCl3) or deuterium dimethyl sulfoxide (DMSO-d6) using tetramethylsilane as an internal standard. A δ value is expressed in ppm, and a binding constant (J) is expressed in Hz. In data, s means singlet, d means doublet, t means triplet, q means quartet, m means multiplet, br means broad, and brs means broad singlet.
  • Each abbreviation has the following meaning.
    • THF: Tetrahydrofuran
    • DMF: N,N-dimethylformamide
    • HOBt: 1-Hydroxybenzotriazole
    • DMAP: 4-Dimethylaminopyridine
    • EDC: 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
    • IBX: 1-Hydroxy-1,2-benziodooxol-3(1H)-one 1-oxide
    • Me: Methyl
    • Et: Ethyl
    • But: tert-Butyl
    • Ts: p-Toluenesulfonyl
    • BINAP: 2,2′-Bis(diphenylphosphino)-1,1′-binaphthyl
    • Pd2(dba)3: Bis(dibenzylideneacetone)palladium(0)
    • DMPO: 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone
    • MOM: Methoxymethyl
    REFERENCE EXAMPLE 1 Synthesis of Compound 3
  • Figure US20110172415A1-20110714-C00085
  • Under the nitrogen atmosphere, Compound 1 (576 mg, 5.0 mmol) and Compound 2 (985 mg, 6.0 mmol) were dissolved in DMF (5 ml), potassium carbonate (829 mg, 6.0 mmol) was added, and the mixture was stirred at 120° C. for 24 hours. The solvent was distilled off, and water was added to the residue, followed by extraction with chloroform. After dried with anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform/acetonitrile) to obtain Compound 3 (671 mg, yield 52%).
  • 1H NMR (CDCl3/TMS) δppm: 1.40-1.50 (br, 3H), 1.74 (m, 2H), 1.88 (d, J=12.3 Hz, 2H), 2.85 (t, J=12.3 Hz, 2H), 3.56 (d, J=4.2 Hz, 2H), 3.83 (d, J=12.3 Hz, 2H), 7.00 (br, 2H), 7.48 (d, J=9.0 Hz, 2H).
  • REFERENCE EXAMPLE 2 Synthesis of Compound 5
  • Figure US20110172415A1-20110714-C00086
  • According to the same manner as that of Reference Example 1 except that Compound 4 was used in place of Compound 1, a reaction was performed to obtain Compound 5 (yield 47%).
  • 1H-NMR (CDCl3/TMS) δppm: 1.26-1.39 (m, 2H), 1.56 (q, J=6.6 Hz, 2H), 1.64-1.69 (m, 1H), 1.83 (d, J=12.6 Hz, 2H), 2.87 (t, J=12.6 Hz, 2H), 3.71-3.81 (m, 4H), 6.93 (d, J=8.7 Hz, 2H), 7.46 (d, J=8.7 Hz, 2H).
  • REFERENCE EXAMPLE 3 Synthesis of Compound 7
  • Figure US20110172415A1-20110714-C00087
  • Compound 4 (646 mg, 5.0 mmol) and Compound 6 (908 mg, 5.0 mmol) were dissolved in DMF (15 ml), sodium bicarbonate (504 mg, 6.0 mmol) was added, and the mixture was stirred at 80° C. for 2 hours. After cooling, water was added, followed by extraction with ethyl acetate. The organic layer was washed with an aqueous saturated sodium chloride solution, and dried with anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain Compound 7 (1.08 g, yield 78%).
  • 1H-NMR (CDCl3/TMS) δppm: 1.16-1.32 (m, 3H), 1.50-1.60 (m, 2H), 1.68-1.86 (m, 3H), 2.84-2.97 (m, 2H), 3.69-3.78 (m, 2H), 4.34-4.44 (m, 2H), 6.63 (d, J=9.0 Hz, 1H), 7.59 (dd, J=9.0, 1.5 Hz, 1H), 8.37 (d, J=1.5 Hz, 1H).
  • REFERENCE EXAMPLE 4 Synthesis of Compound 10
  • Figure US20110172415A1-20110714-C00088
  • Under the nitrogen atmosphere, toluene was added to BINAP (187 mg, 0.3 mmol), Pd2(dba)3 (92 mg, 0.1 mmol), sodium tert-butoxide (1.19 g, 12.0 mmol), Compound 8 (1.14 g, 11.2 mmol), and Compound 9 (1.36 ml, 10.0 mmol) to react them at 120° C. for 1 hour under microwave irradiation. The reaction solution was filtered using Celite, and the solid was washed with ethyl acetate. The filtrate and the washing solution were combined, and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain Compound 10 (1.45 g, yield 59%).
  • mp 97-98° C.
  • 1H-NMR (CDCl3/TMS) δppm: 1.49-1.56 (m, 2H), 1.62-1.74 (m, 2H), 2.03 (brs, 2H), 3.03-3.10 (m, 2H), 3.63-3.71 (m, 2H), 3.93 (brs, 1H), 6.97 (br, 2H), 7.48 (d, J=8.7 Hz, 2H).
  • REFERENCE EXAMPLE 5 Synthesis of Compound 12
  • Figure US20110172415A1-20110714-C00089
  • Compound 11 (2.12 g, 15.0 mmol) and Compound 8 (1.82 g, 18.0 mmol) were dissolved in DMF (15 ml), potassium carbonate (2.52 g, 18.0 mmol) was added, and the mixture was stirred at 85° C. for 1 hour. The solvent was distilled off under reduced pressure, water was added to the residue, followed by extraction with chloroform. After dried with anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform-acetonitrile) to obtain Compound 12 (3.10 g, yield 93%).
  • mp 115.6-117° C.
  • 1H-NMR (CDCl3/TMS) δppm: 1.62-1.74 (m, 2H), 1.99-2.02 (m, 2H), 2.87-2.95 (m, 2H), 3.47-3.54 (m, 2H), 3.82-3.88 (m, 1H), 6.85 (d, J=8.7 Hz, 2H), 7.19 (d, J=8.7 Hz, 2H).
  • REFERENCE EXAMPLE 6 Synthesis of Compound 13
  • Figure US20110172415A1-20110714-C00090
  • Compound 12 (1.50 g, 6.75 mmol) was dissolved in methanol (25 ml), 10% palladium-carbon (150 mg) was added, and the interior of the system was replaced with a hydrogen gas. After stirred at room temperature for 2 hours, the reaction solution was filtered using Celite, and washed with methanol. The filtrate, and the washing solution were combined, and the solvent was distilled off under reduced pressure to obtain Compound 13 (1.28 g, yield 99%).
  • 1H-NMR (CDCl3/TMS) δppm: 1.70-1.80 (m, 2H), 2.07 (br, 2H), 2.84 (br, 2H), 3.37 (br, 3H), 3.85 (br, 1H), 6.65 (d, J=8.4 Hz, 2H), 6.91 (br, 2H).
  • REFERENCE EXAMPLE 7 Synthesis of Compound 14
  • Figure US20110172415A1-20110714-C00091
  • Compound 13 (1.28 g, 6.66 mmol) was dissolved in 6 mol/L hydrochloric acid (26 ml), and the solution was cooled to −35 to −40° C. with a dry ice-acetone bath. An aqueous solution (5 ml) of sodium nitrite (482 mg, 6.99 mmol) was added dropwise, and this was stirred at −35° C. to −40° C. for 30 minutes. Urea (199 mg, 1.67 mmol), cuprous chloride (725 mg, 7.32 mmol), cupric chloride (985 mg, 7.32 mmol) were added, and the mixture was stirred at 60° C. for 45 minutes. This was cooled with a water bath, aqueous ammonia was added to alkaline, chloroform was added, and insolubles were filtered off using Celite. The filtrate was extracted with chloroform, and the organic layer was washed with water, dried with anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform-methanol) to obtain Compound 14 (1.32 g, yield 94%).
  • 1H-NMR (CDCl3/TMS) δppm: 1.62-1.74 (m, 2H), 1.99-2.02 (m, 2H), 2.87-2.95 (m, 2H), 3.47-3.54 (m, 2H), 3.82-3.88 (m, 1H), 6.85 (d, J=8.7 Hz, 2H), 7.19 (d, J=8.7 Hz, 2H).
  • REFERENCE EXAMPLE 8 Synthesis of Compound 15
  • Figure US20110172415A1-20110714-C00092
  • Compound 10 (1.50 g, 6.12 mmol) was dissolved in ethyl acetate (45 ml), IBX (5.14 g, 18.4 mmol) was added, and the mixture was stirred at 80° C. for 8 hours. This was cooled with an ice bath, and the precipitated solid was filtered off, and washed with ethyl acetate. The filtrate, and the washing solution were combined, and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform) to obtain Compound 15 (1.34 g, yield 90%).
  • 1H-NMR (CDCl3/TMS) δppm: 2.57 (t, J=6.3 Hz, 4H), 3.71 (t, J=6.3 Hz, 4H), 6.97 (d, J=8.7 Hz, 2H), 7.52 (d, J=8.7 Hz, 2H).
  • REFERENCE EXAMPLE 9 Synthesis of Compound 16
  • Figure US20110172415A1-20110714-C00093
  • According to the same manner as that of Reference Example 8 except that Compound 14 was used in place of Compound 10, a reaction was performed to obtain Compound 16 (yield 92%).
  • 1H-NMR (CDCl3/TMS) δppm: 2.57 (t, J=6.0 Hz, 4H), 3.58 (t, J=6.0 Hz, 4H), 6.91 (d, J=9.0 Hz, 2H), 7.24 (d, J=9.0 Hz, 2H).
  • REFERENCE EXAMPLE 10 Synthesis of Compound 17
  • Figure US20110172415A1-20110714-C00094
  • According to the same manner as that of Reference Example 8 except that Compound 3 was used in place of Compound 10, a reaction was performed to obtain Compound 17 (yield 79%).
  • 1H-NMR (CDCl3/TMS) δppm: 1.72-1.85 (m, 2H), 2.01-2.09 (m, 2H), 2.43-2.52 (m, 1H), 2.95-3.04 (m, 2H), 3.69-3.76 (m, 2H), 6.94 (d, J=8.7 Hz, 2H), 7.48 (d, J=8.7 Hz, 2H), 9.71 (s, 1H).
  • REFERENCE EXAMPLE 11 Synthesis of Compound 19
  • Figure US20110172415A1-20110714-C00095
  • Compound 2 (3.28 g, 20.0 mmol) and Compound 18 (3.77 g, 24.0 mmol) were dissolved in DMF (10 ml), potassium carbonate (3.32 g, 24.0 mmol) was added, and the mixture was stirred at 120° C. for 24 hours. The solvent was distilled off under reduced pressure, and water was added to the residue, followed by extraction with toluene. The organic layer was washed with water, and dried with anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The resulting residue was purified by silica gel column chromatography (toluene-ethyl acetate) to obtain Compound 19 (2.35 g, yield 39%).
  • 1H-NMR (CDCl3/TMS) δppm: 1.27 (t, J=7.1 Hz, 3H), 1.76-1.92 (m, 2H), 1.97-2.08 (m, 2H), 2.42-2.54 (m, 1H), 2.84-2.96 (m, 2H), 3.70-3.79 (m, 2H), 4.16 (q, J=7.1 Hz, 2H), 6.92 (d, J=9.0 Hz, 2H), 7.46 (d, J=9.0 Hz, 2H).
  • REFERENCE EXAMPLE 12 Synthesis of Compound 21
  • Figure US20110172415A1-20110714-C00096
  • 1-(4-Chlorophenyl)piperazine hydrochloride 20 (1.00 g, 4.3 mmol) was dissolved in toluene (5 ml), and the solution was cooled with an ice bath. A solution of ethyl chloroglyoxylate (0.64 g, 4.7 mmol) in toluene (2 ml) was added dropwise, and the mixture was stirred at 0° C. for 0.5 hour. The reaction solution was extracted with ethyl acetate. The organic layer was washed with an aqueous saturated sodium chloride solution, and dried with anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain Compound 21 (1.27 g, yield 100%).
  • 1H-NMR (CDCl3/TMS) δppm: 1.38 (t, J=7.1 Hz, 3H), 3.15-3.20 (m, 4H), 3.60 (t, J=5.2 Hz, 2H), 3.78 (t, J=5.2 Hz, 2H), 4.36 (q, J=7.1 Hz, 2H), 6.84 (d, J=9.1 Hz, 2H), 7.22 (d, J=9.1 Hz, 2H).
  • REFERENCE EXAMPLE 13 Synthesis of Compound 24
  • Figure US20110172415A1-20110714-C00097
  • a) Synthesis of Compound 23
  • 2-Amino-5-nitrophenol 22 (22.20 g, 144 mmol) was dissolved in THF (100 ml), and the interior of the system was replaced with a nitrogen gas, and cooled with an ice bath. A suspension (100 ml) of 1,1′-carbonyldiimidazole (28.03 g, 173 mmol) in THF was added in portions at 0 to 5° C., and the mixture was stirred at room temperature for 15 hours. The solvent was distilled off under reduced pressure, water (144 ml) was added to the residue, this was cooled with an ice bath, 2 mol/L hydrochloric acid (144 ml, 288 mmol) was added, and the mixture was stirred at room temperature for 3 hours. The precipitated solid was collected by filtration, washed with water, and dried to obtain Compound 23 (25.81 g, yield 99%).
  • 1H-NMR (DMSO-d6/TMS) δppm: 7.28 (d, J=8.6 Hz, 1H), 8.13 (dd, J=2.0, 8.6 Hz, 1H), 8.19 (d, J=2.0 Hz, 1H), 12.43 (brs, 1H).
  • b) Synthesis of Compound 24
  • Compound 23 (40.00 g, 222 mmol) was suspended in THF-water (9:1) mixed solution (400 ml), 10%-palladium-carbon (8.00 g, 53% water-containing product) was added, and the mixture was stirred at room temperature for 9 hours under the hydrogen atmosphere. The reaction solution was filtered using Celite, and the residue was washed with THF-water (9:1) mixed solution (500 ml). The filtrate and the washing solution were combined, and concentrated to 96 g under reduced pressure, water (100 ml) was added, and the solid was collected by filtration. The solid was washed with water, and dried to obtain Compound 24 (32.20 g, yield 97%).
  • 1H-NMR (DMSO-d6/TMS) δ ppm: 5.01 (s, 1H), 6.35 (dd, J=2.0, 8.2 Hz, 1H), 6.50 (d, J=2.0 Hz, 1H), 6.74 (d, J=8.2 Hz, 1H), 11.03 (brs, 1H).
  • EXAMPLE 1 Synthesis of Compound (I-2)
  • Figure US20110172415A1-20110714-C00098
  • a) Synthesis of Compound 25
  • Under the nitrogen atmosphere, Compound 5 (339 mg, 1.46 mmol) obtained in Reference Example 2 was dissolved in THF (10 ml), phthalimide (279 mg, 1.90 mmol), triphenylphosphine (498 mg, 1.90 mmol), and diisopropyl azodicarboxylate (0.37 ml, 1.90 mmol) were added, and the mixture was stirred at room temperature for 1 hour.
  • The solvent was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (toluene-ethyl acetate) to obtain Compound 25 (541 mg, yield 92%). mp 203-205° C.
  • 1H-NMR (CDCl3/TMS) δ ppm: 1.38-1.55 (m, 3H), 1.68 (q, J=6.6 Hz, 2H), 1.92 (d, J=9.9 Hz, 2H), 2.81 (t, J=11.4 Hz, 2H), 3.74-3.80 (m, 4H), 6.96 (br, 2H), 7.46 (d, J=9.0 Hz, 2H), 7.71-7.74 (m, 2H), 7.84-7.87 (m, 2H).
  • b) Synthesis of Compound 21
  • Compound 26 (537 ng, 1.33 mmol) was dissolved in ethanol (10 ml), hydrazine monohydrate (0.16 ml, 3.33 mmol) was added, and this was refluxed for 2 hours. After allowing to cool, the precipitated solid was filtered off. The filtrate and the solid were heated with chloroform-methanol (9:1 mixed solution), filtered, resulting filtrates were combined, and the solvent was distilled off under reduced pressure. To the residue was added a 1 mol/L aqueous sodium hydroxide solution added, and this was extracted with chloroform. The organic layer was washed with water, dried with anhydrous magnesium dulfate, the solvent was distilled off, and the resulting residue was purified by alumina column chromatography (chloroform-methanol) to obtain Compound 26 (280 mg, yield 77%).
  • 1H-NMR (CDCl3/TMS) δ ppm: 1.27-1.40 (m, 2H), 1.46-1.60 (m, 3H), 1.79 (d, J=12.9 Hz, 2H), 2.13 (br, 5H), 2.74-2.85 (m, 4H), 3.78 (d, J=12.6 Hz, 2H), 6.91 (d, J=8.7 Hz, 2H), 7.45 (d, J=8.7 Hz, 2H).
  • c) Synthesis of Compound (I-2)
  • To Compound 26 (276 mg, 1.01 mmol) were added DMF (5 ml), 6-hydroxynicotinic acid (155 mg, 1.11 mmol), HOBt (164 mg, 1.11 mmol), triethylamine (0.17 ml, 1.21 mmol), DMAP (6 mg, 0.05 mmol), and EDC (232 mg, 1.21 mmol), and the mixture was stirred at room temperature for 2 hours. The solvent was concentrated under reduced pressure, the resulting residue were added water, and 2 mol/L hydrochloric acid, followed by extraction with chloroform-methanol (9:1 mixed solution). The organic layer was washed with water, an aqueous saturated sodium bicarbonate solution, and water, and dried with anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The resulting residue was recrystallized from methanol-ethyl acetate to obtain Compound (I-2) (256 mg, yield 65%).
  • mp 232-233° C.
  • 1H-NMR (DMSO-d6/TMS) δ ppm: 1.14-1.25 (m, 2H), 1.46 (t, J=6.9 Hz, 2H), 1.53 (brs, 1H), 1.77 (d, J=11.7 Hz, 2H), 2.77 (t, J=11.7 Hz, 2H), 3.26 (q, J=5.7 Hz, 2H), 3.85 (d, J=12.9 Hz, 2H), 6.34 (d, J=9.6 Hz, 1H), 7.03 (d, J=8.7 Hz, 2H), 7.46 (d, J=8.7 Hz, 2H), 7.85 (dd, J=9.6, 2.7 Hz, 1H), 7.97 (d, J=2.4 Hz, 1H), 8.19 (t, J=5.0 Hz, 1H), 11.93 (s, 1H).
  • EXAMPLE 2 Synthesis of Compound (I-7)
  • Figure US20110172415A1-20110714-C00099
  • a) Synthesis of Compound 27
  • Under the nitrogen atmosphere, Compound 5 (1.37 g, 5.0 mmol) was dissolved in methylene chloride (15 ml), triethylamine (0.84 ml, 6.0 mmol) was added, and this was cooled with an ice bath. p-Toluenesulfonyl chloride (1.14 g, 6.0 mmol) was added, and the mixture was stirred at 0° C. for 45 minutes, and at room temperature for 3.5 hours. Aqueous ammonia was added, this was stirred for 15 minutes, and water was added, followed by extraction with chloroform. The organic layer was dried with anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified with silica gel column chromatography (chloroform) to obtain Compound 27 (1.74 g, yield 81%).
  • 1H-NMR (CDCl3/TMS) δ ppm: 1.22-1.34 (br, 2H), 1.56-1.73 (m, 5H), 2.46 (s, 3H), 2.75 (t, J=11.7 Hz, 2H), 3.74 (d, J=12.6 Hz, 2H), 4.10 (t, J=6.0 Hz, 2H), 6.91 (d, J=8.4 Hz, 2H), 7.36 (d, J=8.4 Hz, 2H), 7.45 (d, J=8.4 Hz, 2H), 7.80 (d, J=8.4 Hz, 2H).
  • b) Synthesis of Compound 28
  • Under the nitrogen atmosphere, Compound 22 (1.74 g, 4.07 mmol) was dissolved in DMF (17 ml), sodium cyanide (299 mg, 6.11 mmol) was added, and the mixture was stirred at 60° C. for 5 hours. The solvent was distilled off under reduced pressure, and water was added to the resulting residue, followed by extraction with toluene. The organic layer was washed with water, dried with anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (toluene-ethyl acetate) to obtain Compound 28 (1.07 g, yield 93%).
  • 1H-NMR (CDCl3/TMS) δ ppm: 1.31-1.42 (m, 2H), 1.64-1.69 (m, 3H), 1.83 (d, J=13.2 Hz, 2H), 2.42 (t, J=6.9 Hz, 2H), 2.78-2.87 (m, 2H), 3.81 (d, J=13.2 Hz, 2H), 6.93 (d, J=8.4 Hz, 2H), 7.47 (d, J=8.4 Hz, 2H).
  • c) Synthesis of Compound 29
  • Compound 28 (1.06 g, 3.75 mmol) was dissolved in methanol (10 ml), and 85% potassium hydroxide (2.31 g, 35.0 mmol), and water (10 ml) were added, followed by refluxing for 20 hours. After allowing to cool to room temperature, the solvent was distilled off under reduced pressure, and the resulting residue was neutralized with 5 mol/L hydrochloric acid. The precipitated solid was collected by filtration, washed with water, and dried to obtain Compound 29 (1.07g, yield 95%).
  • mp 204-206° C. (decompose)
  • 1H NMR (DMSO-d6/TMS) δ ppm: 1.10-1.22 (m, 2H), 1.45-1.49 (m, 3H), 1.73 (d, J=13.5 Hz, 2H), 2.25 (t, J=7.5 Hz, 2H), 2.75 (t, J=10.5 Hz, 2H), 3.85 (d, J=13.5 Hz, 2H), 7.03 (d, J=8.7 Hz, 2H), 7.46 (d, J=8.7 Hz, 2H).
  • d) Synthesis of Compound (I-7)
  • To Compound 29 (362 mg, 1.2 mmol) were added DMF (5 ml), 6-amino-3H-benzoxazole-2-one (150 mg, 1.0 mmol), HOBt (162 mg, 1.2 mmol), triethylamine (0.17 ml, 1.2 mmol), DMAP (6.0 mg, 0.05 mmol), and EDC (230 mg, 1.2 mmol), and the mixture was stirred at room temperature for 15 hours. The solvent was distilled off under reduced pressure, to the residue were added chloroform-methanol (9:1 mixed solution), and an aqueous saturated sodium bicarbonate solution, and the precipitated solid was collected by filtration, washed with water, and dried to obtain 261 mg of a solid. Separately, the filtrate was extracted with chloroform-methanol (9:1 mixed solution), washed with water, and dried with anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform-methanol) to obtain 66 mg of a solid. The resulting solids were combined, purified by silica gel column chromatography (chloroform-methanol) and, further, recrystallized from methanol to obtain Compound (I-7) (244 mg yield 56%).
  • mp 254-256° C. (decompose)
  • 1H-NMR (DMSO-d6/TMS) δ ppm: 1.16-1.25 (m, 2H), 1.46-1.52 (m, 1H), 1.55 (t, J=7.2 Hz, 2H), 1.76 (d, J=12.0 Hz, 2H), 2.34 (t, J=6.6 Hz, 2H), 2.78 (t, J=12.6 Hz, 2H), 3.87 (d, J=13.5 Hz, 2H), 7.01 (d, J=8.4 Hz, 1H), 7.04 (d, J=9.0 Hz, 2H), 7.21 (dd, J=8.4, 1.8 Hz, 1H), 7.46 (d, J=9.0 Hz, 2H), 7.69 (d, J=1.5 Hz, 1H), 9.95 (s, 1H), 11.51 (s, 1H).
  • EXAMPLE 3 Synthesis of Compound (I-8)
  • Figure US20110172415A1-20110714-C00100
  • a) Synthesis of Compound 30
  • Under the nitrogen atmosphere, Compound 15 (1.34 g, 5.51 mmol) obtained in Reference Example 8 was dissolved in THF (20 ml), and ethyl diethylphosphonoacetate (1.36 g, 6.06 mmol), and lithium hydroxide (435 mg, 18.2 mmol) were added, followed by refluxing for 2 hours. After cooled with an ice bath, 7 ml of 2 mol/l hydrochloric acid was added, followed by extraction with diethyl ether. The organic layer was washed with an aqueous saturated sodium chloride solution, dried with anhydrous sodium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform). Recrystallization with diethyl ether/hexane afforded Compound 30 (1.22 g, yield 71%).
  • mp 71-74° C.
  • 1H-NMR (CDCl3/TMS) δ ppm: 1.29 (t, J=7.2 Hz, 3H), 2.46 (t, J=5.7 Hz, 2H), 3.11 (t, J=5.7 Hz, 2H), 3.45 (q, J=6.0 Hz, 4H), 4.17 (q, J=7.2 Hz, 2H), 5.75 (s, 1H), 6.94 (d, J=8.7 Hz, 2H), 7.48 (d, J=8.7 Hz, 2H).
  • b) Synthesis of Compound 31
  • Compound 30 (500 mg, 1.60 mmol) was dissolved in ethanol (15 ml), 10% palladium-carbon (50 mg) was added, the interior of the system was replaced with a hydrogen gas, and the mixture was stirred at room temperature for 1.5 hours. The reaction solution was filtered, insolubles were removed, and the filtrate was distilled off under reduced pressure. To the resulting residue was added diethyl ether, this was filtered using Celite, and washed with diethyl ether. The filtrate, and the washing solution were combined, and the solvent was distilled off under reduced pressure to obtain Compound 31 (488 mg, yield 97%).
  • 1H-NMR (CDCl3/TMS) δ ppm: 1.27 (t, J=7.2 Hz, 3H), 1.38-1.46 (m, 2H), 1.84 (d, J=12.9 Hz, 2H), 1.95-2.04 (m, 1H), 2.28 (d, J=12.9 Hz, 2H), 2.84 (dt, J=2.1, 12.6 Hz, 2H), 4.15 (q, J=7.2 Hz, 2H), 6.93 (d, J=8.7 Hz, 2H), 7.46 (d, J=8.7 Hz, 2H).
  • c) Synthesis of Compound 32
  • Compound 31 (485 mg, 1.54 mmol) was dissolved in methanol (10 ml), 2 mol/L sodium hydroxide (2 ml, 4.0 mmol) was added, and the mixture was stirred at 65° C. for 45 minutes. The solvent was distilled off under reduced pressure, and 2 mol/L hydrochloric acid was added to the residue to acidic, and the precipitated crystal was collected by filtration. The crystal was washed with water, and dried to obtain Compound 32 (399 mg, yield 96%). mp 103-104° C.
  • 1H-NMR (CDCl3/TMS) δ ppm: 1.36-1.49 (m, 2H), 1.88 (d, J=12.3 Hz, 2H), 1.97-2.05 (m, 1H), 2.35 (d, J=6.9 Hz, 2H), 2.84 (dt, J=2.4, 12.6 Hz, 2H), 3.79 (d, J=12.6 Hz, 2H), 6.93 (d, J=9.0 Hz, 2H), 7.46 (d, J=9.0 Hz, 2H).
  • d) Synthesis of Compound (I-7)
  • To Compound 32 (388 mg, 1.35 mmol) were added methylene chloride (10 ml), 6-amino-3H-benzoxazole-2-one (203 mg, 1.35 mmol), HOBt (219 mg, 1.62 mmol), triethylamine (0.23 ml, 1.62 mmol), DMAP (8.0 mg, 0.07 mmol), and EDC (311 mg, 1.62 mmol), and the mixture was stirred at room temperature for 19 hours. An aqueous saturated sodium bicarbonate solution was added, and the precipitated solid was collected by filtration, washed with water, and dried to obtain 105 mg of a solid. Separately, the filtrate was extracted with chloroform, and dried with anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (acetonitrile-chloroform) and, further, recrystallized from acetone-isopropanol to obtain 121 mg of a solid. The resulting solids were combined, purified by silica gel column chromatography (chloroform-methanol) and, further, recrystallizaed with ethyl acetate-methanol-isopropanol to obtain Compound (I-7) (153 mg, yield 27%).
  • mp 245-246° C. (decompose)
  • 1H-NMR (DMSO-d6/TMS) δ ppm: 1.23-1.34 (m, 2H), 1.75 (d, J=12.0 Hz, 2H), 1.96-2.06 (m, 1H), 2.25 (d, J=7.2 Hz, 2H), 2.83 (t, J=12.3 Hz, 2H), 3.86 (d, J=12.0 Hz, 2H), 7.02 (t, J=9.9 Hz, 3H), 7.22 (dd, J=8.7, 1.8 Hz, 1H), 7.47 (d, J=8.7 Hz, 2H), 7.70 (d, J=1.8 Hz, 1H), 9.95 (s, 1H), 11.51 (s, 1H).
  • EXAMPLE 4 Synthesis of Compound (I-16)
  • Figure US20110172415A1-20110714-C00101
  • a) Synthesis of Compound 33
  • Compound 30 (376 mg, 1.2 mmol) was dissolved in methanol (10 ml), lithium hydroxide (252 mg, 6.0 mmol), and water (1 ml) were added, and the mixture was stirred at room temperature for 85 minutes, and at 65° C. for 45 minutes. The solvent was distilled off under reduced pressure, water, and 2 mol/L hydrochloric acid were added to the residue to acidic, and the precipitated crystal was collected by filtration. After washing with water, the solid obtained by drying was purified by silica gel column chromatography (chloroform-methanol) to obtain Compound 33 (286 mg, yield 84%).
  • 1H-NMR (CDCl3/TMS) δ ppm: 2.36 (br, 1H), 3.14 (s, 2H), 3.49 (t, J=5.7 Hz, 2H), 3.86 (br, 1H), 5.73 and 5.79 (s, 1H), 6.90 (d, J=8.7 Hz, 2H), 7.48 (d, J=8.7 Hz, 2H).
  • b) Synthesis of Compound (I-16)
  • To Compound 33 (280 mg, 0.98 mmol) were added methylene chloride (10 ml), 6-amino-3H-benzoxazole-2-one (147 mg, 0.98 mmol), HOBt (159 mg, 1.18 mmol), triethylamine (0.16 ml, 1.18 mmol), DMAP (6.0 mg, 0.05 mmol), and EDC (226 mg, 1.18 mmol), and the mixture was stirred at room temperature for 4 days. The precipitated solid was collected by filtration, washed with methylene chloride, and dried to obtain 338 mg of a solid. Separately, the filtrate was concentrated under reduced pressure, to the residue were added an aqueous saturated sodium bicarbonate solution, and diethyl ether, and the solid was collected by filtration. This was washed with water, and diethyl ether, and dried to obtain 35 mg of a solid. Resulting solids were combined, purified by silica gel column chromatography (chloroform/methanol), and recrystallized from ethyl acetate/methanol to obtain Compound (I-16) (225 mg, yield 55%).
  • mp 203-205° C. (decompose)
  • 1H-NMR (DMSO-d6/TMS) δ ppm: 2.26 (br, 2H), 3.09 (s, 2H), 3.47 (t, J=5.7 Hz, 2H), 3.78 (br, 2H), 5.69 (s, 1H), 7.02 (d, J=8.1 Hz, 1H), 7.03 (d, J=8.7 Hz, 2H), 7.23 (dd, J=8.4, 1.8 Hz, 1H), 7.49 (d, J=8.7 Hz, 2H), 7.69 (d, J=1.5 Hz, 1H), 10.06 (s, 1H), 11.53 (s, 1H).
  • EXAMPLE 5 Synthesis of Compound (I-18)
  • Figure US20110172415A1-20110714-C00102
  • a) Synthesis of Compound 34
  • Compound 19 (2.35 gt, 7.80 mmol) obtained in Reference Example 11 was dissolved in methanol (24 ml), and a 2 mol/L aqueous sodium hydroxide solution (7.8 ml, 15.6 mmol) was added, followed by refluxing for 30 minutes. The solvent was distilled off under reduced pressure, 2 mol/L hydrochloric acid was added to the residue to acidic, and the precipitated crystal was collected by filtration. After washing with water, drying afforded Compound 34 (2.06 g, yield 97%).
  • mp 206-208° C. (decompose)
  • b) Synthesis of Compound (I-18)
  • To Compound 34 (273 mg, 1.0 mmol) were added DMF (5 ml), 6-amino-3H-benzoxazole-2-one (150 mg, 1.0 mmol), HOBt (162 mg, 1.2 mmol), triethylamine (0.17 ml, 1.2 mmol), DMAP (12.0 mg, 0.1 mmol), and EDC (230 mg, 1.2 mmol), and the mixture was stirred at room temperature for 41 hours. The solvent was distilled off under reduced pressure, to the residue were added an aqueous saturated sodium bicarbonate solution, and water, and the solid was collected by filtration. The resulting solid was purified by silica gel column chromatography (chloroform-acetone), and recrystallizaed with acetone-methanol to obtain Compound (I-18) (341 mg, yield 84%).
  • mp 302-304° C. (decompose)
  • 1H-NMR (DMSO-d6/TMS) δ ppm: 1.63-1.77 (m, 2H), 1.87 (d, J=10.2 Hz, 2H), 2.53-2.61 (m, 1H), 2.87 (t, J=9.9 Hz, 2H), 3.95 (d, J=13.2 Hz, 2H), 7.01 (d, J=8.4 Hz, 1H), 7.08 (d, J=8.7 Hz, 2H), 7.25 (dd, J=8.7, 2.1 Hz, 1H), 7.49 (d, J=8.7 Hz, 2H), 7.70 (d, J=2.1 Hz, 1H), 9.99 (s, 1H), 11.50 (s, 1H).
  • EXAMPLE 6 Synthesis of Compound (I-23)
  • Figure US20110172415A1-20110714-C00103
  • a) Synthesis of Compound 35
  • Compound 10 (981 mg, 4.0 mmol) obtained in Reference Example 4 was dissolved in THF (40 ml), phthalimide (765 mg, 5.2 mmol), triphenylphosphine (1.36 g, 5.2 mmol), and diisopropyl azodicarboxylate (1.08 ml, 5.2 mmol) were added, and the mixture was stirred at room temperature for 16 hours. The solvent was concentrated under reduced pressure, and an aqueous saturated sodium bicarbonate solution, and water were added to the resultant residue, followed by extraction with chloroform. The organic layer was dried with anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was washed with methanol to obtain Compound 35 (1.08 g, yield 72%).
  • 1H-NMR (CDCl3/TMS) δ ppm: 1.77-1.86 (m, 2H), 2.55-2.72 (m, 2H), 2.86-2.99 (m, 2H), 3.89-3.99 (m, 2H), 4.27-4.40 (m, 1H), 6.96(d, J=8.7 Hz, 2H), 7.49 (d, J=8.7 Hz, 2H), 7.72 (dd, J=3.0, 5.6 Hz, 2H), 7.84 (dd, J=3.0, 5.6 Hz, 2H).
  • b) Synthesis of Compound 36
  • Compound 30 (262 mg, 0.7mmol) was dissolved in ethanol (7 ml), and hydrazine monohydrate (0.087 ml, 1.75 mmol) was added, followed by refluxing for 2 hours. After allowing to cool, the precipitated solid was filtered off, and the filtrate was distilled off under reduced pressure. The resulting residue was purified by silica gel column chromatography (amino column, chloroform-methanol) to obtain Compound 36 (125 mg, yield 73%).
  • 1H-NMR (CDCl3/TMS) δ ppm: 1.30 (brs, 2H), 1.38-1.53 (m, 2H), 1.87-1.98 (m, 2H), 2.82-2.94 (m, 3H), 3.71-3.81 (m, 2H), 6.92 (d, J=8.7 Hz, 2H), 7.45 (d, J=8.7 Hz, 2H).
  • c) Synthesis of Compound (I-23)
  • Compound 37 (60 mg, 0.22 mmol) was dissolved in acetonitrile (2 ml), and triethylamine (0.034 ml, 0.24 mmol) was added. A solution of Compound 36 (49 mg, 0.20 mmol) in acetonitrile (1 ml) was added, followed by refluxing for 6 hours. The precipitated crystal was filtered off, washed with water, and ethyl acetate, and dried to obtain (I-23) (50 mg, yield 59%).
  • mp 294-296° C.
  • 1H-NMR (DMSO-d6/TMS) δ ppm: 1.31-1.55 (m, 2H), 1.80-2.00 (m, 2H), 2.88-3.10 (m, 2H), 3.60-3.85 (m, 3H), 6.17 (s, 1H), 6.95 (s, 2H), 7.06 (d, J=5.4 Hz, 2H), 7.48 (d, J=6.0 Hz, 2H), 7.54 (s, 1H), 8.35 (s, 1H), 11.35 (brs, 1H).
  • EXAMPLE 7 Synthesis of Compound (I-26)
  • Figure US20110172415A1-20110714-C00104
  • a) Synthesis of Compound 39
  • Under the nitrogen atmosphere, a solution of Compound 15 (1.18 g, 4.85 mmol), Compound 38 (1.45 g, 5.09 mmol), DMPO (1.80 g, 14.1 mmol) in THF (10 ml) was cooled with an ice bath, and a suspension of sodium hydride (60% oily, 204 mg, 5.09 mmol) in THF (10 ml) was added dropwise. After stirred at room temperature for 3 hours, ice water was added, followed by extraction with diethyl ether. The organic layer was washed with an aqueous saturated sodium chloride solution, dried with anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform) to obtain Compound 39 (1.43 g, yield 79%).
  • H-NMR (CDCl3/TMS) δ ppm: 1.35 (t, J=6.9 Hz, 3H), 2.73 (t, J=6.0 Hz, 2H), 2.79 (t, J=6.0 Hz, 2H), 3.40-3.45 (m, 4H), 3.51 (s, 3H), 4.27 (q, J=6.9 Hz, 2H), 4.85 (s, 2H), 6.93 (d, J=8.7 Hz, 2H), 7.49 (d, J=8.7 Hz, 2H).
  • b) Synthesis of Compound 40
  • Compound 39 (1.43 g, 3.83 mmol) was dissolved in ethanol (30 ml), p-toluenesulfonic acid monohydrate (73 mg, 0.38 mmol) was added, followed by refluxing for 15 hours. After allowing to stand to cool to room temperature, the solvent was distilled off under reduced pressure, to the residue were added water, and an aqueous saturated sodium bicarbonate solution, followed by extraction with chloroform. The organic layer was dried with anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform-acetonitrile) to obtain Compound 40 (1.19 g, yield 95%).
  • 1H-NMR (CDCl3/TMS) δ ppm: 1.35 (t, J=6.9 Hz, 3 H), 2.73 (t, J=6.0 Hz, 2H), 2.79 (t, J=6.0 Hz, 2H), 3.40-3.45 (m, 4H), 3.51 (s, 3H), 4.27 (q, J=6.9 Hz, 2H), 4.85 (s, 2H), 6.93 (d, J=8.7 Hz, 2H), 7.49 (d, J=8.7 Hz, 2H).
  • c) Synthesis of Compound 41
  • Compound 40 (329 mg, 1.0 mmol) was dissolved in ethanol (10 ml), 85% potassium hydroxide (99 mg, 1.5 mmol), and water (1 ml) were added, and the mixture was stirred at room temperature for 75 minutes. The solvent was distilled off under reduced pressure, an ice, and 2 mol/L hydrochloric acid (0.8 ml, 1.6 mmol) were added to the residue to acidic, and the precipitated solid was collected by filtration. After the solid was washed with water, it was dried to obtain crude Compound 41 (261 mg, crude yield 87%).
  • d) Synthesis of Compound (I-26)
  • To Compound 41 (261 mg, 0.87 mmol) were added DMF (5 ml), 6-amino-3H-benzoxazole-2-one (156 mg, 1.04 mmol), HOBt (140 mg, 1.04 mmol), triethylamine (0.15 ml, 1.04 mmol), DMAP (11.0 mg, 0.09 mmol), and EDC (199 mg, 1.04 mmol), and the mixture was stirred at room temperature for 64 hours. The solvent was distilled off under reduced pressure, to the residue were added an aqueous saturated sodium bicarbonate solution, and water, and a solid was collected by filtration. The resulting solid was purified by silica gel column chromatography (chloroform-methanol) and, further, recrystallized from acetone-ethyl acetate to obtain Compound (I-26) (179 mg, yield 48%).
  • mp 230-232° C.
  • 1H-NMR (DMSO-d6/TMS) δ ppm: 1.48-1.62 (m, 2H), 1.95 (d, J=11.7 Hz, 2H), 2.99 (t, J=11.7 Hz, 2H), 3.53-3.60 (m, 1H), 3.92 (d, J=12.9 Hz, 2H), 7.08 (d, J=8.7 Hz, 3H), 7.49 (d, J=8.7 Hz, 2H), 7.57 (dd, J=8.7, 1.8 Hz, 1H), 7.82 (d, J=1.8 Hz, 1H), 10.63 (s, 1H), 11.64 (s, 1H).
  • EXAMPLE 8 Synthesis of Compound (I-34)
  • Figure US20110172415A1-20110714-C00105
  • a) Synthesis of Compound 42
  • Under the nitrogen atmosphere, a solution of diisopropylamine (0.50 ml, 3.57 mmol) in THF (5 ml) was cooled to −78° C. with a dry-ice acetone bath, to this was added dropwise a 2.67M n-butyllithium-hexane solution (1.20 ml, 3.09 mmol), and the mixture was stirred at −78° C. for 15 minutes. A solution of ethyl acetate (0.30 ml, 3.09 mmol) in THF (2 ml) was added dropwise, the mixture was stirred at −78° C. for 30 minutes, a solution of Compound 16 (500 mg, 2.38 mmol) obtained in Reference Example 9 in THF (5 ml) was added, and the mixture was stirred at −78° C. for 50 minutes. A solution of ammonium chloride (330 mg, 6.18 mmol) in water (2 ml) was added, a temperature was raised to room temperature, and water was added, followed by extraction with diethyl ether. The organic layer was washed with an aqueous saturated sodium chloride solution, dried with anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform-acetonitrile) to obtain Compound 42 (703 mg, yield 99%).
  • 1H-NMR (CDCl3/TMS) δ ppm: 1.30 (t, J=7.2 Hz, 3H), 1.73-1.84 (m, 4H), 2.51 (s, 2H), 3.20 (t, J=9.9 Hz, 2H), 3.36 (q, J=7.2 Hz, 2H), 3.61 (s, 1H), 6.88 (d, J=8.7 Hz, 2H), 7.20 (d, J=8.7 Hz, 2H).
  • b) Synthesis of Compound 43
  • Compound 42 (703 mg, 2,36 mmol) was dissolved in methanol (10 ml), a 2 mol/L aqueous sodium hydroxide solution (2.4 ml, 4.8 mmol) was added, followed by refluxing for 20 minutes. Acetic acid (0.55 ml, 9.6 mmol) was added, the solvent was distilled off under reduced pressure, water was added to the residue, and the precipitated crystal was collected by filtration. After washing with water, drying afforded Compound 43 (526 mg, yield 83%).
  • mp 130-133° C.
  • 1H-NMR (CDCl3/TMS) δ ppm: 1.86-1.98 (m, 4H), 2.61 (s, 2H), 3.27-3.40 (m, 4H), 7.09 (d, J=8.7 Hz, 2H), 7.26 (d, J=8.7 Hz, 2H).
  • c) Synthesis of Compound (I-34)
  • To Compound 43 (70 mg. 1.0 mmol)were added DMF (5 ml), 6-amino-3H-benzoxazole-2-one (150 mg, 1.0 mmol), HOBt (162 mg, 1.2 mmol), DMAP (12.0 mg, 0.1 mmol), and EDC (230 mg, 1.2 mmol), and the mixture was stirred at room temperature for 63 hours. The solvent was distilled off under reduced pressure, to the residue were added an aqueous saturated sodium bicarbonate solution, and water, and a solid was collected by filtration. The resulting solid was purified by silica gel column chromatography (choloroform-methanol) and, further, recrystallized from THF-ethyl acetate to obtain Compound (I-34) (314 mg, yield 78%).
  • mp 255-257° C. (decompose)
  • 1H-NMR (DMSO-d6/TMS) δ ppm: 1.63-1.80 (m, 4H), 2.46 (s, 2H), 3.04-3.13 (m, 2H), 3.34-3.40 (m, 2H), 4.75 (s, 1H), 6.94 (d, J=8.7 Hz, 2H), 7.01 (d, J=8.7 Hz, 1H), 7.19 (d, J=8.7 Hz, 2H), 7.13 (dd, J=8.7, 1.8 Hz, 1H), 7.70 (d, J=1.8 Hz, 1H), 9.94 (s, 1H), 11.53 (brs, 1H).
  • EXAMPLE 9 Synthesis of Compound (I-19)
  • Figure US20110172415A1-20110714-C00106
  • a) Synthesis of Compound 45
  • Under the nitrogen atmosphere, Compound 44 (7.52 g, 16.4 mmol) was dissolved in THF (30 ml), potassium hexamethyldisilazide (6.90 g, 32.9 mmol) was added, and the mixture was stirred at room temperature for 30 minutes. A solution of Compound 15 (1.00 g, 4.11 mmol) in THF (10 ml) was added, and the mixture was stirred at room temperature for 3 hours. Water, and 2 mol/L hydrochloric acid were added, followed by extraction with ethyl acetate. The organic layer was washed with an aqueous saturated sodium chloride solution, and dried with anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain Compound 45 (0.48 g, yield 34%).
  • 1H-NMR (CDCl3/TMS) δ ppm: 1.26 (t, J=7.1 Hz, 3H), 2.26-2.32 (m, 2H), 2.34-2.42 (m, 6H), 3.29-3.36 (m, 4H), 4.13 (q, J=7.1 Hz, 2H), 5.20-5.26 (m, 1H), 6.91 (d, J=8.7 Hz, 2H), 7.46 (d, J=8.7 Hz, 2H).
  • b) Synthesis of Compound 46
  • Compound 45 (470 mg, 1.38 mmol) was dissolved in methanol (10 ml), a 1 mol/L aqueous sodium hydroxide solution (2.1 ml, 2.1 mmol) was added, and the mixture was stirred at room temperature for 4 hours. 2 mol/L hydrochloric acid was added to acidic, followed by extraction with ethyl acetate. The organic layer was dried with anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain Compound 46 (420 mg, yield 99%).
  • 1H-NMR (DMSO-d6/TMS) δ ppm: 2.12-2.32 (m, 8H), 3.23-3.40 (m, 4H), 5.18-5.27 (m, 1H), 7.05 (d, J=6.3 Hz, 2H), 7.48 (d, J=6.3 Hz, 2H),
  • c) Synthesis of Compound 47
  • Compound 46 (420 mg, 1.34 mmol), and N-methylmorpholine (0.15 ml, 1.34 mmol) were dissolved in THF (8 ml), and the solution was cooled with an ice bath. Isobutyl chlorocarbonate (0.17 ml, 1.34 mmol), triethylamine (0.21 ml, 1.47 mmol), and a solution of N,O-dimethoxyamine hydrochloride (131 mg, 1.34 mmol) in DMF (3 ml) were sequentially added, and the mixture was stirred at 0° C. for 30 minutes, and at room temperature for 5 hours. The solvent was distilled off under reduced pressure, the residue was added water, followed by extraction with ethyl acetate. The organic layer was washed with an aqueous saturated sodium chloride solution, and dried with anhydrous magnesium sulfate, the solvent was distilled off, and the resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain Compound 47 (427 mg, yield 89%).
  • 1H-NMR (CDCl3/TMS) δ ppm: 2.26-2.53 (m, 8H), 3.18 (s, 3H), 3.30-3.36 (m, 4H), 3.68 (s, 3H), 5.25-5.30 (m, 1H), 6.91 (d, J=8.7 Hz, 2H), 7.46 (d, J=8.7 Hz, 2H)
  • d) Synthesis of Compound 48
  • Under the nitrogen atmosphere, 5-bromo-2-tert-butoxypyridine (400 mg, 1.74 mmol) was dissolved in THF (8 ml), and the solution was cooled to −78° C. with a dry ice-acetone bath. A 2.6 M n-butyllitium-hexane solution (0.72 ml, 1.86 mmol) was added dropwise, the mixture was stirred at −78° C. for 30 minutes, a solution of Compound 42 (415 mg, 1.16 mmol) in THF (4 ml) was added, and the mixture was stirred at −78° C. for 1 hour, and at −40° C. for 5 hours. An aqueous saturated ammonium chloride solution and water were added, a temperature was raised to room temperature, followed by extraction with ethyl acetate. The organic layer was washed with an aqueous saturated sodium chloride solution, and dried with anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform-acetonitrile) to obtain Compound 48 (275 mg, yield 53%).
  • 1-H-NMR (CDCl3/TMS) δ ppm: 1.61 (s, 9H), 2.25-2.32 (m, 2H), 2.35-2.42 (m, 2H), 2.43-2.52 (m, 2H), 2.90-2.99 (m, 2H), 3.29-3.34 (m, 4H), 5.26-5.32 (m, 1H), 6.66 (d, J=8.7 Hz, 1H), 6.90 (d, J=8.7 Hz, 2H), 7.46 (d, J=8.7 Hz, 2H), 8.07 (dd, J=2.6, 8.7 Hz, 1H), 8.74 (d, J=2.6 Hz, 1H).
  • e) Synthesis of Compound (I-19)
  • Compound 48 (120 mg, 0.27 mmol) was dissolved in chloroform (3 ml), and the solution was cooled with an ice bath. Trifluoroacetic acid (2 ml) was added, the mixture was stirred at 0° C. for 1.5 hours, an aqueous saturated sodium bicarbonate solution was added, followed by extraction with chloroform. The organic layer was dried with anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, the resulting residue was purified by silica gel column chromatography (chloroform-methanol). The resulting solid was recrystallized from methanol-water to obtain Compound (I-19) (77 mg, yield 73%).
  • mp 137-139° C.
  • 1H-NMR (DMSO-d6/TMS) δ ppm: 2.19-2.22 (m, 2H), 2.22-2.39 (m, 4H), 2.78-2.92 (m, 2H), 3.20-3.47 (m, 4H), 5.18-5.30 (m, 1H), 6.36 (d, J=9.6 Hz, 1H), 7.04 (d, J=8.8 Hz, 2H), 7.47 (d, J=8.8 Hz, 2H), 7.87 (dd, J=2.4, 9.6 Hz, 1H), 8.22 (d, J=2.4 Hz, 1H), 12.12 (brs, 1H).
  • EXAMPLE 10 Synthesis of Compound (I-20)
  • Figure US20110172415A1-20110714-C00107
  • a) Synthesis of Compound 50
  • Compound 49 (144 mg, 0.32 mmol) was dissolved in ethyl acetate (5 ml), 10% palladium-carbon (15 mg) was added, the interior of the system was replaced with a hydrogen gas, and the mixture was stirred at room temperature for 16 hours. The reaction solution was filtered using Celite, the filtrate was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain Compound 50 (88 mg, yielded 61%).
  • 1H NMR (CDCl3/TMS) δ ppm: 1.23-1.53 (m, 511), 1.62 (s, 9H), 1.73-1.85 (m, 4H), 2.72-2.84 (m, 2H), 2.48-2.94 (m, 2H), 3.76-3.81 (m, 2H), 6.67 (d, J=8.7 Hz, 1H), 6.91 (d, J=8.7 Hz, 2H), 7.45 (d, J=8.7 Hz, 2H), 8.08 (dd, J=8.7 Hz, 1H), 8.75 (d, J=2.4 Hz, 1H).
  • b) Synthesis of Compound (I-20)
  • Compound 50 (85 mg, 0.19 mmol) was dissolved in chloroform (2 ml), and the solution was cooled with an ice bath. Trifluoroacetic acid (1 ml) was added, the mixture was stirred at 0° C. for 1.5 hours, an aqueous saturated sodium bicarbonate solution was added, followed by extraction with ethyl acetate. The organic layer was washed with an aqueous saturated sodium chloride solution, dried with anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform-methanol). The resulting solid was recrystallized from methanol-water to obtain Compound (I-20) (61 mg, yield 82%).
  • mp 171-173° C.
  • 1-H-NMR (DMSO-d6/TMS) δ ppm: 1.08-1.31 (m, 41), 1.38-1.51 (m, 1H), 1.52-1.65 (m, 2H), 1.65-1.80 (m, 2H), 2.68-2.87 (m, 4H), 3.72-3.90 (m, 2H), 6.37 (d, J=7.2 Hz, 1H), 7.02 (d, J=6.6 Hz, 2H), 7.46 (d, J=6.6 Hz, 2H), 7.87 (dd, J=1.8, 7.2 Hz, 1H), 8.25 (d, J=1.8 Hz, 1H), 12.11 (brs, 1H).
  • EXAMPLE 11 Synthesis of Compound (1-24)
  • Figure US20110172415A1-20110714-C00108
  • a) Synthesis of Compound 52
  • In methylene chloride (20 ml) was dissolved 1-(4-chlorophenyl)piperazine hydrochloride 51 (2.33 g, 10.0 mmol), a 2 mol/L aqueous sodium hydroxide solution (13.0 ml, 26.0 mmol) was added, and this was cooled with an ice bath. A solution of chloroacetyl chloride (1.47 g, 13.0 mmol) in methylene chloride (5 ml) was added, the mixture was stirred at 0° C. for 1 hour, 2 mol/L hydrochloric acid (7.0 ml, 14.0 mmol) was added, followed by extraction with ethyl acetate. The organic layer was washed sequentially with an aqueous saturated sodium bicarbonate solution, and an aqueous saturated sodium chloride solution, dried with anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The resulting residue was recrystallized from ethyl acetate-hexane to obtain Compound 52 (2.26 g, yielded 83%).
  • 1H NMR (CDCl3/TMS) δ ppm: 3.15 (t, J=5.2 Hz, 2H), 3.20 (t, J=5.2 Hz, 2H), 3.68 (t, J=5.2 Hz, 2H), 3.78 (t, J=5.2 Hz, 2H), 4.11 (s, 2H), 6.85 (d, J=9.1 Hz, 2H), 7.23 (d, J=9.1 Hz, 2H).
  • b) Synthesis of Compound (I-244)
  • Compound 52 (546 mg, 2.0 mmol) and 6-amino-3H-benzoxazole-2-one (300 mg, 2.0 mmol) was dissolved in DMF (10 ml), and the solution was stirred at 80° C. for 1 hour, and at 100° C. for 4 hours. The solvent was distilled off under reduced pressure, and an aqueous saturated sodium bicarbonate solution was added to the residue, followed by extraction with an ethyl acetate-THF (1:1) mixed solution. The organic layer was dried with anhydrous sodium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform-methanol). An amorphous substance was crystallized using methanol, and this was collected by filtration, washed with diethyl ether, and dried to obtain compound (I-244) (135 mg, yielded 17%).
  • mp 211-213° C.
  • 1H-NMR (DMSO-d6/TMS) δ ppm: 3.11-3.23 (m, 4H), 3.58-3.68 (m, 4H), 3.93 (d, J=5.1 Hz, 2H), 5.56 (t, J=5.1 Hz, 1H), 6.48 (dd, J=2.0, 8.6 Hz, 1H), 6.70 (d, J=2.0 Hz, 1H), 6.81 (d, J=8.7 Hz, 1H), 6.98 (d, J=9.1 Hz, 2H), 7.26 (d, J=9.1 Hz, 2H), 11.12 (brs, 1H).
  • According to the same manner, other Compound (I) is synthesized below. Following are a structural formula and a physical constant.
  • TABLE 4
    Compound
    No. Structural formula Melting point
    I-1
    Figure US20110172415A1-20110714-C00109
    232-234
    I-2
    Figure US20110172415A1-20110714-C00110
    232-233(d)
    I-3
    Figure US20110172415A1-20110714-C00111
    283-284(d)
    I-4
    Figure US20110172415A1-20110714-C00112
    274-275(d)
    I-5
    Figure US20110172415A1-20110714-C00113
    236-238(d)
    I-6
    Figure US20110172415A1-20110714-C00114
    232-234
  • TABLE 5
    I-7
    Figure US20110172415A1-20110714-C00115
    254-256
    I-8
    Figure US20110172415A1-20110714-C00116
    245-246
    I-9
    Figure US20110172415A1-20110714-C00117
    243-245
    I-10
    Figure US20110172415A1-20110714-C00118
    259-261
    I-11
    Figure US20110172415A1-20110714-C00119
    244-247
    I-12
    Figure US20110172415A1-20110714-C00120
    297-300
  • TABLE 6
    I-13
    Figure US20110172415A1-20110714-C00121
    241-243
    I-14
    Figure US20110172415A1-20110714-C00122
    253-255
    I-15
    Figure US20110172415A1-20110714-C00123
    286-288
    I-16
    Figure US20110172415A1-20110714-C00124
    203-205
    I-17
    Figure US20110172415A1-20110714-C00125
    256-261
  • TABLE 7
    I-18
    Figure US20110172415A1-20110714-C00126
    302-304
    I-19
    Figure US20110172415A1-20110714-C00127
    137-139
    I-20
    Figure US20110172415A1-20110714-C00128
    171-173
    I-21
    Figure US20110172415A1-20110714-C00129
    229-230
    I-22
    Figure US20110172415A1-20110714-C00130
    242-244
    I-23
    Figure US20110172415A1-20110714-C00131
    294-296
  • TABLE 8
    I-24
    Figure US20110172415A1-20110714-C00132
    227-229
    I-25
    Figure US20110172415A1-20110714-C00133
    231-233
    I-26
    Figure US20110172415A1-20110714-C00134
    230-232
    I-27
    Figure US20110172415A1-20110714-C00135
    235-237
    I-28
    Figure US20110172415A1-20110714-C00136
    127-129
    I-29
    Figure US20110172415A1-20110714-C00137
    195-197
  • TABLE 9
    I-30
    Figure US20110172415A1-20110714-C00138
    215-217
    I-31
    Figure US20110172415A1-20110714-C00139
    234-236
    I-32
    Figure US20110172415A1-20110714-C00140
    232-234
    I-33
    Figure US20110172415A1-20110714-C00141
    202-203
    I-34
    Figure US20110172415A1-20110714-C00142
    255-257
    I-35
    Figure US20110172415A1-20110714-C00143
    167-169
  • TABLE 10
    I-36
    Figure US20110172415A1-20110714-C00144
    187-189
    I-37
    Figure US20110172415A1-20110714-C00145
    213-215
    I-38
    Figure US20110172415A1-20110714-C00146
    257-259
    I-39
    Figure US20110172415A1-20110714-C00147
    205-206
    I-40
    Figure US20110172415A1-20110714-C00148
    244-246
    I-41
    Figure US20110172415A1-20110714-C00149
    230-232
    I-42
    Figure US20110172415A1-20110714-C00150
    244-246
  • TABLE 11
    I-43
    Figure US20110172415A1-20110714-C00151
    202-204
    I-44
    Figure US20110172415A1-20110714-C00152
    218-221
    I-45
    Figure US20110172415A1-20110714-C00153
    230
    I-46
    Figure US20110172415A1-20110714-C00154
    137-139
    I-47
    Figure US20110172415A1-20110714-C00155
    219-221
    I-48
    Figure US20110172415A1-20110714-C00156
    228-230
  • TABLE 12
    I-49
    Figure US20110172415A1-20110714-C00157
    268-269
    I-50
    Figure US20110172415A1-20110714-C00158
    244-246
    I-51
    Figure US20110172415A1-20110714-C00159
    273-275
    I-52
    Figure US20110172415A1-20110714-C00160
    212-214
    I-53
    Figure US20110172415A1-20110714-C00161
    206-208
    I-54
    Figure US20110172415A1-20110714-C00162
    262-263
  • TABLE 13
    I-55
    Figure US20110172415A1-20110714-C00163
    247-249
    I-56
    Figure US20110172415A1-20110714-C00164
    206-209
    I-57
    Figure US20110172415A1-20110714-C00165
    219-222
    I-58
    Figure US20110172415A1-20110714-C00166
    270-273
    I-59
    Figure US20110172415A1-20110714-C00167
    245-248
    I-60
    Figure US20110172415A1-20110714-C00168
    266
  • TABLE 14
    Compound
    No. Structural formula Melting point
    I-61
    Figure US20110172415A1-20110714-C00169
    218-219
    I-62
    Figure US20110172415A1-20110714-C00170
    229-230
    I-63
    Figure US20110172415A1-20110714-C00171
    236-237
    I-64
    Figure US20110172415A1-20110714-C00172
    222-223
    I-65
    Figure US20110172415A1-20110714-C00173
    260-261
    I-66
    Figure US20110172415A1-20110714-C00174
    219-220
    I-67
    Figure US20110172415A1-20110714-C00175
    199-200
  • TABLE 15
    I-68
    Figure US20110172415A1-20110714-C00176
    243-245
    I-69
    Figure US20110172415A1-20110714-C00177
    214-215
    I-70
    Figure US20110172415A1-20110714-C00178
    247-248
    I-71
    Figure US20110172415A1-20110714-C00179
    243-245
    I-72
    Figure US20110172415A1-20110714-C00180
    263-265
    I-73
    Figure US20110172415A1-20110714-C00181
    265-267
    I-74
    Figure US20110172415A1-20110714-C00182
    253-255
  • TABLE 16
    I-75
    Figure US20110172415A1-20110714-C00183
    199
    I-76
    Figure US20110172415A1-20110714-C00184
    277-279
    I-77
    Figure US20110172415A1-20110714-C00185
    177-178
    I-78
    Figure US20110172415A1-20110714-C00186
    178-180
    I-79
    Figure US20110172415A1-20110714-C00187
    314-315
    I-80
    Figure US20110172415A1-20110714-C00188
    206-207
    I-81
    Figure US20110172415A1-20110714-C00189
    205-206
  • TABLE 17
    I-82
    Figure US20110172415A1-20110714-C00190
    252-254
    I-83
    Figure US20110172415A1-20110714-C00191
    256-258
    I-84
    Figure US20110172415A1-20110714-C00192
    >300
    I-85
    Figure US20110172415A1-20110714-C00193
    >300
    I-86
    Figure US20110172415A1-20110714-C00194
    211-213
    I-87
    Figure US20110172415A1-20110714-C00195
    271-273
    I-88
    Figure US20110172415A1-20110714-C00196
    232-233
  • TABLE 18
    I-89
    Figure US20110172415A1-20110714-C00197
    244-246
    I-90
    Figure US20110172415A1-20110714-C00198
    279-280
    I-91
    Figure US20110172415A1-20110714-C00199
    247-248
    I-92
    Figure US20110172415A1-20110714-C00200
    251-252
    I-93
    Figure US20110172415A1-20110714-C00201
    287-288
    I-94
    Figure US20110172415A1-20110714-C00202
    277-279
  • TABLE 19
    I-95
    Figure US20110172415A1-20110714-C00203
    253-255
    I-96
    Figure US20110172415A1-20110714-C00204
    236-237
    I-97
    Figure US20110172415A1-20110714-C00205
    211-212
    I-98
    Figure US20110172415A1-20110714-C00206
    246-247
    I-99
    Figure US20110172415A1-20110714-C00207
    240-241
    I-100
    Figure US20110172415A1-20110714-C00208
    185-186
    I-101
    Figure US20110172415A1-20110714-C00209
    315
  • TABLE 20
    I-102
    Figure US20110172415A1-20110714-C00210
    252
    I-103
    Figure US20110172415A1-20110714-C00211
    228-230
    I-104
    Figure US20110172415A1-20110714-C00212
    259-261
    I-105
    Figure US20110172415A1-20110714-C00213
    274-276
    I-106
    Figure US20110172415A1-20110714-C00214
    212-213
    I-107
    Figure US20110172415A1-20110714-C00215
    269-270
    I-108
    Figure US20110172415A1-20110714-C00216
    235-236
  • TABLE 21
    I-109
    Figure US20110172415A1-20110714-C00217
    236-237
    I-110
    Figure US20110172415A1-20110714-C00218
    251-253
    I-111
    Figure US20110172415A1-20110714-C00219
    248-250
    I-112
    Figure US20110172415A1-20110714-C00220
    244-245
    I-113
    Figure US20110172415A1-20110714-C00221
    293-294
    I-114
    Figure US20110172415A1-20110714-C00222
    173-174
    I-115
    Figure US20110172415A1-20110714-C00223
    234-235
  • TABLE 22
    I-116
    Figure US20110172415A1-20110714-C00224
    189-190
    I-117
    Figure US20110172415A1-20110714-C00225
    265-267
    I-118
    Figure US20110172415A1-20110714-C00226
    246-248
    I-119
    Figure US20110172415A1-20110714-C00227
    I-120
    Figure US20110172415A1-20110714-C00228
    I-121
    Figure US20110172415A1-20110714-C00229
    I-122
    Figure US20110172415A1-20110714-C00230
    I-123
    Figure US20110172415A1-20110714-C00231
  • TABLE 23
    I-124
    Figure US20110172415A1-20110714-C00232
    I-125
    Figure US20110172415A1-20110714-C00233
    I-126
    Figure US20110172415A1-20110714-C00234
    I-127
    Figure US20110172415A1-20110714-C00235
    I-128
    Figure US20110172415A1-20110714-C00236
    I-129
    Figure US20110172415A1-20110714-C00237
    I-130
    Figure US20110172415A1-20110714-C00238
    I-131
    Figure US20110172415A1-20110714-C00239
  • TABLE 24
    I-132
    Figure US20110172415A1-20110714-C00240
    I-133
    Figure US20110172415A1-20110714-C00241
    I-134
    Figure US20110172415A1-20110714-C00242
    I-135
    Figure US20110172415A1-20110714-C00243
    I-136
    Figure US20110172415A1-20110714-C00244
    I-137
    Figure US20110172415A1-20110714-C00245
    I-138
    Figure US20110172415A1-20110714-C00246
    I-139
    Figure US20110172415A1-20110714-C00247
  • TABLE 25
    I-140
    Figure US20110172415A1-20110714-C00248
    I-141
    Figure US20110172415A1-20110714-C00249
    I-142
    Figure US20110172415A1-20110714-C00250
    I-143
    Figure US20110172415A1-20110714-C00251
    I-144
    Figure US20110172415A1-20110714-C00252
    I-145
    Figure US20110172415A1-20110714-C00253
    I-146
    Figure US20110172415A1-20110714-C00254
    I-147
    Figure US20110172415A1-20110714-C00255
  • TABLE 26
    I-148
    Figure US20110172415A1-20110714-C00256
    I-149
    Figure US20110172415A1-20110714-C00257
    I-150
    Figure US20110172415A1-20110714-C00258
    I-151
    Figure US20110172415A1-20110714-C00259
    I-152
    Figure US20110172415A1-20110714-C00260
    I-153
    Figure US20110172415A1-20110714-C00261
    I-154
    Figure US20110172415A1-20110714-C00262
    199-200
    I-155
    Figure US20110172415A1-20110714-C00263
    262-263
  • TABLE 27
    I-156
    Figure US20110172415A1-20110714-C00264
    I-157
    Figure US20110172415A1-20110714-C00265
    I-158
    Figure US20110172415A1-20110714-C00266
    I-159
    Figure US20110172415A1-20110714-C00267
    I-160
    Figure US20110172415A1-20110714-C00268
    I-161
    Figure US20110172415A1-20110714-C00269
    I-162
    Figure US20110172415A1-20110714-C00270
    198-199
    I-163
    Figure US20110172415A1-20110714-C00271
  • TABLE 28
    I-164
    Figure US20110172415A1-20110714-C00272
    I-165
    Figure US20110172415A1-20110714-C00273
    I-166
    Figure US20110172415A1-20110714-C00274
    I-167
    Figure US20110172415A1-20110714-C00275
    I-168
    Figure US20110172415A1-20110714-C00276
    I-169
    Figure US20110172415A1-20110714-C00277
    183-185
    I-170
    Figure US20110172415A1-20110714-C00278
    114-116
  • TABLE 29
    I-171
    Figure US20110172415A1-20110714-C00279
    I-172
    Figure US20110172415A1-20110714-C00280
    I-173
    Figure US20110172415A1-20110714-C00281
    108-109
    I-174
    Figure US20110172415A1-20110714-C00282
    208-210
    I-175
    Figure US20110172415A1-20110714-C00283
    I-176
    Figure US20110172415A1-20110714-C00284
    120-123
    I-177
    Figure US20110172415A1-20110714-C00285
    117-119
    I-178
    Figure US20110172415A1-20110714-C00286
    124-127
  • TABLE 30
    I-179
    Figure US20110172415A1-20110714-C00287
    119-121
    I-180
    Figure US20110172415A1-20110714-C00288
    217-220
    I-181
    Figure US20110172415A1-20110714-C00289
    233-235(d)
    I-182
    Figure US20110172415A1-20110714-C00290
    205-206
    I-183
    Figure US20110172415A1-20110714-C00291
    I-184
    Figure US20110172415A1-20110714-C00292
    217-219
    I-185
    Figure US20110172415A1-20110714-C00293
    I-186
    Figure US20110172415A1-20110714-C00294
    200-202
  • TABLE 31
    I-187
    Figure US20110172415A1-20110714-C00295
    222-224
    I-188
    Figure US20110172415A1-20110714-C00296
    214-216
    I-189
    Figure US20110172415A1-20110714-C00297
    240-242
    I-190
    Figure US20110172415A1-20110714-C00298
    216-218
    I-191
    Figure US20110172415A1-20110714-C00299
    I-192
    Figure US20110172415A1-20110714-C00300
    190-192
    I-193
    Figure US20110172415A1-20110714-C00301
    237-239
    I-194
    Figure US20110172415A1-20110714-C00302
  • TABLE 32
    I-195
    Figure US20110172415A1-20110714-C00303
    I-196
    Figure US20110172415A1-20110714-C00304
    215-217
    I-197
    Figure US20110172415A1-20110714-C00305
    242-244
    I-198
    Figure US20110172415A1-20110714-C00306
    285-287
    I-199
    Figure US20110172415A1-20110714-C00307
    208-209
    I-200
    Figure US20110172415A1-20110714-C00308
    241-242
    I-201
    Figure US20110172415A1-20110714-C00309
    250-251
    I-202
    Figure US20110172415A1-20110714-C00310
    227-228
  • TABLE 33
    Compound No. Structural formula Melting point
    I-203
    Figure US20110172415A1-20110714-C00311
    264-266(d)
    I-204
    Figure US20110172415A1-20110714-C00312
    241-243
    I-205
    Figure US20110172415A1-20110714-C00313
    209-211
    I-206
    Figure US20110172415A1-20110714-C00314
    107-108
    I-207
    Figure US20110172415A1-20110714-C00315
    202-203
    I-208
    Figure US20110172415A1-20110714-C00316
    230-232
    I-209
    Figure US20110172415A1-20110714-C00317
    197-198
  • TABLE 34
    I-210
    Figure US20110172415A1-20110714-C00318
    195-197
    I-211
    Figure US20110172415A1-20110714-C00319
    229-230
    I-212
    Figure US20110172415A1-20110714-C00320
    185-187
    I-213
    Figure US20110172415A1-20110714-C00321
    253-255
    I-214
    Figure US20110172415A1-20110714-C00322
    272-274
    I-215
    Figure US20110172415A1-20110714-C00323
    237-240
    I-216
    Figure US20110172415A1-20110714-C00324
    208-209
  • TABLE 35
    I-217
    Figure US20110172415A1-20110714-C00325
    197-198
    I-218
    Figure US20110172415A1-20110714-C00326
    160-162
    I-219
    Figure US20110172415A1-20110714-C00327
    139-141
    I-220
    Figure US20110172415A1-20110714-C00328
    197-199
    I-221
    Figure US20110172415A1-20110714-C00329
    192-193
    I-222
    Figure US20110172415A1-20110714-C00330
    223-226
    I-223
    Figure US20110172415A1-20110714-C00331
    197-198
    I-224
    Figure US20110172415A1-20110714-C00332
    245-247
  • TABLE 36
    I-225
    Figure US20110172415A1-20110714-C00333
    226-228
    I-226
    Figure US20110172415A1-20110714-C00334
    250-252
    I-227
    Figure US20110172415A1-20110714-C00335
    194-196
    I-228
    Figure US20110172415A1-20110714-C00336
    191-193
    I-229
    Figure US20110172415A1-20110714-C00337
    229-231
    I-230
    Figure US20110172415A1-20110714-C00338
    217-219
    I-231
    Figure US20110172415A1-20110714-C00339
    239-241
  • TABLE 31
    I-232
    Figure US20110172415A1-20110714-C00340
    215-216
    I-233
    Figure US20110172415A1-20110714-C00341
    208-212
    I-234
    Figure US20110172415A1-20110714-C00342
    219-220
    I-235
    Figure US20110172415A1-20110714-C00343
    245-246
    I-236
    Figure US20110172415A1-20110714-C00344
    243-245
    I-237
    Figure US20110172415A1-20110714-C00345
    224-226
    I-238
    Figure US20110172415A1-20110714-C00346
    227-229
    I-239
    Figure US20110172415A1-20110714-C00347
    239-241
  • TABLE 38
    I-240
    Figure US20110172415A1-20110714-C00348
    223-225
    I-241
    Figure US20110172415A1-20110714-C00349
    123-125
    I-242
    Figure US20110172415A1-20110714-C00350
    233-235
    I-243
    Figure US20110172415A1-20110714-C00351
    191-192
    I-244
    Figure US20110172415A1-20110714-C00352
    211-213
    I-245
    Figure US20110172415A1-20110714-C00353
    194-196
    I-246
    Figure US20110172415A1-20110714-C00354
    114-116
  • TABLE 39
    Compound No. Structural formula Melting point
    I-247
    Figure US20110172415A1-20110714-C00355
    224-226
    I-248
    Figure US20110172415A1-20110714-C00356
    118-120
    I-249
    Figure US20110172415A1-20110714-C00357
    123-125
    I-250
    Figure US20110172415A1-20110714-C00358
    201-203
    I-251
    Figure US20110172415A1-20110714-C00359
    122-124
    I-252
    Figure US20110172415A1-20110714-C00360
    I-253
    Figure US20110172415A1-20110714-C00361
    226-228
  • TABLE 40
    I-254
    Figure US20110172415A1-20110714-C00362
    106-108
    I-255
    Figure US20110172415A1-20110714-C00363
    108-110
    I-256
    Figure US20110172415A1-20110714-C00364
    220-222
    I-257
    Figure US20110172415A1-20110714-C00365
    220-202
    I-258
    Figure US20110172415A1-20110714-C00366
    106-108
    I-259
    Figure US20110172415A1-20110714-C00367
    I-260
    Figure US20110172415A1-20110714-C00368
  • TABLE 41
    I-261
    Figure US20110172415A1-20110714-C00369
    I-262
    Figure US20110172415A1-20110714-C00370
    275-227
    I-263
    Figure US20110172415A1-20110714-C00371
    226-228
    I-264
    Figure US20110172415A1-20110714-C00372
    114-116
    I-265
    Figure US20110172415A1-20110714-C00373
    110-112
    I-266
    Figure US20110172415A1-20110714-C00374
    123-125
  • TEST EXAMPLE 1 Test of Binding with NMDR Receptor (NR1/NR2B Receptor)
  • Using Ifenprodil which is an antagonist specific for a NR1/NR2B subtype receptor as a ligand, an experiment of competition between a receptor and a test compound was performed.
  • Using a male Slc: Wistar rat as an animal, a brain was isolated after decapitation, and a cerebral cortex was fractionated. The cerebral cortex was homogenized with a 20-fold amount of an ice-cooled 50 mM Tris/HCl buffer (pH 7.4), and the homogenate was centrifuged at 4° C. and 27,500×g for 10 minutes. The resulting precipitate was suspended in the same buffer, and this was again centrifuged. This operation was repeated for three times, the resulting precipitate was suspended in a buffer, and this was stored at −80° C. Immediately before an experiment, the frozen suspension was thawed at room temperature, this was centrifuged at 4° C. and 27,500×g for 10 minutes, and the resulting precipitate was suspended in a buffer. Further, the suspension was diluted 10-fold with a buffer, and this was used as a membrane specimen in an experiment. In a binding experiment, to 470 μl of the membrane specimen were added 10 μl of each of test compounds having different concentrations, 10 μl of a labeled ligand [3H]-Ifenprodil and 10 μl GBR-12909, followed by incubation at an ice temperature for 120 minutes. A concentration of [3H]-Ifenprodil of the labeled ligand was finally 5 nM, and a concentration of GBR-12909 was finally 3 μM. For measuring a total binding amount, DMSO as a solvent was used and, for measuring a non-specific binding amount, 100 μM Ifenprodil was used. GBR-12909 was added in order to block binding of [3H]-Ifenprodil to non-polyamine-sensitive site. After incubation, a bound form and a free form were separated using Whatman GF/C filter (manufactured by Whatman), and the filter was washed with 2.5 ml ice-cooled buffer four times. The filter was immersed in liquid scintillation (Cryasol I, manufactured by Nacalai tesque), and radioactivity (dpm) was measured with a liquid scintillation counter. From a measured value, a binding inhibition rate (%) was obtained by the following equation, and a dose at which binding is inhibited 50% (IC50) was calculated. An IC50 value of a test substance is shown in Table 42. A formula of GBR-12909 (vanoxerine) is shown below.
  • Figure US20110172415A1-20110714-C00375

  • Binding inhibition rate (%)=100−[(binding amount in the presence of test compound−non-specific binding amount)/(total binding amount−non-specific binding amount)]×100
  • TABLE 42
    Compound NR2B
    No. (IC50 μM)
    I-1   0.043
    I-2   0.033
    I-5   0.043
    I-21  0.096
    I-23  0.040
    I-30  0.077
    I-42  0.107
    I-43  0.017
    I-55  0.025
    I-66  0.090
    I-70  0.068
    I-73  0.015
    I-79  0.013
    I-85  0.067
    I-87  0.012
    I-90  0.026
    I-98  0.015
    I-100 0.074
    I-101 0.011
    I-103 0.018
    I-104 0.016
    I-105 0.045
    I-109 0.012
    I-113 0.034
    I-116 0.049
    I-154 0.044
    I-177 0.059
    I-178 0.029
    I-180 0.062
    I-184 0.041
    I-187 0.054
    I-188 0.021
    I-192 0.052
    I-196 0.023
    I-198 0.073
    I-200 0.081
    I-201 0.074
  • The following compounds showed 1050 of 0.1 μM or lower. I-45, I-99, I-84, I-86, I-107, I-114, I-204, I-205, I-206, I-207, I-208, I-209, I-211, I-221, I-225, I-226, I-227, I-228, I-230, I-232, I-233, I-235, I-237, I-238, I-239, I-241, I-247 and I-249.
  • From the above result, it was made clear that the present compound exhibits strong binding property on the NR1/NR2B subtype receptor.
  • TEST EXAMPLE 2 Measurement of Expression of NMDA Receptor and Ca Ion Influx Amount
  • A complementary DNA (c DNA) of a mouse NMDA receptor subunit was transiently introduced into a HEK293 cell and, after 1 day from introduction, change in a glutamic acid/glycine-induced intracelluar Ca amount was measured using a Ca ion reactive fluorescent coloring matter.
  • The HEK293 cell was cultured, and passaged using a modified Dulbecco's Eagle medium (DMEM, low glucose).
  • The HEK293 cell (20,000/well) was seeded on a 96-well plate, a NR1 subunit and a NR2B subunit of the NMDA receptor incorporated into the pcDNA3.1 plasmid were transiently introduced into a cell, and the subunits were co-expressed. An introduction amount of a DNA was 0.025 μg in the case of the NR1 subunit, and 0.075 μg in the case of NR2B subunit per well. For the cell after introduction, cell death was inhibited using 50 μM of the NMDA receptor antagonist MK-801.
  • For adjusting a test compound and washing a cell, Krebs/Ringer/Hepes buffer (KRH, Ca: 5 mM) was used.
  • After 1 day from introduction, the NMDA receptor antagonist MK-801 was washed out using the KRH buffer, and a Ca ion indication fluorescent coloring matter Fluo-3/AM was made to be taken into the cell. Ca ion influx was induced with 20 μM glutamic acid/2 μM glycine. Change in a fluorescent amount due to Ca ion influx into the cell was measured at excitation of 480 nm using a fluorescent imaging system FDSS 3000.
  • Usually, if a test compound exhibits the antagonism of the NMDA receptor, Ca ion influx into the cell is reduced, a fluorescent amount is reduced.
  • From a measured value of the test compound, a Ca ion influx inhibition rate (%) was obtained by the following equation, and a dose at which influx is inhibited 50% (IC50) was calculated. An IC50 value of the test substance is shown in Table 43.

  • Ca ion influx inhibition rate (%)=100−[(fluorescent amount in the presence of test compound−background fluorescent amount)/(total fluorescent amount−background fluorescent)]×100
  • TABLE 43
    Compound Ca2+
    No. IC50 (μM)
    I-2   0.014
    I-5   0.020
    I-6   0.039
    I-8   0.048
    I-11  0.069
    I-16  0.037
    I-21  0.037
    I-23  0.025
    I-25  0.063
    I-26  0.048
    I-30  0.004
    I-33  0.037
    I-34  0.020
    I-40  0.015
    I-41  0.092
    I-42  0.013
    I-43  0.009
    I-45  0.023
    I-53  0.067
    I-55  0.007
    I-61  0.037
    I-62  0.092
    I-63  0.079
    I-66  0.025
    I-70  0.015
    I-73  0.008
    I-74  0.039
    I-78  0.031
    I-79  0.002
    I-80  0.052
    I-81  0.062
    I-84  0.011
    I-89  0.087
    I-94  0.051
    I-100 0.010
    I-101 0.001
    I-104 0.001
    I-105 0.010
    I-109 0.001
    I-110 0.009
    I-113 0.034
    I-116 0.049
    I-122 0.024
    I-138 0.044
    I-140 0.044
    I-154 0.004
    I-155 0.053
    I-180 0.013
    I-184 0.011
    I-187 0.014
    I-196 0.015
    I-197 0.059
  • The following compounds exhibited IC50 of 0.1 μM lower. I-76, I-86, I-87, I-90, I-98, I-99, I-103, I-107, I-111, I-114, I-176, I-177, I-178, I-207, I-208, I-209, I-211, I-212, I-221, I-225, I-227, I-228, I-230, I-233, I-237, I-238 and I-249.
  • From the above results, it was made clear that the present compound exhibits the NMDA receptor antagonism.
  • INDUSTRIAL APPLICABILITY
  • The present invention is usefull as an analgesic and/or nerve protecting agent, which exhibits specific antagonism for a glutamic acid receptor of a central nervous cell, particularly, NR1/NR2B receptor being one kind of NMDA receptors, and has little side effect on motion function (abnormal sensation) and mental symptom (schizophrenia).

Claims (14)

1. A compound represented by the formula (I):
Figure US20110172415A1-20110714-C00376
wherein Z is N or CR1;
A1 is a nitrogen-containing aromatic monocyclic group which is optionally substituted, or a nitrogen-containing aromatic fused cyclic group which is optionally substituted, the nitrogen-containing aromatic monocyclic group or the nitrogen-containing aromatic fused cyclic group satisfies at least one of the following conditions:
i) the group has at least one group selected from optionally substituted hydroxy, optionally protected amino and optionally substituted aminooxy, and
ii) the group contains —NH— in the ring;
A2 is an aromatic hydrocarbon cyclic group which is optionally substituted, or an aromatic heterocyclic group which is optionally substituted;
R1 and R2 are each independently hydrogen, hydroxy or lower alkyl, or R1 and R2 may be taken together to form a single bond;
Ra, Rb, Rc and Rd are each independently hydrogen or lower alkyl and, when there are a plurality of Ras, a plurality of Rbs, a plurality of Rcs or a plurality of Rds, they may be different from each other;
w is 2 or 3;
t is 1 or 2;
X is:
—(CR3R4)m-,
—CO(CR3R4)n-,
—(CR3R4)mCO—,
—CONR5(CR3R4)n-,
—NR5CO(CR3R4)n-,
—(CR3R4)mNR5CO—,
—NR5CONR6(CR3R4)n-,
—C(═N—OR7)(CR3R4)n-,
—(CR8R9)rO(CR3R4)n-,
—(CR8R9)rS(CR3R4)n-,
—(CR8R9)rSO(CR3R4)n-,
—(CR8R9)rSO2(CR3R4)n-,
—CR9═N—O(CR3R4)n-,
—C(═O)O(CR3R4)n-,
—(CR3R4)mC(═N—OR8)-,
—CH(OR8)(CR3R4)n-,
—(CR3R4)mCH(OR8)-,
NR5COCO(CR3R4)n-,
(CR3R4)mNR'COCO—,
—COCONR5(CR3R4)n-,
—NR5COCH(OR8)(CR3R4)n-,
—CH(OR8)(CR3R4)nNR5CO—,
—NR5(CR3R4)mCO—,
-A3-(CR3R4)n-,
—(CR3R4)m-A3-,
-A3-CR10═CR11(CR3R4)n-,
—CR10═CR11(CR3R4)n-A3-,
-A3-NR6(CR3R4)n-,
—(CR3R4)nNR6-A3- or
—NR6(CR3R4)m-A3-,
further, X may be
—CONR5(CR3R4)m-NR6—,
—(CR3R4)mCONR5—,
—(CR3R4)mNR5CONR6—,
—CO(CR3R4)mNR5—, or
-A3-(CR3R4)mNR6— when Z is CR1;
m is an integer of 1 to 4;
n and r are an integer of 0 to 4;
A3 is an aromatic hydrocarbon cyclic group which is optionally substituted, an aromatic heterocyclic group which is optionally substituted, or a non-aromatic heterocyclic group which is optionally substituted;
R3 and R4 are each independently hydrogen, halogen, hydroxy, optionally substituted lower alkyl, or optionally substituted lower alkoxy, and when there are a plurality of R3s and R4s, respectively, they may be different from each other;
R5, R6, R7, R8, R9, R10 and R11 are each independently hydrogen or lower alkyl, and when m or n is 1 or more, R1 may be taken together with R3 on CR3R4 adjacent to a carbon atom to which R1 binds, to form a single bond,
wherein the case where Z is N, A1 is
Figure US20110172415A1-20110714-C00377
and X is —NR5CO(CR3R4)n-, —NR5COCO(CR3R4)n- or —NR5(CR3R4)mCO— is excluded,
or a pharmaceutically acceptable salt, or a solvate thereof.
2. The compound according to claim 1, wherein w is 2 or 3, and t is 1, or a pharmaceutically acceptable salt, or a solvate thereof.
3. The compound according to claim 1, wherein X is —(CR3R4)m-, —CO(CR3R4)n-, —CONR5(CR3R4)n-, —(CR3R4)mCONR5—, —NR5CO(CR3R4)n-, —(CR3R4)mNR5CO—, —NR5CONR6(CR3R4)n-, —C(═N—OR7)(CR3R4)n-, —CH(OR8)(CR3R4)n-, —NR5COCO(CR3R4)n-, —NR5COCH(OR8)(CR3R4)n-, -A3-(CR3R4)n-, -A3-CR10═(CR3R4)n-, —NR5(CR3R4)mCO— or -A3-(CR3R4)nNR6—, or a pharmaceutically acceptable salt, or a solvate thereof.
4. The compound according to claim 1, wherein A1 is pyridyl substituted with at least hydroxy, quinolyl substituted with at least hydroxy, benzoxazolyl substituted with at least hydroxy, benzimidazolyl substituted with at least hydroxy, pyridyl substituted with at least optionally protected amino, imidazolyl in which ring constituting atoms other than —NH— may be substituted, pyrrolyl in which ring constituting atoms other than —NH— may be substituted, pyrazolyl in which ring constituting atoms other than —NH— may be substituted, benzpyrazolyl in which ring constituting atoms other than —NH— may be substituted, benzimidazolyl in which ring constituting atoms other than —NH— may be substituted, or indolyl in which ring constituting atoms other than —NH— may be substituted, or a pharmaceutically acceptable salt, or a solvate thereof.
5. The compound according to claim 1, wherein A1 is:
Figure US20110172415A1-20110714-C00378
or a pharmaceutically acceptable salt, or a solvate thereof.
6. The compound according to claim 1, wherein X is —CO(CHR3)n-, —CONH(CHR3)n-, —NHCO(CHR3)n-, —NHCONH(CHR3)n-, —NHCOCO(CHR3)n- or —NR5(CR3R4)mCO— or a pharmaceutically acceptable salt, or a solvate thereof.
7. The compound according to claim 1, wherein X is —CO(CHR3)2—, —CONHCHR3—, —CONH(CHR3)2—, —NHCOCHR3—, —NHCO(CHR3)2—, —NHCONH—, —NHCOCO— or —NHCH2CO— or a pharmaceutically acceptable salt, or a solvate thereof.
8. The compound according to claim 1, wherein Z is CR1, R1 and R2 are each independently hydrogen or hydroxy, or R1 and R2 are taken together to form a single bond and, when m or n is 1 or more, R1 is taken together with R3 on CR3R4 adjacent to a carbon atom to which R1 binds, to form a single bond, or a pharmaceutically acceptable salt, or a solvate thereof.
9. The compound according to claim 1, wherein Z is N, or a pharmaceutically acceptable salt, or a solvate thereof.
10. The compound according to claim 1, wherein A2 is phenyl optionally substituted with one or more groups selected from halogen, cyano, lower alkyl, halogeno lower alkyl, lower alkoxy and halogeno lower alkoxy or pyridyl optionally substituted with one or more groups selected from halogen, cyano, lower alkyl, halogeno lower alkyl, lower alkoxy and halogeno lower alkoxy, or a pharmaceutically acceptable salt, or a solvate thereof.
11. The compound according to claim 1, wherein A2 is para-substituted phenyl, meta and para-di-substituted phenyl or meta and para-tri-substituted phenyl, or a pharmaceutically acceptable salt, or a solvate thereof
12. A pharmaceutical composition containing the compound according to claim 1, or a pharmaceutically acceptable salt, or a solvate thereof.
13. The pharmaceutical composition according to claim 12, which has the NMDA receptor antagonism.
14. The pharmaceutical composition according to claim 13, which has the NR1/NR2B receptor antagonism.
US13/050,465 2006-02-23 2011-03-17 Nitrogen-containing heterocycle derivatives substituted with cyclic group Abandoned US20110172415A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/050,465 US20110172415A1 (en) 2006-02-23 2011-03-17 Nitrogen-containing heterocycle derivatives substituted with cyclic group

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP2006-046740 2006-02-23
JP2006046740 2006-02-23
JP2006149750 2006-05-30
JP2006-149750 2006-05-30
JP2006-318360 2006-11-27
JP2006318360 2006-11-27
PCT/JP2007/053166 WO2007099828A1 (en) 2006-02-23 2007-02-21 Nirogenous heterocyclic derivatives substituted with cyclic groups
US27841208A 2008-08-06 2008-08-06
US13/050,465 US20110172415A1 (en) 2006-02-23 2011-03-17 Nitrogen-containing heterocycle derivatives substituted with cyclic group

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2007/053166 Division WO2007099828A1 (en) 2006-02-23 2007-02-21 Nirogenous heterocyclic derivatives substituted with cyclic groups
US27841208A Division 2006-02-23 2008-08-06

Publications (1)

Publication Number Publication Date
US20110172415A1 true US20110172415A1 (en) 2011-07-14

Family

ID=38458939

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/278,412 Expired - Fee Related US7935706B2 (en) 2006-02-23 2007-02-21 Nitrogen-containing heterocycle derivatives substituted with cyclic group
US13/050,465 Abandoned US20110172415A1 (en) 2006-02-23 2011-03-17 Nitrogen-containing heterocycle derivatives substituted with cyclic group

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/278,412 Expired - Fee Related US7935706B2 (en) 2006-02-23 2007-02-21 Nitrogen-containing heterocycle derivatives substituted with cyclic group

Country Status (5)

Country Link
US (2) US7935706B2 (en)
EP (2) EP1988077A4 (en)
JP (1) JPWO2007099828A1 (en)
TW (1) TW200800182A (en)
WO (1) WO2007099828A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016100349A3 (en) * 2014-12-16 2016-08-18 Rugen Holdings (Cayman) Limited Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
US10294230B2 (en) 2015-06-01 2019-05-21 Rugen Holdings (Cayman) Limited 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
US10420768B2 (en) 2014-09-15 2019-09-24 Rugen Holdings (Cayman) Limited Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
US11000526B2 (en) 2016-11-22 2021-05-11 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
KR20220006254A (en) * 2020-07-08 2022-01-17 원광대학교산학협력단 Piperidine compound and method for producing the same
WO2023006013A1 (en) * 2021-07-29 2023-02-02 上海齐鲁制药研究中心有限公司 Novel parp7 inhibitor and use thereof

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2007099828A1 (en) * 2006-02-23 2009-07-16 塩野義製薬株式会社 Nitrogen-containing heterocyclic derivatives substituted with cyclic groups
JP5187901B2 (en) 2006-08-30 2013-04-24 塩野義製薬株式会社 Hydrazine amide derivatives
US8088777B2 (en) 2006-08-30 2012-01-03 Shionogi & Co., Ltd. Urea derivative
EP2066619A2 (en) * 2006-11-02 2009-06-10 Arete Therapeutics, INC. Soluble epoxide hydrolase inhibitors
AU2008246202B2 (en) * 2007-04-27 2011-12-01 Purdue Pharma L.P. Therapeutic agents useful for treating pain
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
US8420680B2 (en) 2007-06-29 2013-04-16 Emory University NMDA receptor antagonists for neuroprotection
EP2184272A4 (en) * 2007-08-21 2011-11-09 Shionogi & Co Piperazine derivative
KR20110016891A (en) * 2008-05-09 2011-02-18 에모리 유니버시티 Nmda receptor antagonists for the treatment of neuropsychiatric disorders
WO2013156614A1 (en) 2012-04-20 2013-10-24 Ucb Pharma S.A. Methods for treating parkinson's disease
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
US9187506B2 (en) * 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
US9221796B2 (en) 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists
AR101704A1 (en) 2014-08-28 2017-01-04 Otsuka Pharma Co Ltd FUSED HETEROCYCLIC COMPOUNDS
WO2016126869A1 (en) * 2015-02-04 2016-08-11 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists
US10501451B2 (en) 2015-10-14 2019-12-10 Bristol-Myers Squibb Company Selective NR2B antagonists
WO2017066366A1 (en) 2015-10-14 2017-04-20 Bristol-Myers Squibb Company Selective nr2b antagonists
HUE054382T2 (en) 2016-12-30 2021-09-28 Mitobridge Inc Poly-adp ribose polymerase (parp) inhibitors
GB202019475D0 (en) 2020-12-10 2021-01-27 Cancer Research Tech Ltd Therapeutic compounds and their use
WO2024032530A1 (en) * 2022-08-11 2024-02-15 江苏恩华药业股份有限公司 Aromatic heterocyclic cyclohexyl aminoalkyl piperidine derivative, preparation method and use thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3407199A (en) * 1966-01-18 1968-10-22 Endo Lab Tertiaryamino ethyl or propyl pyrrol-2-yl ketones
US3538089A (en) * 1965-03-05 1970-11-03 Ciba Geigy Corp 5-nitro-2-thiazolyl-oxamides
US4455422A (en) * 1980-03-06 1984-06-19 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and pharmaceutical composition containing the same
US4960778A (en) * 1988-10-04 1990-10-02 Adir Et Cie Benzoxazolinone compounds
US5283242A (en) * 1991-10-24 1994-02-01 American Home Products Corporation Substituted benzimidazoles and quinazolines as antihypertensives
US5576318A (en) * 1991-07-30 1996-11-19 Boehringer Ingelheim Italia S.P.A. Benzimidazolone derivatives
US5948784A (en) * 1994-08-26 1999-09-07 Kyowa Hakko Kogyo Co., Ltd. Quinazoline derivatives
US6352981B1 (en) * 1996-01-12 2002-03-05 Basf Aktiengesellschaft Substituted AZA- and diazacycloheptane and -cyclooctane
US20050124627A1 (en) * 2002-03-12 2005-06-09 Oliver Schadt Cyclic amides

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1595920B2 (en) * 1964-11-04 1978-08-10 Merck Patent Gmbh, 6100 Darmstadt 4- (co-piperazinoalkyl) pyrazoles, their salts and processes for their preparation
CH460017A (en) 1965-03-05 1968-07-31 Ciba Geigy Process for the preparation of new nitrothiazole compounds
CH460016A (en) 1965-03-05 1968-07-31 Ciba Geigy Process for the preparation of new nitrothiazole compounds
IT1056055B (en) * 1974-03-01 1982-01-30 Malesci Sas Inst Farmaco Bilog Substd 1-alkyl 4-phenylpiperazines - with anti-hypertensive, vasodilating, alpha-inhibiting, anti-histamine and anti-bradykinin activity
IT1183061B (en) 1984-07-31 1987-10-05 Zambon Spa COMPOUNDS EQUIPPED WITH ANTI-ALLERGIC ACTIVITY
JPH0822834B2 (en) 1986-01-10 1996-03-06 財団法人野口研究所 2-Keto-3-deoxyaldonic acid derivative and method for producing the same
FI95572C (en) 1987-06-22 1996-02-26 Eisai Co Ltd Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt
JP2608788B2 (en) * 1988-10-31 1997-05-14 大塚製薬 株式会社 Schizophrenia remedy
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2777159B2 (en) 1988-12-22 1998-07-16 エーザイ株式会社 Pharmaceuticals containing cyclic amine derivatives
ES2027898A6 (en) * 1991-01-24 1992-06-16 Espanola Prod Quimicos 2-Methoxyphenylpiperazine derivatives.
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
HUP0203657A3 (en) 1998-05-22 2005-03-29 Scios Inc Sunnyvale Heterocyclic compounds and methods to treat cardiac failure and other disorders
DE60041584D1 (en) * 1999-07-28 2009-04-02 Aventis Pharma Inc SUBSTITUTED OXOAZAHETEROZYCLIC COMPOUNDS
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6372752B1 (en) * 2000-02-07 2002-04-16 Genzyme Corporation Inha inhibitors and methods of use thereof
AR030357A1 (en) * 2000-08-18 2003-08-20 Lundbeck & Co As H DERIVATIVES 4 -, 5 -, 6 - AND 7-INDOL
HU227197B1 (en) * 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
US20020183316A1 (en) * 2000-10-27 2002-12-05 Kevin Pan Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
MXPA03005648A (en) 2000-12-22 2003-10-06 Astrazeneca Ab Carbazole derivatives and their use as neuropeptide y5 receptor ligands.
PL364625A1 (en) 2001-02-23 2004-12-13 Merck & Co, Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
MXPA02002749A (en) * 2001-03-27 2002-10-28 Warner Lambert Co Cyclohexylamine derivatives as subtype selective n-methyl-d-aspartate antagonists.
AU2002338334B8 (en) * 2001-04-03 2008-09-18 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists
ES2312603T3 (en) 2001-07-24 2009-03-01 Richter Gedeon Nyrt PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE NMDA RECEIVER.
HUP0103987A3 (en) * 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
CN1620294A (en) 2001-12-20 2005-05-25 Osi药物公司 Pyrimidine A2b selective antagonist compounds, their synthesis and use
MXPA03000145A (en) * 2002-01-07 2003-07-15 Pfizer Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators.
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
DE10248067A1 (en) 2002-10-07 2004-04-15 Proteosys Ag New N-diaminophenylpropyl- or N-heteroarylpropyl-piperazine or piperidine derivatives, useful as dopaminergic and/or serotoninergic agents for e.g. treating Parkinson's disease or schizophrenia
DE10248925A1 (en) 2002-10-15 2004-04-29 Proteosys Ag New compounds with dopaminergic and / or serotonergic activity
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
TW200507841A (en) * 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
JP2006528236A (en) 2003-05-16 2006-12-14 ファイザー・プロダクツ・インク How to enhance cognition with ziprasidone
CA2526361C (en) * 2003-05-20 2012-05-15 Ajinomoto Co., Inc. Amide derivative
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
CA2555970A1 (en) * 2004-02-11 2005-09-01 Pfizer Inc. Therapeutic amide derivatives
ZA200700527B (en) * 2004-07-20 2008-08-27 Siena Biotech Spa Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
HU227119B1 (en) 2004-07-29 2010-07-28 Richter Gedeon Nyrt Indole and benzimidazole carboxylic acid amide derivatives and pharmaceutical compositions containing them
HU227000B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them
HUP0401526A2 (en) * 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet Aryloxy acetic acid amide derivatives, pharmaceutical compositions comprising thereof, methods for their preparation and their use
HU226977B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
HUP0401522A2 (en) 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
RU2384576C2 (en) 2004-10-29 2010-03-20 Калипсис, Инк Sulfonyl-substituted bicyclic compounds as ppar modulators
WO2006058338A2 (en) * 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
CN101384263A (en) 2004-12-02 2009-03-11 艾博特股份有限两合公司 Triazole compounds suitable for treating disorders that respond to modulaiont of the dopamine d3 receptor
WO2006090272A1 (en) 2005-02-22 2006-08-31 Warner-Lambert Company Llc Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia
WO2006090273A2 (en) 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
JPWO2007099828A1 (en) * 2006-02-23 2009-07-16 塩野義製薬株式会社 Nitrogen-containing heterocyclic derivatives substituted with cyclic groups

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3538089A (en) * 1965-03-05 1970-11-03 Ciba Geigy Corp 5-nitro-2-thiazolyl-oxamides
US3407199A (en) * 1966-01-18 1968-10-22 Endo Lab Tertiaryamino ethyl or propyl pyrrol-2-yl ketones
US4455422A (en) * 1980-03-06 1984-06-19 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and pharmaceutical composition containing the same
US4960778A (en) * 1988-10-04 1990-10-02 Adir Et Cie Benzoxazolinone compounds
US5576318A (en) * 1991-07-30 1996-11-19 Boehringer Ingelheim Italia S.P.A. Benzimidazolone derivatives
US5283242A (en) * 1991-10-24 1994-02-01 American Home Products Corporation Substituted benzimidazoles and quinazolines as antihypertensives
US5948784A (en) * 1994-08-26 1999-09-07 Kyowa Hakko Kogyo Co., Ltd. Quinazoline derivatives
US6352981B1 (en) * 1996-01-12 2002-03-05 Basf Aktiengesellschaft Substituted AZA- and diazacycloheptane and -cyclooctane
US20050124627A1 (en) * 2002-03-12 2005-06-09 Oliver Schadt Cyclic amides

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10420768B2 (en) 2014-09-15 2019-09-24 Rugen Holdings (Cayman) Limited Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
WO2016100349A3 (en) * 2014-12-16 2016-08-18 Rugen Holdings (Cayman) Limited Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
US10294230B2 (en) 2015-06-01 2019-05-21 Rugen Holdings (Cayman) Limited 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
US10584127B2 (en) 2015-06-01 2020-03-10 Rugen Holdings (Cayman) Limited 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
US11136328B2 (en) 2015-06-01 2021-10-05 Rugen Holdings (Cayman) Limited 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
US11000526B2 (en) 2016-11-22 2021-05-11 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
US11752155B2 (en) 2016-11-22 2023-09-12 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
KR20220006254A (en) * 2020-07-08 2022-01-17 원광대학교산학협력단 Piperidine compound and method for producing the same
KR102458689B1 (en) 2020-07-08 2022-10-25 원광대학교산학협력단 Piperidine compound and method for producing the same
WO2023006013A1 (en) * 2021-07-29 2023-02-02 上海齐鲁制药研究中心有限公司 Novel parp7 inhibitor and use thereof

Also Published As

Publication number Publication date
EP1988077A4 (en) 2009-09-02
JPWO2007099828A1 (en) 2009-07-16
US7935706B2 (en) 2011-05-03
US20090062261A1 (en) 2009-03-05
EP2520567A3 (en) 2012-12-12
EP2520567A2 (en) 2012-11-07
TW200800182A (en) 2008-01-01
WO2007099828A1 (en) 2007-09-07
EP1988077A1 (en) 2008-11-05

Similar Documents

Publication Publication Date Title
US7935706B2 (en) Nitrogen-containing heterocycle derivatives substituted with cyclic group
US10532985B2 (en) Heterocycle and carbocycle derivatives having TRKA inhibitory activity
CN105934246B (en) Tetrahydroquinoline constituent as BET bromine domain inhibitor
US20140235626A1 (en) Pyridine derivatives and a pharmaceutical composition for inhibiting bace1 containing them
US7148237B2 (en) Nitrogen-containing heteroaryl compounds having HIV integrase inhibitory activity
EP3386590B1 (en) Bicyclic inhibitors of pad4
USRE46375E1 (en) 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
US7008954B1 (en) Th2 differentiation inhibitors
US9630922B2 (en) 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors
US8003785B2 (en) Halo-substituted pyrimidodiazepines
US9199959B2 (en) HIV replication inhibitor
US20120015943A1 (en) Substituted hydroxamic acids and uses thereof
US20160039789A1 (en) Substituted hydroxamic acids and uses thereof
EP2143713A1 (en) Novel pyrrolinone derivative and medicinal composition containing the same
US20230012362A1 (en) Wdr5 inhibitors and modulators
US20180360803A1 (en) Pharmaceutical composition for treatment or prevention of nash
US6765096B1 (en) Tricyclic compound having acyloxymethoxycarbonyl side chain
CZ158696A3 (en) Hiv-protease inhibitors and pharmaceutical compositions containing thereof
KR20000005366A (en) Novel carboxylic acid derivatives, their production and use
US20230416262A1 (en) Trpml modulators
US20230119479A1 (en) A histone deacetylase inhibitor having a nitrogen-containing aromatic heterocyclyl group
US20230026466A1 (en) Wdr5 inhibitors and modulators
US10844044B2 (en) WDR5 inhibitors and modulators
JP4737495B2 (en) Erythromycin derivative
RU2795850C2 (en) 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and variants of their use

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION